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NOMENCLATURE 
Roman Symbols 
C  Compliance 
D  Observable model output 
e  normalised time varying elastance 
E  Elastance 
H   Heaviside function 
L  Inertance 
P  Pressure 
P  unknown parameter set 
Q  Flow 
R   Resistance 
S  Septum 
t  Time 
T  Time 
T  period 
V  Volume 
W  Work 
Z   Impedence 
 
Greek Symbols 
λ  Parameter of end diastolic pressure volume relationship  
τ  Decay constant 
  
Subscripts 
6  Six chamber 
a  Arterial 
ao   Aorta 
approx  Approximate 
av   Aortic valve 
d  Unstressed/deadspace volume 
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dia   Diastolic 
es   end systolic 
ed   end diastolic 
ex   excess 
lv  Left ventricle 
lvf  Left ventricle free wall 
max  Maximum 
meas   Measured 
min  Minimum 
mt  Mitral 
0  Value at zero pressure 
pa   Pulmonary artery 
pcd  Pericardium (plus thoracic component) 
peri  Pericardium 
prox  Proximal 
pu   Pulmonary vein 
pul  Pulmonary 
pv  Pulmonary valve 
rv  Right ventricle 
rvf  Right ventricle free wall 
spt   Septum 
sys  Systemic 
sys  Systolic 
tc  Tricuspid 
th   Intrathoracic 
v  venous 
vc   Vena cava  
wk   Windkessel or reservoir  
 
Acronyms 
AF  Atrial Fibrillation 
AP  Arterial pressure 
APE   Acute pulmonary embolism 
CABG  Coronary artery bypass graft 
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CAD   Coronary artery disease 
CO  Cardiac Output 
CT  Computed tomography 
CVD   Cardiovascular disease 
CVP   Central venous pressure 
CVS   Cardiovascular system 
DE   Differential Equation 
DIC  Disseminated intravascular coagulation 
DVT   Deep vein thrombosis 
ECG  Electrocardiogram 
EDV  End diastolic volume 
EDPVR   End diastolic pressure volume relationship 
ESP   End systolic pressure 
ESV  End systolic volume 
ESPVR   End systolic pressure volume relationship 
GEDV  Global end diastolic volume 
HR   Heart rate 
ICU  Intensive care unit 
IHD   Ischemic heart disease 
LPHF   Large pore hemofiltration 
MAP   Mean arterial pressure 
MV   Mitral valve 
MVR  Mitral valve replacement or repair 
PAC  Pulmonary artery catheter 
PAP   Pulmonary artery pressure 
PE  Pulmonary embolism 
PEEP   Peak end expiratory pressure 
PI  Identified pulmonary model parameters  
PIP  Peak inspiratory pressure 
PO  Pulmonary model outputs 
PM   Pulmonary measurement set 
PP   Pulse pressure 
PVR  Pulmonary vascular resistance 
RVEI   Right ventricle expansion index 
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RVVC   Right ventricle vascular coupling 
SD  Standard deviation 
SI  Identified systemic model parameters 
SO  Systemic model outputs 
SM  Systemic model measurement set 
SS  Septic shock 
SV   Stroke volume 
SVR  Systemic vascular resistance 
TBV  Total blood volume 
TPR   Total peripheral resistance 
VAC   Ventricular arterial coupling 
 
Other symbols 
CE  Ratio of left and right ventricle end systolic elastances 
CO2  Carbon dioxide 
FiO2  Fraction of inspired oxygen 
O2  Oxygen 
PCO2   Partial pressure of carbon dioxide 
SpO2  Pulse oximeter oxygen saturation 
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ABSTRACT 
Cardiovascular disease is highly prevalent in modern society due to a mixture of aging demography 
and sedentary lifestyles. In western countries, it is the leading cause of mortality, and a major, 
growing economic cost. As a result, it is also a major problem in the intensive care unit (ICU). 
In critical care, intensive monitoring is required to help diagnose cardiac and circulatory dysfunction, 
and to provide targets to drive therapy. However, complex interactions between a patient’s disease 
and internal compensatory mechanisms can hide the underlying disorder. Hence, two different 
disease states may look the same in the data available from the range of typical monitoring devices. 
In such cases, correct diagnosis is difficult. Clinical staff must rely on their skill and experience to 
choose therapy, increasing the chance of clinical errors, as well as, increasing variability in care and 
patient outcome. 
To simplify this clinical scenario, a method has been developed to identify patient-specific six-
chamber models of the cardiovascular system (CVS) from typically available ICU measurements. The 
approach utilises a proportional gain parameter identification approach to aggregate available 
hemodynamic measurements into an easy to understand framework of cardiac and circulatory 
physiology. The personalised lumped parameter CVS models provide a unique physiologically and 
clinically relevant expression of a patient’s global cardiovascular state. Therefore, they can be used 
to provide useful information to assist clinical staff with diagnosis and treatment decisions. 
This parameter identification approach was validated in two pig studies on septic shock and acute 
pulmonary embolism. The outputs of the subject-specific CVS models were shown to accurately 
converge to the observed measurements. The modelled maximum left and right ventricular 
pressures and volumes were nearly always predicted within median percentage errors of less than 
20% of measured values, which is acceptable for this type of physiological monitoring. These 
measurements were not used during the identification process. Thus, this result is a true 
independent validation of the parameter identification process. 
The identified CVS models were also able to track known disease-dependent trends in the pigs 
during these studies. In acute pulmonary embolism, as blood clots were inserted into the pigs, an 
increase in the modelled pulmonary vascular resistance was observed, as expected. A large increase 
in the ratio of the right to left ventricular end diastolic volumes was seen in the models of the pigs 
near death. This result shows the pigs could no longer compensate for the effects of the pulmonary 
 xxiv | P a g e  
 
emboli, and thus, indicate that the subject-specific models can be used to monitor the severity of 
pulmonary embolism.  
In septic shock, a decrease in systemic vascular resistance was identified in all the pigs after 
endotoxin infusion. Systemic vascular resistance recovered in two of the pigs after hemofiltration 
therapy was initiated. However, this parameter remained decreased in the other two pigs in the 
study, indicating they were not responding positively to therapy. This study and its results show how 
subject-specific CVS models could be used to monitor the effectiveness of therapy and its ability to 
differentiate between (similar) subjects. It also validates the models and methods for a further 
common CVS dysfunction. 
Patient-specific CVS models were also identified from human measurements in patients who were 
recovering from mitral valve surgery in the Christchurch Hospital ICU (New Zealand). This research 
represents the first real clinical test of the approach on humans in an uncontrolled clinical 
environment. In this study, the CVS models noticed decreased pulmonary vascular resistance, and 
reduced pulmonary vein pressures, were responsible for a drop in pulmonary artery pressures in the 
patients. A decrease in left ventricular contractility was seen in one patient indicating cardiac 
decompensation post-surgery. However, the other patients seemed to recover well with improved 
left ventricular function and decreased pulmonary artery pressures. These results indicate how the 
model-based method can help track the path of cardiac recovery post mitral valve surgery, in the 
first human clinical test of the approach. 
A second component of this thesis involved the development of a model-based method for 
examining morphological changes that occur in the aortic pressure waveform (Pao) due to the effects 
of septic shock. In this model, Pao is separated into two components representing viscous effects of 
flow, called the excess pressure (Pex), and the elastic recoil of the arterial walls to the change in 
volume in the arterial system, called the reservoir pressure (Pwk). Subject-specific aortic models, 
identified from measurements from a porcine study on septic shock, were used to calculate the 
hydraulic work associated with the excess and reservoir pressures (Wex, Wwk). Changes in these 
energetics were compared to metrics derived from left ventricular pressure-volume analysis. Total 
aortic work (Wao=Wex+Wwk) compared well to clinically assessed left ventricular work (R
2=0.88). 
Another strong relationship (R2 = 0.76) was found between the inverse of afterload (1/Ea) and Wex. 
As septic shock progressed, a drop in Wwk was seen, indicating the arterial system loses its ability to 
store the stroke volume (SV) from the ventricle for release during diastole, resulting in a flattening of 
the diastolic pressure. These results indicate that one of the main reasons left ventricular afterload 
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decreases during septic shock is because the arterial system loses its ability to act as a storage 
reservoir. 
Overall, this work developed and presented two model-based methods for analysing, diagnosing, 
and monitoring a variety of common cardiovascular diseases. Parameter identification methods 
were used to combine typically available hemodynamic measurements into a clear physiological 
picture of a patient’s cardiac and circulatory physiology. The resultant patient-specific CVS models 
were shown to track known disease and treatment dependent hemodynamic changes and identified 
key determinants of cardiac function, such as preload, afterload, and contractility. They were able to 
clearly differentiate between subjects and their response to therapy, which is clinically very 
important. Hence, the main accomplishment of this thesis was identifying physiologically accurate 
subject-specific CVS models, from available ICU measurements, for simplifying the monitoring of 
cardiovascular status. These methods provide a feasible and potentially practical means of improving 
care and reducing the economic cost of CVS dysfunction in the ICU. 
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CHAPTER 1:  INTRODUCTION AND MOTIVATION 
The intensive care unit (ICU) treats some of the sickest and most critically ill patients in the hospital. 
The majority of these patients would die without therapeutic intervention. Generally, they suffer 
from a severe patho-physiological disorder and require support for failing organs. Intensive 
monitoring is needed to ensure accurate diagnoses, that the correct therapy is applied, and to track 
the effectiveness of the treatment. However, the overflow of monitored information in the ICU can 
overwhelm human cognitive limits. On the other hand, abstract, indirect, or limited data can make 
the clinical picture unclear. Therefore, patient monitoring in the ICU is a balancing act between 
information levels and clarity in an attempt to optimise decision making. 
Patients with severe cardiovascular disease (CVD) generally require intensive monitoring and 
support (Boldt, 2002, Pinsky, 2007, Tibby and Murdoch, 2003). Cardiovascular dysfunction can occur 
in many areas of the cardiovascular system (CVS) as a result of a wide range of causes, including age, 
congenital defects, and/or illness. Compounding the problem is the fact that cardiac and circulatory 
diseases are extremely common in society and are the largest cause of death in the western world, 
accounting for 37% of deaths in New Zealand (World Health Organisation, noncommunicable 
diseases New Zealand profile) and 48% of deaths in Europe (Allender et al., 2008) in 2008. Moreover, 
it has been estimated that more than 50% of postoperative deaths are caused by cardiac events 
(Mangano, 1994, Ramsay, 1999).  
Because of its high prevalence in society, CVD is a major cause of ICU admission and mortality 
(Ramsay, 1999, Dellinger, 2003, Dellinger et al., 2004, Bahloul et al., 2010). Many admissions to the 
ICU are for cardiac and circulatory monitoring or dysfunction (Walsh et al., 2005, Seferian and 
Afessa, 2006, Dellinger et al., 2004), with many further admissions resulting from cardiovascular 
complications that occur intraoperatively (Tuman et al., 1992, Mangano, 1994, Ramsay, 1999). Even 
in non-cardiac surgery patients, one third have coronary artery disease (CAD), or two or more risk 
factors of CAD, or are older than 65 years (Mangano, 1994). In the United States, the cost of 
cardiovascular complications following an operation is estimated to be 33 billion USD (Mangano, 
1994), which is only a fraction of the overall cost of CVD. This total direct medical cost of CVD is 
approximately $273 billion in the United States (Heidenreich et al., 2011) and is expected triple to 
$818 billion by 2030 (Heidenreich et al., 2011), due to increasing obesity, sedentary lifestyles, and an 
aging population. Hence, the treatment and flow-on effects of cardiovascular disorders will continue 
to be a major clinical and cost burden in the ICU for the foreseeable future. 
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Traditional hemodynamic monitoring in critical care is often constrained by the ease and frequency 
at which measurements can be made and taken. The use, number, and positioning of catheter 
containing sensors is determined by the perceived risk to benefit ratio of inserting the device(s). 
Hence, catheters cannot always be placed in the most ideal position for monitoring a certain 
pathological state. Other factors, including expense and obstruction to clinical work flow, limit the 
regularity at which other measurements are taken, such as with the use of computer tomography 
and echocardiography. Due to these constraints clinicians often do not receive a full picture of a 
patient’s hemodynamic state, which can result in misdiagnosis and incorrect treatment, leading to 
inefficient use of hospital resources, increased length of stay, and death (Angus et al., 2001, Brun-
Buisson, 2000, Franklin and Mathew, 1994, Perkins et al., 2003, Smith et al., 2002). 
Hence, there is a need for improved cardiovascular monitoring in intensive care. Integration of all 
available measurements in a mathematical framework of cardiovascular physiology could be 
employed to continuously predict cardiac and circulatory status in regions that cannot be directly 
measured. Such a method would provide one means to untangle the complex, often confusing 
interactions that occur between different measurements to better reveal a patient’s underlying 
disease state, and therefore, maximise the useful information gained from the available ICU data. 
 
1.1 HEMODYNAMIC MONITORING IN THE ICU 
Hemodynamic monitoring is the first port of call when evaluating the state of critically ill patients in 
the ICU. These patients are monitored to diagnose and identify the severity of cardiovascular 
insufficiency, as well as the response to therapy. The rationale behind cardiovascular monitoring is 
that (Pinsky, 2007): 
• Hemodynamic monitoring can help identify disease even though the link between the 
monitored variable and dysfunction is unknown. 
• Hemodynamic parameters define cardiovascular state, and restoration of these parameters 
to normal values will improve tissue perfusion and patient outcomes. 
• Monitored variables can drive goal-directed therapy in a manner that cannot be otherwise 
predicted. 
However, very simply, when monitored hemodynamic variables do not influence therapy, they 
cannot improve outcome. Hemodynamic monitoring can only provide benefit to the patient when 
coupled with treatment. Hence, the insertion of a catheter in the absence of a defined and effective 
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treatment protocol requiring the information it delivers is unlikely to result in improved 
cardiovascular status (Connors et al., 1996, Pinsky, 2007, Sandham et al., 2003, Yu et al., 2003). This 
fact may be the reason why historically many randomised control trials evaluating a given 
intervention fail to produce significant reduction in mortality (Ospina-Tascon et al., 2008). Thus, in 
recent times, many therapies have been developed that couple monitored variables with treatment.  
Even with advances in clinical practice and available technology, there still exist many limitations in 
current day-to-day, clinical hemodynamic management. Variation in clinical management between 
centres (Kennedy et al., 2010, Wennberg, 2002) means that not all patients are receiving the same 
optimal treatment, which can lead to increased cost and length of stay in these patients (Kennedy et 
al., 2010). Even when therapy is standardised, it is optimised to improve population outcomes and 
may neglect the patient-specific needs of the individual. In more general terms, the information 
gained from available measurements is not always maximised to give the greatest benefit to the 
patient.  
To solve these issues, a model-based system could be used to aggregate available ICU 
measurements in a mathematical framework of cardiovascular physiology. This methodology could 
help provide improved patient-specific targets for goal directed therapies and a means to maximise 
the utilisation of available measurements. Hence, such a method enables a way of standardising 
therapy while still accounting for inter-patient variability.  
 
1.1.1 DATA RICH, BUT INFORMATION POOR 
Many measurements can be taken from the typical ICU patient. However, the information gained 
from these measurements is not always maximised (Pinsky, 2003). For example, it is commonplace 
for the whole arterial pressure waveform to be measured. However, treatment is only based on 
discrete measures derived from the arterial pressure waveform including systolic and diastolic 
pressure. All the clinically useful information stored in the shape of the arterial pressure waveform 
(Thiele and Durieux, 2011) is ignored. This outcome indicates that the measurement of arterial 
pressure is not being optimised in critical care.  
Similarly, monitoring stroke volume (SV) and cardiac output (CO), has in recent times been shown to 
have little effect on patient outcomes (Mutoh et al., 2007, Pinsky, 2007). These particular findings 
are strange, as it is obvious that CO is an important measure of cardiovascular health. Thus, the 
results of these studies indicate that both SV and the arterial pressure waveform, to name two 
examples, are being underutilised in the ICU. 
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A majority of hemodynamic pressure measurements in the ICU are taken continuously by catheters 
attached to digital data acquisition systems. However, most of this data is lost, because, in most 
ICUs, only a discrete manual record of these measurements is kept for each patient on their patient 
data sheet. On this record, measurements of pressure and other vital signs are typically recorded at 
hourly intervals, reflecting a very crude temporal depiction of the patient’s recent history. A 
patient’s state can change markedly within a couple of minutes. Thus, measurements recorded 
hourly are insufficient to describe the continuously changing nature of a patient’s clinically relevant 
hemodynamics. Hence, extreme caution must be used when trying to devise any useful trends from 
the data stored on the patient sheet. 
These brief and simple examples illustrate how the ICU is data rich, but in some respects, 
information poor. The information gained from the measurements in ICU is limited by the manual 
nature in which the measurements are initially processed and recorded on patient data sheets. If 
this process could be automated, which is easily achievable in a modern hospital, complete 
continuous real-time data can be recorded electronically. Automation of the data recording would 
reduce the clinical workload, enable the ability to track hemodynamic trends minute-to-minute or 
beat-to-beat, and allow more advanced processing of the available measurements to obtain further 
insight. Thus, automating the information flow, and maximising the information gathered from 
measurements already taken in the typical ICU, would provide many benefits at little extra cost.    
 
1.1.2 ONE SIZE FITS ALL 
Most new clinical practices are based on empirical findings from large multi-centre randomised 
controlled trials (Vincent, 2004). These evidence-based studies statistically analyse treatments that 
influence average outcomes in the study population (Feinstein and Horwitz, 1997, Tonelli, 1998). 
Hence, most treatments in the ICU have been optimised for the ‘average patient’ in a one size fits all 
approach, overlooking the needs of the individual patient (Charlton, 1997, Sleigh, 1997, Feinstein 
and Horwitz, 1997, Tonelli, 1998).  
However, every patient in the ICU is different. Each patient has a unique expression for a given 
disease or disorder, and a distinct response to the corresponding therapy. Therefore, hemodynamic 
management must be personalised to each patient and not just the ‘average patient’ to improve 
current practice. 
One way to personalise hemodynamic management is to track and monitor patient-specific 
hemodynamic parameters for goal directed therapies. To do this, cardiovascular monitoring must be 
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individualised for each patient to help calculate personalised targets for their treatments. This 
approach would enable therapy to be personalised for each patient, while still utilising current 
treatments. Therefore, treatment can be tailored for the individual rather than for the ICU 
population. Such approaches could be implemented at little extra expense, as current therapy 
techniques would only require a slight protocol adaption to modify or optimise current treatment 
using existing sensors for each patient. Moreover, the approach also has the potential to benefit a 
wider portion of the ICU population as it can be tailored to every patient, including those who do not 
fit the ‘average patient’ profile. 
 
1.1.3 MODEL-BASED APPROACHES 
It has been proposed, and proven, with glycaemia control (Le Compte et al., 2009, Lonergan et al., 
2006, Wong et al., 2008, Chase et al., 2008, Evans et al., 2011) and in other fields (Chase et al., 2011, 
Chiari et al., 1998, Pasterkamp et al., 2005, Uckun et al., 1993), that computer-based models can be 
used to assist medical staff with therapy-based decisions. For a model-based method to be clinically 
viable for hemodynamic monitoring in clinical practice it should: 
• accurately predict static markers of the cardiovascular health, 
• track pathologically important hemodynamic trends, 
• track the effectiveness of treatment, 
• be inexpensive and easy to implement, 
• provide continuous real-time feedback, 
• be an improvement on current hemodynamic monitoring methods. 
If these points can be achieved, a better understanding of the patient’s disease state can be 
obtained at little extra cost and without the need for additional invasive measurements. 
Furthermore, the effectiveness of treatment can be monitored with greater accuracy, ultimately 
leading to improved outcome.  
The benefits of using a model-based method is that it provides a means of personalising 
hemodynamic monitoring. Patient-specific models of the CVS could be identified using commonly 
available ICU data. Identified information gained from the patient-specific models can be used to 
predict the response of hemodynamically unstable patients in the ICU to common clinical 
treatments, to answer critical, “holy grail” questions, such as (Pinsky, 2007): 
• Will fluid resuscitation increase cardiac output?  
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• During hypotension is vascular tone increased, decreased, or normal? 
• Is the heart capable of maintaining cardiac output once arterial pressure is restored or will it 
go into failure? 
Where, at present, it is difficult to answer these questions using the currently available information 
in the ICU (Pinsky, 2007).  
Cardiac and circulatory physiology embedded in these patient-specific models can help extrapolate 
and interpolate between measurements, to approximate hemodynamics in unmeasureable regions 
of the CVS. The method could also provide a way of standardising hemodynamic management while 
still allowing patient-specific treatment. Furthermore, the approach could be applied in real-time, 
and at little extra cost, as it would only require measurements that are already commonly recorded 
in the ICU. Hence, model-based monitoring has many advantages and few disadvantages. 
 
1.2 GOALS OF THIS RESEARCH 
The aim of this thesis is to use patient-specific computer models of the CVS to simplify and improve 
hemodynamic monitoring in critical care. CVS models can be personalised to each patient using 
common ICU measurements to track an individual’s cardiovascular response to a disease or 
treatment. Identified parameters and outputs of these models can provide improved indices of 
cardiovascular health and help better track disease and treatment dependent hemodynamic 
changes. 
This research utilises the physiologically validated CVS model developed by Smith (Smith, 2004, 
Smith et al., 2004) to help identify the cardiovascular phenomena. Smith’s lumped parameter model 
is capable of representing many hemodynamic situations commonly seen in the ICU (Smith et al., 
2007, Starfinger et al., 2008a, Starfinger et al., 2008b, Starfinger et al., 2007) using only a minimal 
number of physiological parameters. Thus, the CVS model provides a good initial platform for 
identifying clinically relevant cardiovascular dynamics. 
Starfinger proposed and developed a method for identifying parameters from Smith’s CVS model 
(Starfinger, 2008, Starfinger et al., 2008a, Starfinger et al., 2008b, Starfinger et al., 2007). However, 
Starfinger’s method could not uniquely identify all the parameters of the CVS model from the 
minimal measurement set available in the ICU. Hence, this research builds on the prior work of 
Starfinger et al (Starfinger, 2008, Starfinger et al., 2008a, Starfinger et al., 2008b, Starfinger et al., 
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2007) in an attempt to try and fully identify patient-specific CVS models from the measurements 
available in intensive care. 
1.3 APPLICATION OF RESEARCH 
In this research, subject-specific models of cardiovascular dynamics were retrospectively fitted to 
porcine measurements to analyse the viability of this approach. Measurements were obtained from 
two pig studies on pulmonary embolism and septic shock. Subject-specific models were 
retrospectively fitted to these measurements to track the progression of disease and internal reflex 
response of the animals. More specifically, the effects of these diseases on identified metrics of 
ventricular preload, contractility, and afterload were analysed.  
The method was also tested retrospectively on human measurements. Patient-specific models were 
fitted to patients recovering from mitral valve surgery. The parameters and outputs of the model 
were analysed to monitor the recovery, response to therapy, and compensation of the left ventricle 
to a new or repaired mitral valve, in these patients. The results of this research provide the first 
human validation of the model identification method. 
Finally, a second model-based method was used to model aortic energetics. The new model was 
identified from porcine measurements to analyse the effects of septic shock on ventricular-vascular 
coupling. This method provides an alternative approach which can be used to model important 
hemodynamic variables when the pulmonary artery pressure is unknown. 
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CHAPTER 2: CARDIOVASCULAR PHYSIOLOGY 
This chapter gives a brief overview of the important aspects of cardiovascular physiology. It is 
designed to provide the essential foundation information required to understand the research, 
models, results, and discussions in the following chapters. 
 
2.1 CARDIOVASULAR SYSTEM OVERVIEW 
The CVS consists of 3 main components including the heart, blood, and blood vessels.  These 
components are responsible for passing nutrients, gases, hormones, blood cells, etc. to and from the 
cells in the body to help maintain homeostasis. The heart acts as the pump for this hydraulic system 
providing the driving force for the flow through the blood vessels by means of repeated rhythmic 
contractions.  The blood vessels make up the two major circuits within the CVS, the systemic 
circulation and the pulmonary circulation, which are connected in series by the heart.  
In the pulmonary circulation, blood is pumped through the right atrium and ventricle into the 
pulmonary artery and through the lungs, where carbon dioxide is exchanged with oxygen. The 
oxygenated blood returns to the heart via the pulmonary vein, where it is pumped through the left 
atrium and ventricle into the systemic circulation, beginning with the aorta. The aorta and arterial 
network deliver blood from the left ventricle to the systemic capillaries providing nourishment to 
body’s tissues. The systemic veins complete the closed circuit system, returning blood from the 
capillaries to the right atrium, to be re-pumped through the pulmonary circulation.  
Figure 2.1 shows an overview of the CVS, and these two primary circuits. Oxygenated blood in the 
pulmonary veins, left heart, and systemic arteries is shown in red. Deoxygenated blood in the 
systemic veins, right heart, and pulmonary arteries is shown in blue. 
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Figure 2.1:  Overview of the anatomy of the cardiovascular system (McKinlay and O'Loughlin, 2007) 
showing the heart, systemic circuit, and pulmonary circuit. 
  
2.2 THE CIRCULATION 
The circulation is split up into two circuits: the systemic circuit and the pulmonary circuit. Both 
circuits are made of three parts: an arterial system, a capillary network, and a venous system. These 
three components are discussed in further detail in the following. 
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2.2.1 ARTERIAL SYSTEM 
The arterial system transports blood from the heart to capillaries. The aorta is the root of the arterial 
system, which receives the blood ejected from the left ventricle via the aortic valve. As the aorta 
branches, and these arteries branch further, they become successively smaller in diameter. The 
smallest are the arterioles which supply the capillaries.  
These arteries can be divided into two types, elastic and muscular, depending on their structure. In 
general, the larger arteries are elastic and the smaller arteries are muscular. The function of the 
elastic arteries is to diffuse the flow pulse ejected from the ventricle, and thus smooth the pressure 
and flow profile of the blood before it reaches the capillaries. Blood flows with almost no resistance 
in these larger arteries.  
In contrast, the resistance to flow is considerable in the much smaller arterioles. These vessels 
control local blood flow and collectively have the greatest influence on systemic blood pressure. The 
arterioles make up the greatest component of, and act to regulate, the resistance of the systemic 
circulation. Hence, they are the principal determinant of flow through the CVS.  
The combination of the elastic arteries and resistance regulating arterioles provide a means for the 
arterial network to distribute a constant flow of blood from the ventricle to capillary beds. This 
blood carries oxygen and nutrient to the tissues. The constant flow through the capillaries ensures a 
consistence and smooth supply of nutrients to the organs across a heartbeat. 
 
2.2.2 THE CAPILLARIES 
The capillaries bridge the arterial and venous systems via a parallel network. The capillaries are 
where all the important exchanges occur in the circulatory system. These exchanges include the 
diffusion and transfer of gases, sugars, hormones, waste products, and other nutrients to 
surrounding tissue. Equally, these surrounding tissues surrender waste products, such as carbon 
dioxide, to be returned via the venous system. Figure 2.2 shows an example of a network of 
capillaries connecting an arteriole and venule. 
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Figure 2.2: Example of capillaries connecting the venous and arterials systems via an arteriole and a 
venule (Starfinger, 2008). 
 
2.2.3 VENOUS SYSTEM 
The venous system returns blood from the capillaries to the heart. Flow enters the venous system 
via transfer between the capillaries and the venules. The venous system transports blood from the 
venules to the heart, via a converging network of veins, which increase in diameter as they approach 
the heart. The walls of these veins are thin and very compliant and can expand to store blood, if 
required. They are thus complimentary to the arterial system controlling the venous return of blood 
to the heart. 
 
2.3 THE HEART 
2.3.1 ANATOMY 
The heart is the main pump of the CVS. It consists of two sides and four distinct chambers. The left 
side, including the left atrium and left ventricle chambers, pumps oxygenated flow from the 
pulmonary veins into the aorta. The right side, consisting of the right atrium and right ventricle 
chambers, pumps deoxygenated flow from the vena cava into the pulmonary artery. The sides of the 
heart are separated via two septal walls one situated between the atria and the other between the 
ventricles. 
Four heart valves control flow between these chambers. The mitral (or left atrioventricular) and 
aortic (aortic semilunar) valves regulate the flow in and out of the left ventricle, and the tricuspid 
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(right atrioventricular) and pulmonary artery (pulmonary semilunar) valves regulate flow in the right 
ventricle.  These valves ensure one way flow through heart, avoiding regurgitation, allowing pressure 
to build in the ventricles during myocardium contraction.  
All the chambers of the heart are encapsulated inside a fibrous sac called the pericardium. The 
pericardium provides a reactor wall against which the heart can push as it pumps blood. The 
structure of the heart is illustrated on Figure 2.3. Please note the pericardium is not included in 
Figure 2.3 but can be seen in Figure 2.12. 
Superior vena cava
Right pulmonary arteries
Right pulmonary veins
Right atrium
Tricuspid Valve
Chordae tendineae
Right ventricle
Inferior vena cava
Aorta
Left pulmonary 
arteries
Left pulmonary 
veins
Left atrium
Semilunar valves
Mitral valve
Left ventricle
Septum
 
Figure 2.3: Anatomical features of the heart not including the pericardium. 
 
2.3.2 ELECTRICAL ACTIVATION 
Each contraction of the heart is initiated by an electrical stimulus. A region of the heart called the 
sinoatrial node acts as the pacemaker for these contractions controlling the rate at which cardiac 
muscle cells contract. At the start of a heartbeat, electrical impulses produced in the sinoatrial node 
cause contraction in the atria. At the same time, action potentials travel to the atrioventricular node 
via intermodal pathways. Here, the electrical impulses are delayed by approximately 0.1s, before 
being conducted through the bundle of His to the bundle branches. The stimulus travels through 
these branches, via the purkinje fibres, exciting the endocardium at the apex of the heart, and finally 
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the ventricular myocardium, into contraction. The total travel time of the electrical impulses from 
the sinoatrial node to the ventricular myocardium, is approximately 0.19s in normal individuals. The 
total cycle between electrical pulses is approximately 0.8s, equivalent to a single heartbeat. An 
illustration of the electrical conduction pathway in the heart is shown in Figure 2.4. 
1. Sinoatrial node
2. Atrioventricular
node
3. Bundle of His
4. Left bundle branch
5. Left posterior 
fascicle
6. Left anterior 
fascicle
7. Left ventricle
8. Ventricular septum
9. Right ventricle
10. Right bundle 
branch
 
Figure 2.4: Electrical conduction system of the heart. Picture modified from the work of (Lynch and 
Jaffe, 2006). 
  
The electrical impulses produced during the heart cycle conduct throughout the body. On the skin 
these impulses can be detected using an electrode and recorded as an electrocardiogram (ECG). An 
example of an ECG is shown in Figure 2.5. On the ECG, the P-wave represents the conduction of 
electrical impulses through the atria, the QRS-complex depicts the spread of electrical activity 
throughout the ventricular myocardium, and the T-wave portrays the repolarisation of the 
ventricles, the last event of the electrical cycle. 
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Figure 2.5:  Electrocardiogram showing the P-wave, QRS complex, and T wave. 
 
An electrochemical mechanism turns the electrical impulses in the heart into muscle contraction.  
When myocardial cells are stimulated above a certain threshold voltage-gated calcium channels 
open allowing positively charged Ca2+ to enter the cell. These ions cause depolarisation in the cell 
resulting in muscle contraction. After a delay, potassium channels open resulting in a flow of K+ out 
of the cell causing repolarisation and relaxation of the myocardial cell. Hence, the cell returns to its 
resting state, until it is re-stimulated. 
The electrical activation of the heart controls the sequence of the events that occur within the 
cardiac cycle. The electrical impulses, initiated by the sinoatrial node, set the heart rate and instigate 
heart muscle contraction. Furthermore, the pathway of electrical conductance ensures the atria 
contract prior to the ventricles to keep the heart running efficiently. Hence, the sinoatrial node and 
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electrical conductance pathway play an important role in ordering the mechanical events of the 
cardiac cycle. 
 
2.3.3 THE CARDIAC CYCLE 
The electrochemical reaction in the heart causes the myocardium to repeatedly contract and relax. 
This contraction and relaxation of the heart can be broken up into four segments representing one 
full cardiac cycle. The contractile phase in the cardiac cycle is called systole, representing an 
isovolumetric contraction period followed by ventricular ejection.  The relaxation phase is called 
diastole which consists of a short isovolumetric relaxation segment followed by filling. Figure 2.6 
shows the relationship between the electrical activation of the heart and left ventricular dynamics 
during the filling, contraction, ejection, and relaxation phases of the cardiac cycle. 
These four stages of the cardiac cycle can be described with reference to the pressure and volume in 
the ventricle, flows in and out of the mitral and aortic valves, and pressures in the left atrium and 
aorta, as shown on Figure 2.6. During ventricular filling left atrial pressure is higher than left 
ventricular pressure. Hence, the mitral valve opens and blood flows into the left ventricle. This filling 
phase ends at the beginning of contraction, when the myocardium begins to contract, causing left 
ventricular pressure to increase, resulting in closure of the mitral valve. Isovolumetric contraction 
follows, where pressure increases sharply with little change in volume. When ventricular pressure 
increases above aortic pressure, the aortic valve opens, indicating the beginning of the ejection 
phase and causing blood to be ejected into the aorta. Ventricular ejection continues until the 
myocardium starts to relax and ventricular pressure decreases, causing the aortic valve to close. A 
short isovolumetric relaxation period follows, where pressure decreases quickly with little change in 
volume. The mitral valve opens once ventricular pressure drops below the left atrial pressure, and 
the whole cycle starts again.  
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Figure 2.6:  Example of the cardiac events which occur during the cardiac cycle. Two complete 
cardiac cycles are illustrated showing the pressures in the left atrium, left ventricle, and aorta; 
volume in the left ventricle; and electrocardiogram.  
 
2.4 BASIC CONCEPTS 
The cardiac cycle can also be analysed via ventricular pressure-volume (P-V) loops. Figure 2.7 shows 
an example of a ventricular P-V loop. A given P-V loop is confined between the end diastolic pressure 
volume relationship (EDPVR) and the end systolic pressure volume relationship (ESPVR). The 
difference between the end diastolic volume (EDV, maximum ventricular volume) and the end 
systolic volume (ESV, minimum ventricular volume) represents the stroke volume of the ventricle. 
 ESVEDVSV −=  (2.1) 
 
 The arterial load on the ventricle (Ea) can be inferred from the relation between end systolic 
pressure (ESP) and SV on the P-V loop (Kelly et al., 1992), as shown on Figure 2.7.  
 SV
ESPEa =  (2.2) 
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Moreover, the area enclosed by the P-V loop represents the hydraulic work done by the ventricle 
over one heartbeat.  
Changes in the shape of the P-V loop reflect alterations in cardiac state, including changes in 
preload, afterload, and contractility of the ventricle, which are defined in Sections 2.4.1, 2.4.2, and 
2.4.3 respectively. However, P-V loops do not reveal temporal factors, such as changes in heart rate, 
which is another important determinant of cardiac function. The combination of these four factors: 
• Preload 
• Afterload  
• Contractility 
• Heart rate 
determine the amount of forward flow, cardiac output, and the blood pressure in the cardiovascular 
system. 
Ventricle volumeV0 = Volume at zero pressure 
Vd = Unstressed chamber volume
 
Figure 2.7:  Pressure-volume loop showing the four phases of the cardiac cycle. The pressure volume 
loop is confined below the end systolic pressure-volume relationship (ESPVR) and above end 
diastolic pressure-volume relationship (EDPVR). The arterial elastance (Ea) reflects the arterial load 
imposed on the ventricle. The stroke volume of the ventricle is the difference between the end 
diastolic volume (EDV) and end systolic volume (ESV). Qav and Qmt represent flow through the aortic 
and mitral valves.  
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2.4.1 PRELOAD 
Preload is the end volumetric pressure that stretches the ventricle to it greatest geometrical 
dimension during a heartbeat. Strictly speaking, it is defined as the initial stretch of a single cardiac 
cell prior to contraction. However, it is not feasible to measure the stretch of a cardiac cell in vivo. 
Hence, in practice, the more clinically available measurement of EDV is often used to represent 
preload. 
Physiologically, preload plays an important role in determining stroke volume, and consequentially 
cardiac output. Increased ventricular filling, or preload, augments the stroke volume, whereas 
decreased ventricular filling drops stroke volume. In other words, the ventricular muscles contract 
with more force when they are preloaded or stretched prior to contraction (Frank, 1895, Starling and 
Visscher, 1927). This mechanism is commonly known as the Frank-Starling mechanism (see Section 
2.6.2).  
Figure 2.8 shows the effects of changing preload on the ventricular P-V loops. In this example, 
preload is considered to be the EDV of the ventricle, and ventricular contractility and afterload are 
kept constant. It is seen that an increase in preload causes an increase in SV and systolic pressure in 
the ventricle. SV increases because EDV increases more than end diastolic volume. The opposite 
effects are seen when the preload is decreased. 
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Figure 2.8: Effect of changing preload (end diastolic volume) on the ventricular pressure volume 
loop. The control pressure-volume loop is plotted in black. 
 
 19 | P a g e  
 
Many factors influence the preload on the ventricle (Klabunde, 2004) including but not limited to:  
• Venous return and pressure 
o Venous tone 
o Total blood volume 
o Respiration 
• Outflow resistance and afterload 
• Ventricular compliance 
• Atrial contractility 
Clinically, preload can be improved through fluid resuscitation, which increases total blood volume, 
augmenting venous return and venous pressure, increasing the volume in the ventricle (O'Neill and 
Perrin, 2002). However, positive pressure ventilation increases intrathoracic pressure (Pth), which 
augments atrial pressure, decreasing the pressure gradient driving flow back to the heart (Pinsky, 
2005, Shekerdemian and Bohn, 1999, Soni and Williams, 2008). Hence, venous return drops, 
diminishing both preload and SV. These two examples indicate how common therapies can be used 
to influence preload. However, other factors, such as disease and auto regulatory responses, can 
also significantly alter ventricular blood volume. Therefore, it can be difficult to determine the main 
reasons for changes in preload in clinical setting.  
 
2.4.2 AFTERLOAD 
Afterload is the load against which the heart must contract to eject blood. It is technically defined as 
the tension or stress developed in the wall of the ventricle during ejection. Under normal healthy 
conditions, afterload is imposed on the heart by the arterial system. However, during cardiovascular 
disease, afterload can be augmented by factors other than the properties of the arterial system, 
such as aortic stenosis. There are several measurements or surrogates that reflect afterload, 
including: 
• Aortic or arterial pressure (Pao) 
• Systemic resistance (Rsys) 
• Arterial impedance (Za) 
• Arterial elastance (Ea)   
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Arterial elastance (Ea) is the gold standard clinical measure of afterload (Kelly et al., 1992). Changes 
in Ea are used to analyse the effects of afterload on the ventricular P-V loops, as illustrated in Figure 
2.9. An increase in afterload, independent of changes in contractility and preload, causes an increase 
in systolic pressure and a decrease in SV. However, a decrease in Ea causes increased SV and 
decreased systolic pressure. 
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Figure 2.9: Effect of changing afterload (arterial elastance, Ea) on the ventricular pressure volume 
loop. The control pressure-volume loop is plotted in black. 
 
In the ICU, afterload can be altered through the administration of vasoactive drugs. Drugs that cause 
vasodilation decrease afterload by decreasing vascular tone, increasing vascular diameter and 
decreasing resistance to flow. Whereas, vasoconstriction results in a narrowing of blood vessels, 
and, as a consequence, increases resistance to flow and afterload. In a setting where blood pressure 
is measured, such as in the ICU, vasoconstrictor and vasodilator agents can be titrated to alter 
afterload and achieve a desired blood pressure. 
 
2.4.3 CONTRACTILITY 
Ventricular contractility represents the ability of the myocardium to contract independent of 
changes in preload and afterload. The gold standard measure of contractility is end systolic elastance 
(Ees) (Grossman et al., 1977, Sagawa, 1981, Suga et al., 1973) represented by the slope of the ESPVR 
on Figure 2.7 . This relationship defines the maximum pressure that can be produced by the ventricle 
for a given unit of volume, for any one heartbeat. Ees is often considered to be relatively constant 
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over a normal range of loading conditions for a given inotropic state (Kass et al., 1987), and thus, it 
can be represented by the following relationship: 
 
des
es
es VV
P
E
−
=  
(2.3) 
 
where Pes and Ves are the end systolic pressure and volume in the ventricle and Vd is the unstressed 
volume.  
The effects of Ees on the ventricle P-V loops are shown in Figure 2.10. Increased contractility leads to 
a rise in systolic pressure and SV. Conversely, decreased contractility results in a drop in systolic 
pressure and SV. 
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Figure 2.10: Effect of changing contractility (slope of ESPVR, Ees) on the ventricular pressure volume 
loop. The control pressure-volume loop is plotted in black. 
 
In the ICU patient, contractility can be altered through the use of inotropes (Paolocci et al., 2003, 
Sagawa, 1981, Suga et al., 1983). Positive inotropic agents increase myocardial contractility, and 
hence, augment SV. While, negative inotropic agents decrease myocardial contractility, and can be 
used to decrease cardiac workload. 
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2.4.4 HEART RATE 
Heart rate (HR) is the number of heartbeats which occur within a minute. As mentioned in Section 
2.3.2, HR is determined by the rhythm produced by the sinoatrial node. It is the inverse of the 
interval between adjacent R-waves as seen on the ECG (Figure 2.5).  
During treatment, chronotropic drugs can be use to change HR by affecting the rhythm produced by 
the sinoatrial node. Positive chronotropes increase HR, whereas negative chronotropes decrease HR. 
 
2.4.5 CARDIAC OUTPUT 
Cardiac output (CO) is the volume of blood pumped by the heart over one minute. It is defined as:  
 SVHRCO ⋅=  (2.4) 
 
Where HR is the heart rate (beats per minute) and SV is the stroke volume (in litres). Hence, CO 
(litres/minute) is a product of HR and also preload, afterload, and contractility, which effect SV.  
In a healthy person, CO adjusts to meet the metabolic demands, ensuring sufficient oxygen and 
nutrient supply to the cells of the body. However, detrimental changes in CO can be caused by 
cardiovascular disorders, especially in hypotension and heart failure, creating an imbalance between 
nutrient supply and metabolic demand. Cardiovascular disorders can be associated with an increase 
in CO, as occurs during septic shock (MacLean et al., 1967), or a decrease in CO, as for example in 
cardiogenic shock (Hollenberg et al., 1999, Hochman and Ohman, 2009) and hypovolemia 
(Kreimeier, 2000). These diseases and disorders are common problems in the ICU (Martin et al., 
2003, Hochman and Ohman, 2009, Antonelli et al., 2007). Hence, the ability to monitor, and 
accurately interpret the reasons for changes in, CO in critical care is of great importance. 
In the ICU, CO can be continuously estimated using a number of pulse pressure analysis methods 
(Cottis et al., 2003, Linton et al., 1993, Opdam et al., 2007). These methods are normally calibrated 
against a dilution technique (Cottis et al., 2003, Opdam et al., 2007). In general they are well 
accepted measures. 
 
2.4.6 BLOOD PRESSURE 
Blood pressure is one of the principal vital signs used to guide therapy in critical care. It represents 
the pressure exerted on the vascular walls in the CVS. The term ‘blood pressure’ when used without 
 23 | P a g e  
 
specification, normally refers to arterial pressure of the systemic circulation. During each heartbeat 
blood pressure varies between a maximum systolic pressure (Psys) and a minimum diastolic pressure 
(Pdia). This pressure is principally produced by the pumping action of the heart. The flow ejected 
from the heart is converted to pressure by the resistance of the vasculature. Differences in blood 
pressure cause blood to flow through the CVS. Mean blood pressure decreases as flow moves away 
from the heart, through the arteries, capillaries and veins, due to the effects of viscosity. 
Mean arterial pressure (MAP) is the average of arterial pressure over one heartbeat. It can be 
represented by the product of CO and total peripheral resistance (TPR) plus central venous pressure 
(CVP) (Stouffer, 2008). 
 
 CVPTPRCOMAP +×=  (2.5) 
 
In a healthy person normal autonomic reflex responses regulate vascular resistance and the output 
of the heart to ensure a suitable blood pressure. However, cardiovascular disorders can cause 
abnormal changes in the heart’s output and resistance of the blood vessels, which overwhelm reflex 
responses, and, as a result, alter blood pressure. Hence, monitoring blood pressure can help assess 
pathological induced changes in cardiac function and vascular tone.  
In the ICU, blood pressure is often monitored using invasive, fluid filled catheters, which are inserted 
into the radial or femoral artery. These catheters provide a continuous measurement of the arterial 
pressure waveform. From the waveform, MAP is often estimated from Psys and Pdia, while there is a 
normal resting heart rate (Stouffer, 2008). 
( )diasysdia PPPMAP −+≈ 3
1
 (2.6) 
 
2.4.7 SUMMARY OF CONCEPTS 
Preload, afterload, contractility, and heart rate are the four main independent determinants of 
cardiovascular performance. The product of these factors contributes to the blood pressure and 
cardiac output observed in the circulation. For example, in this fundamental model of cardiovascular 
performance, if CO increases while preload, afterload, and heart rate are held constant, then the 
change in CO must be due to the change in contractility. The same principles apply if preload, 
afterload, or heart rate were changed independently of the other metrics, as summarised in Table 
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2.1. Hence, analysis of these factors can be used to help interpret patho-physiological and treatment 
dependent changes that occur in the CVS. 
 
Table 2.1: The effect on stroke volume (SV), cardiac output (CO), and blood pressure (BP) when one 
of preload, afterload, contractility, or heart rate are changed independent of the other factors. 
Intervention Effect 
SV CO BP 
↑ Preload ↑ ↑ ↑ 
↑ Afterload ↓ ↓ ↑ 
↑ Contractility ↑ ↑ ↑ 
↑ Heart Rate - ↑ ↑ 
 
 
2.5 INTERDEPENDENCE OF PRELOAD, AFTERLOAD AND CONTRACTILITY 
The previous section presented the independent effects of preload, afterload, and contractility. In 
reality, these factors are interdependent. Hence, the interaction between these factors also plays an 
important part in determining cardiovascular performance. 
 
2.5.1 PRELOAD  AFTERLOAD 
Increased preload augments the SV of the ventricle. This change leads to increased CO and arterial 
blood pressure, causing the afterload on the ventricle to increase, partially offsetting the increased 
SV by increasing ESV (Klabunde, 2004). Conversely, a decrease in preload reduces SV, which is 
partially offset by a decrease in afterload. Hence, there is a proportional dependency between 
preload and afterload. 
 
2.5.2 AFTERLOAD  PRELOAD 
Increased afterload causes the heart to eject a smaller SV, predominantly due to an increased ESV. 
With more volume remaining at the end of systole, the ventricle fills to a greater EDV after diastole. 
This increase in EDV is smaller than ESV, so SV is still decreased. However, as a secondary effect, 
preload is partially increased (Klabunde, 2004). Hence, there exists a proportional relationship 
between afterload and preload.  
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2.5.3 CONTRACTILITY  PRELOAD 
Increased contractility causes the heart to eject a larger SV, mostly due to decreased ESV. With less 
blood volume remaining in the ventricle after ejection, the ventricle fills to a smaller EDV during 
diastole (Klabunde, 2004). This secondary effect results in a decrease in preload on the ventricle, 
although the drop in EDV is smaller than ESV, so SV is still increased. The opposite effect is seen if 
contractility is decreased. Therefore, changes in contractility have an inverse effect on preload. 
 
2.5.4 SUMMARY OF PRELOAD, AFTERLOAD AND CONTRACTILITY INTERDEPENDENCE 
In the CVS, preload, afterload, and contractility interact with each other. This interdependence 
generally acts like a negative feedback mechanism, partially offsetting large changes in SV and BP. A 
summary of the main interactions between preload, afterload and contraction is shown in Table 2.2. 
 
Table 2.2: Summary of the interdependence between preload, afterload, and contractility. Please 
note that the magnitudes of the secondary and tertiary effects are smaller than the magnitude of 
the primary intervention. SV, stroke volume; BP, blood pressure; ESV, end systolic volume; EDV, end 
diastolic volume. 
Primary Intervention Secondary Effect 
Result Effect Result Effect 
↑ Preload SV↑ & BP↑ ↑ Afterload ESV↑ & SV↓ 
↑ Afterload SV↓ & BP↑ ↑ Preload EDV↑ & SV↑ 
↑ Contractility SV↑ & BP↑ ↓ Preload EDV↓ & SV↓ 
 
2.6 HOMEOSTASIS MECHANISMS 
There exist many homeostasis mechanisms within the cardiovascular system. These reflex actions 
help maintain the balance of metabolic demand and nutrient supply in the body. In the CVS, neural 
regulation, auto regulatory mechanisms, and humoral regulation make up the three main types of 
homeostasis mechanisms. 
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2.6.1 NEURAL REGULATION 
Neural regulation represents the homeostasis mechanisms that act via the autonomous nervous 
system. These control mechanisms act through two main pathways: 1) the parasympathetic nervous 
system; and 2) the sympathetic nervous system. The sympathetic nervous system promotes the 
‘fight or flight’ response in the body by increasing heart rate and contractility, and diverting blood 
flow to skeletal muscle and the lungs. In contrast, activation of the parasympathetic nervous system 
causes a ‘rest and digest’ response decreasing heart rate and contraction, and diverting blood to the 
gastro-intestinal tract to improve digestion. An example of neural regulation is the baroreflex 
(Klabunde, 2004). 
The baroreflex is one of the body’s mechanisms for maintaining blood pressure. It provides a 
negative feedback loop, in which an elevated blood pressure causes heart rate to decrease, and, in 
consequence, a decrease in blood pressure. Similarly, decreased blood pressure activates the 
baroreflex, causing heart rate and blood pressure to increase. The baroreflex is activated via 
baroreceptors, which make up a system of pressure sensors around the CVS that communicate with 
the sympathetic and parasympathetic nervous systems. Elevated blood pressure causes sympathetic 
inhibition and parasympathetic activation, leading to decreased heart rate. Conversely, lowered 
blood pressure results in sympathetic activation and parasympathetic inhibition. These factors cause 
vasoconstriction, and increased heart rate and contractility,  and thus, an increase in blood pressure. 
Hence, the baroreflex helps to lessen the effects of acute changes in arterial pressure. 
 
2.6.2 AUTO REGULATORY MECHANISMS 
In this thesis, auto regulatory mechanisms refer to local mechanisms that help maintain 
homeostasis, independent of neural factors. Some of the main auto regulatory mechanisms in the 
CVS include: 1) circulatory auto regulation; 2) the Frank-Starling mechanism; 3) the Anrep effect; and 
4) the Bowditch effect.  
Circulatory auto regulation refers to local blood flow regulation. It is defined as the intrinsic ability of 
an organ to maintain a constant blood flow despite changes in perfusion pressure (Klabunde, 2004). 
Most organs of the body show some degree of auto regulation. However, it is most noticeable in the 
vital organs, including the brain, heart and the kidney (Klabunde, 2004). When perfusion pressure, 
defined as arterial minus venous pressure (Pa –Pv), across these organs falls, blood flow (Q) 
decreases as described by the following relationship: 
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R
PPQ va −=  (2.7) 
 
To increase flow, the small arteries and arterioles dilate causing arterial resistance (R) to drop. As a 
result, blood flow increases in response to the decreased resistance (Klabunde, 2004). Thus, 
circulatory auto regulation ensures the blood flow, and thus oxygen, is diverted to the parts of the 
body where it is most needed. 
The Frank-Starling mechanism (or law) states that the SV of a ventricle increases in response to 
increased volume of blood filling that ventricle (EDV).  The increased volume stretches the 
ventricular wall, causing the myocardium to contract more forcefully, and produce a larger SV 
(Frank, 1898, Frank, 1895, Guyton and Hall, 2000, Starling and Visscher, 1927). This mechanism 
allows the heart to act like a ‘demand pump’ in that it ejects whatever blood it receives from the 
venous return. This functionality ensures intrinsic synchronisation between the cardiac output and 
the venous return, without the need for external regulation. 
The Anrep effect represents the intrinsic ability of the heart to increase contractility in response to 
increased afterload (Anrep, 1912). The significance of this effect is that the increase in contractility 
partially compensates for the decreased SV during increased afterload. Without this function, 
increased afterload would cause greater reduction in SV than normally observed. 
The Bowditch effect (or Treppe phenomena) represents a frequency-force relationship of myocardial 
contractility (Bowditch, 1871, Klabunde, 2004). When HR is increased, CO is elevated through an 
increased number of heart beats per minute. In a healthy heart, increased frequency also leads to a 
rise in contractility (Bowditch, 1871, Klabunde, 2004) known as the Bowditch effect. However, in a 
failing myocardium, the relationship between heart rate and contractility may be inversed.  
 
2.6.3  HUMORAL REGULATION 
Humoral regulation refers to the control of circulatory dynamics through the release and absorption 
of hormones and ions into the body’s fluids. Some of these substances are produced in special 
glands and are transported in bloodstream throughout the body. In contrast, other substances are 
formed in localised areas of the CVS and only cause localised circulatory effects.  These substances 
can cause vasoconstriction and vasodilation within the CVS, and hence, provide a means of 
controlling the relationship between pressure and flow. One example of the humoral regulation is 
the renin-angiotensin system (Klabunde, 2004). 
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The rennin-angiotensin system is a hormone system that regulates pressure and volume in the CVS. 
When blood volume is low the kidney releases renin into the blood stream. Renin initiates a 
chemical process leading to production of angiotensin II, a potent vasoconstrictor. The resulting 
vasoconstriction of the vessels causes blood pressure to increase (Klabunde, 2004).  Angiotensin II 
also stimulates the secretion of aldosterone which increases the volume of fluid in the body 
(Klabunde, 2004) and, as a result, also increases blood pressure. 
 
2.7 VENTRICULAR INTERACTION 
Inter-ventricular communication plays a significant part in defining ventricular dynamics. The main 
physical conduits for this parallel interaction between the ventricles are the inter-ventricular 
septum and the pericardium (Williams and Frenneaux, 2006). 
 
2.7.1 INTER-VENTRICULAR SEPTUM 
The inter-ventricular septum is an active muscular membrane separating the left and right 
ventricular chambers. It is normally convex towards the right ventricle, as seen in Figure 2.11. 
Changes in the pressure difference between the ventricles can cause the septum to shift, altering 
the ratio of volume between the chambers. Hence, the septum acts to balance the pressure and 
volume between the left and right ventricles.  
During right ventricular distension and pulmonary hypertension, the septum is pushed towards the 
left ventricle (Atherton et al., 1997). This left-ward shift decreases left ventricular preload, 
compromising left ventricular function (Atherton et al., 1998). Therefore, analysis of the septum 
motion can be diagnostic of specific cardiac dysfunction. 
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Figure 2.11: Cross-sectional schematic of heart showing normal position of inter-ventricular septum 
(S) with respect to the left ventricle (LV) and right ventricle (RV), from (Starfinger, 2008). 
  
2.7.2 PERICARDIUM 
The pericardium is a passive fibrous sac that encapsulates the entire heart, as seen in Figure 2.12. 
When the total volume of the heart increases, the pericardial sac stretches, exerting an added 
pressure on the heart chambers. Therefore, the pericardium acts to stop the heart overfilling by 
acting as a reaction wall against which the heart exerts pumping pressure (Elzinga et al., 1974, Little 
and Freeman, 2006). Moreover, the pericardium appears to play an important bi-ventricular role in 
compensating for sudden changes in the atrial volumes (Kroeker et al., 2003). However, pericardium 
disorders can thus significantly affect the heart’s ability to pump blood, as in pericarditis (Little and 
Freeman, 2006). 
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Pericardium
Pericardium
 
Figure 2.12: Illustration of the pericardium (Starfinger, 2008). 
 
2.8 CARDIOPULMONARY INTERACTION 
The cardiovascular and pulmonary systems are highly integrated to ensure end organ perfusion and 
oxygenation. Due to this high integration, and the close proximity of the heart and lungs, there exists 
strong mechanical cardiopulmonary coupling. Hence, the pressures and volumes in the lungs affect 
cardiovascular dynamics.  
Changes in respiratory dynamics influence hemodynamics via the alteration of intrathoracic pressure 
and pulmonary vascular resistance (Pinsky, 2005, Shekerdemian and Bohn, 1999, Soni and Williams, 
2008). The effects of cardiopulmonary interaction are normally well tolerated in healthy individuals. 
However, they can be detrimental to the hemodynamics of critically ill patients in the presence of 
cardiac or pulmonary pathologies. Moreover, the use of positive pressure ventilation can amplify 
these effects, negatively or positively modifying cardiovascular pressures, volumes, and flows. 
Hence, it is important to understand cardiopulmonary interaction when trying to analyse cardiac and 
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circulatory function. In this section, respiratory induced changes in cardiovascular dynamics are 
discussed through analysis of intrathoracic pressure and lung volume. 
 
2.8.1 INTRATHORACIC PRESSURE 
Intrathoracic pressure (Pth), also known as intrapleural pressure, represents the pressure in the 
thoracic cavity. The heart and pulmonary vessels reside inside the thoracic chamber. Therefore, 
changes in Pth influence the pressures within the heart chambers, and affect the pressure gradients 
of both the venous return to the right ventricle and outflow to the left ventricle.  A rise in Pth, 
increases right atrial pressure, and decreases transmural left ventricular systolic pressure (Pinsky, 
2005, Shekerdemian and Bohn, 1999, Soni and Williams, 2008). Both these factors reduce the 
pressure gradients of venous return and left ventricle ejection, leading to decreases in intrathoracic 
volume (Pinsky, 2005). The opposite occurs when Pth decreases, resulting in increased intrathoracic 
volume. 
During spontaneous, unassisted breathing Pth is normally negative, augmenting venous return at the 
cost of added left ventricle afterload (increased left ventricle transmural pressure), which is easily 
compensated for in a healthy subject. On the other hand, positive pressure ventilation increases Pth 
and right atrial pressure, decreasing venous return and preload, resulting in diminished stroke 
volume and cardiac output (Pinsky, 2005, Shekerdemian and Bohn, 1999, Soni and Williams, 2008). 
Therefore, positive pressure ventilation generally has a negative effect on left ventricle filling. 
However, higher Pth reduces left ventricle afterload, which may outweigh the cost of decreased 
venous return in patients with compromised cardiac function (Pinsky, 2005). 
 
2.8.2 LUNG VOLUME 
Pulmonary vascular resistance (PVR) represents the resistance of blood flow through the lungs. 
During spontaneous inspiration lung volume increases causing the alveoli capillaries to stretch, 
increasing PVR, through decreasing the cross sectional area of these vessels. During forced 
expiration Pth becomes positive causing the lung volume to decrease. The positive Pth compresses 
the extra-alveolar vessels (larger pulmonary arteries and veins) causing the resistance in these 
vessels to increase. Hence, at low lung volumes the resistance of the extra-alveolar vessels is largest, 
whereas, at high volumes the resistance of the alveolar capillaries dominate. The combination of 
both these components that contribute to PVR means there is optimal volume range, around 
functional residual capacity (FRC), where PVR is minimal (Levitzky, 2007), as shown by Figure 2.13. 
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Figure 2.13: Effect of lung volume on pulmonary vascular resistance (PVR). PVR is lowest near 
function residual capacity (FRC) and increases as lung volume decreases towards residual volume 
(RV) or increases to total lung capacity (TLC) (Shekerdemian and Bohn, 1999).  
 
The oscillatory changes in pulmonary vascular resistance during spontaneous breathing result in 
transient increases in right ventricle preload. These increases cause the inter-ventricular septum to 
shift leftward, decreasing left ventricle preload. These respiratory induced changes in ventricular 
interaction, result in transient decreases in left ventricle SV, and, as a consequence, inspiratory-
associated decreases in arterial pulse pressure, known as pulsus paradoxus (Pinsky, 2005). 
During positive pressure ventilation, the inflated lungs result in increased PVR and may lead to 
pulmonary hypertension. However, the increased pressure and lung volume also help reduce the 
effects of hypoxic pulmonary vasoconstriction, symptomatic of acute hypoxemic respiratory failure, 
which causes alveolar collapse and a decrease in PVR (Pinsky, 2005). Hence, increased lung volume 
and pressure may decrease PVR if it reverses hypoxic vasoconstriction (Pinsky, 2005). Otherwise, 
lung inflation will increase PVR, increasing pulmonary pressures and may precipitate acute right 
ventricle failure. 
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During hyperinflation the lungs compress against the heart. This added external force on the heart 
causes ventricular preload to decrease, leading to decreased cardiac output. However, with 
sufficient fluid resuscitation, preload and CO can be returned to their original levels (Pinsky, 2005). 
 
2.9 VENTRICULAR ARTERIAL COUPLING 
Ventricular arterial coupling (VAC) reflects the interaction between the ventricle and the arterial 
system. It describes the relationship between ventricular contractility and afterload and is normally 
represented as the ratio of the end systolic ventricular elastance over the arterial elastance (Ees/Ea) 
(Sunagawa et al., 1983). This ratio defines the efficiency of which the myocardium is pumping blood 
through the arteries. Theoretically, optimal transmission from the ventricles to arteries occurs when 
Ees/Ea is between 1 and 2 (Starling, 1993). A low Ees/Ea is reflective of myocardial dysfunction (Asanoi 
et al., 1989) or hypertension (Osranek et al., 2008), where the contractility of the heart can no 
longer maintain optimal efficiency. A high VAC can be seen during hypotension, such as in sepsis 
(Lambermont et al., 2004), where a drop in vascular tone leads to a decrease in afterload. The 
compromised afterload causes arterial pressure to drop, in the presence of adequate cardiac output, 
indicating inefficient energy transfer between the ventricle and arterial system. 
VAC is an important measure of pumping efficiency. However, it is not used clinically as it is difficult 
to measure. Ea can be estimated from the arterial pressure waveform. However, determination of Ees 
requires invasive measures of the left ventricular pressure volume loop. Hence, a non-invasive 
method for accurately estimating VAC, to optimise the ratio of contractility and afterload in the CVS, 
would be of significant benefit when trying to optimise treatments in the ICU.  
 
2.10 SUMMARY 
This chapter outlined an overview of cardiac and circulatory anatomy and basic hemodynamic 
concepts. The idea of preload, afterload, and contractility were introduced along with principles of 
ventricular interaction and cardiopulmonary integration. These fundamental concepts are used as 
the physiological foundation for the development of the mathematical CVS model presented in the 
next chapter. 
 
  Cardiovascular System Model 
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CHAPTER 3: CARDIOVASCULAR SYSTEM MODEL 
A cardiovascular system (CVS) model is used to describe cardiac and circulatory dynamics. This 
lumped parameter model is used to represent and simulate the essential dynamics and features of 
the CVS, while only requiring a minimal number of parameters. The CVS model presented in this 
chapter has been previously published by Smith et al (Smith, 2004, Smith et al., 2004, Smith et al., 
2005, Smith et al., 2006) and Starfinger (Starfinger, 2008). This model provides a framework of 
cardiovascular physiology for which patient-specific cardiac and circulatory metrics can be identified 
to help monitor cardiovascular disorders and treatments (please see Chapters 4, 5, 6, 7, and 8). 
 
3.1 INTRODUCTION 
The model presented simulates the main hemodynamics of the cardiovascular system. The aim is to 
accurately represent all the important hemodynamics using a minimal number of parameters. The 
goal of this approach is to optimise the balance between accuracy and complexity. To optimise this 
ratio a six-chamber lumped parameter model was developed, representing a closed loop system of 
the left and right ventricles and the systemic and pulmonary circulations.  Such a model can be used 
to represent the cardiac and circulatory state of the CVS in a variety of pathological, physiological,  
and clinical conditions (Revie et al., 2011a, Smith et al., 2007, Smith et al., 2006, Starfinger et al., 
2008a, Starfinger et al., 2008b).  
Figure 3.1 shows a schematic of the CVS model made of six elastic chambers connected in series by 
resistances, inductors, and diodes. The diodes represent heart valves and the inductors describe the 
inertial effects of blood flowing into and out of the ventricular chambers. The resistances capture 
the pressure drop between chambers as blood flows through the circulation. The six elastic 
chambers simulate the pressure volume relationship in the: 
• Left ventricle (lv) 
• Aorta (ao) 
• Vena cava (vc) 
• Right ventricle (rv) 
• Pulmonary artery (pa) 
• Pulmonary veins (pu) 
  Cardiovascular System Model 
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Due to the lumped parameter nature of the model, each chamber actually represents an average or 
sum of a number of smaller physiological chambers. The aortic chamber describes the summed 
elastance of all the large arteries and not solely the dynamics of the aorta. Similarly, the pulmonary 
artery chamber simulates the elastance of the main arteries feeding the lungs. The vena cava and 
pulmonary vein chambers represent the main veins of their respective circulations and they also 
incorporate the elastances of their adjacent atriums. Hence, the model of Figure 3.1 divides the CVS 
into six lumped blood reservoirs representing the main hemodynamic components of the circulation. 
P, V
Left
Ventricle
P, V
Pulmonary
Vein
P, V
Right
Ventricle
P, V
Pulmonary
Artery
P, V
Vena
Cava
P, V
Aorta
Qsys
Qtc
Qpv
Qpul
Qmt
Qav
Rav
Rsys
Rtc
Rpul
Rpv
Rmt
Lav
Ltc
Lpv
Lmt
Septum
Pericardium
Thoracic Cavity
Ees,lvf Ees,rvf
Eao
Evc
EpaEpu
 
Figure 3.1: Schematic of the cardiovascular system model with elastances (E), resistances (R), and 
inertance (L). The circles represent pressure-volume (P, V) chambers. The subscripts represent: mt, 
mitral; es, end systolic; lvf, left ventricle free wall; av, aortic valve; sys, systemic; tc, tricuspid; pv, 
pulmonary valve; rvf, right ventricle free wall; pul, pulmonary; pu, pulmonary vein. 
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The left and right ventricles act as the pumps for the model and are dynamically elastic. The non-
linear relationship between pressure and volume in these chambers is simulated using normalised 
time-varying elastance, also known as the driver function. The other chambers are passively elastic, 
and thus, modelled using constant elastance, enforcing a linear relationship between pressure and 
volume.   
The series of resistances (R) and inertances (L) define the flow between the elastic chambers. Each R 
represents the pressure drop between adjacent chambers and each L defines the pressure gradient 
required to cause a change in flow-rate. Pressure- and flow-gated valves (Hann et al., 2005, Smith et 
al., 2004) describe flow through the heart valves (mitral, aortic, tricuspid, and pulmonary), which 
open when the upstream pressure is higher than the downstream pressure and close when the flow 
through the valves becomes negative. These heart valves are shown as diodes in Figure 3.1. As with 
elastance, these resistance and inertance parameters represent the lumped effects of the flow. 
Parallel interaction between the systemic and pulmonary circulations is also modelled through left 
and right ventricular coupling. The effects of the inter-ventricular septum that separates the 
ventricles, and the pericardium that encapsulates the heart, are simulated to account for inter-
ventricular interaction, as seen in Figure 3.1. Furthermore, the effects of respiration, which acts on 
every chamber excluding the aortic, can be simulated via changes in the thoracic pressure, as shown 
in Figure 3.1. The difference between the model shown in Figure 3.1 and the model of Smith et al. 
(Smith et al., 2004) is that the vena cava chamber now sits inside the thoracic cavity, and hence, is 
influenced by changes in thoracic pressure during breathing. This change more realistically 
represents the effects on the circulation by decreasing the afterload on the ventricle when 
intrathoracic pressure is positive (Pinsky, 2005, Shekerdemian and Bohn, 1999, Soni and Williams, 
2008). 
The following sections of this chapter develop the basic concepts and mathematics of the CVS model 
previously described in (Smith, 2004, Smith et al., 2005, Smith et al., 2006, Starfinger, 2008).  The 
interaction between pressure, volume, and flow in the CVS is described using elastance, resistance, 
and inertia. Governing equations will be developed for a one chamber passive model and a one 
chamber ventricular model, along with equations for heart valve flow and ventricular interaction. 
The cardiovascular system will then be discretised and specific equations will be defined for each 
chamber. Finally, the validity of the model assumptions and equations will be discussed in Section 
3.6. 
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3.2 MODEL ASSUMPTIONS 
Several assumptions were required to minimise the number of parameters in the CVS model. These 
assumptions include: 
• Conservation of mass 
• Poiseuille flow 
• Constant elastance (in passive chambers) 
• Constant resistance 
• Constant inertance 
• No backflow through heart valves 
• Linear ESPVR 
• Exponential EDPVR 
• Effects of atria are small 
The validity of these assumptions is discussed in Section 3.6. 
 
3.3 MODEL DEVELOPMENT 
The following sections develop and introduce the governing equations (shown in grey) and 
accompanying equations used to describe the CVS model.  
 
3.3.1 PASSIVE CHAMBER 
A single elastic chamber is represented by the circle in Figure 3.2. This figure illustrates the 
pressures, volumes, and flows acting on the chamber. 
Qin(t) Qout(t)
E, Vd
P(t),V(t)
 
Figure 3.2: Single passively elastic chamber.  
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Pressure and volume in the chamber can vary with time (P(t), V(t)) and are related to each other 
through constants representing the elastance and unstressed volume of the chamber (E, Vd). V(t) 
represents the stressed volume and Vd is the unstressed volume that does not contribute to 
increases in P(t).  Changes in V(t) are dependent on the flow in and out (Qin, Qout) of the chamber. 
Hence, a differential equation (DE) can be derived by considering a mass balance over the chamber. 
 
 )()()( tQtQtV outin −=&  (3.1) 
 ( )dVtVEtP −= )()(  (3.2) 
 
These governing equations of the CVS model represent the interaction between pressure, volume 
and flow in a single passive chamber. These equations are used to represent the pressure-volume 
relationship in non-cardiac chambers, specifically, the aorta, vena cava, pulmonary artery, and 
pulmonary vein as shown in Figure 3.1. 
 
3.3.2 INTER CHAMBER FLOW (NON-VALVULAR) 
Flow between adjacent chambers is illustrated by Figure 3.3. In this example, the upstream and 
downstream chambers act as two time varying pressure sources (P1(t) and P2(t)).  
P1(t) P2(t)
Q12(t)
R12
 
Figure 3.3:  Schematic of inter chamber flow 
 
Flow between the chambers (Q12) is dependent on the pressure difference, P1(t) – P2(t), and the 
resistance to flow R12, which is assumed to be constant. Thus, assuming poiseuille flow the following 
governing equation for non-valvular flow can be derived: 
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3.3.3 HEART VALVE FLOW 
A schematic of flow through a heart valve is shown in Figure 3.4. In this illustration, P1(t) could be the 
ventricular pressure and P2(t) would be the pressure of the downstream artery. However, the same 
methodology can be used to represent flow into the ventricles, where P2 becomes the ventricular 
pressure and P1 is the upstream venous pressure.  
P1(t) P2(t)
Q12(t)
R12 L12
 
Figure 3.4: Illustration of flow across a heart valve. 
 
The diode in Figure 3.4 represents a heart valve and the inductor (L12) represents the inertance of 
blood flowing through the valve. It is assumed that there is no backwards flow through the heart 
valve. A non-linear differential equation (DE) can be used to describe the flow (Q12) across the heart 
valve: 
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A Heaviside function (H(x), where H=0 when x<0 and H=1 when x >0) is used to enforce forward flow 
though the heart valve. The valve opens when the pressure difference, P1-P2, is greater than zero, as 
there is initially no flow through the valve during diastole. It closes when the change in flow 
becomes negative. 
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3.3.4 VENTRICULAR CHAMBERS 
The pressure-volume relationship in a ventricular chamber is more complicated than that in the 
passive chambers. Due to the effects of myocardial contraction the pressure-volume relationship is 
non-linear in these chambers. Time varying elastance is the most commonly used method of 
describing pressure-volume interaction in the ventricle (Beyar et al., 1987, Burkhoff and Tyberg, 
1993, Chung et al., 1997, Santamore and Burkhoff, 1991). Maximum and minimum limits for this 
time-varying elastance are usually defined by the end systolic and end diastolic pressure volume 
relationships (ESPVR, EDPVR), as shown on Figure 3.5.  
ESPVR has been found to be quasi-linear over a physiological range of loading conditions. This 
relationship describes the maximum pressure that can be produced by the ventricle for a certain 
volume. Similarly, EDPVR describes the minimum pressure produced by the ventricle for a certain 
volume. Both these relationships are commonly modelled using a straight line (ESPVR) and 
exponential curve (EDPVR) (Amoore et al., 1992, Campbell et al., 1990, Suga et al., 1973, Weber et 
al., 1982). Thus, due to their relative simplicity, the most commonly used equations for modelling 
ESPVR and EDPVR are defined (Beyar et al., 1987, Chung et al., 1997, Santamore and Burkhoff, 
1991): 
 ( )deses VVEVP −=)(  (3.5) 
 ( ) ( )( )1exp 0V-V0 −= λPVPed  (3.6) 
 
The end systolic pressure (Pes) is related to volume (V) using end systolic elastance (Ees) and the 
unstressed chamber volume (Vd), which define a linear relationship. The end diastolic pressure (Ped) 
is also a function of volume and is characterised by an exponential equation with constants P0, λ, and 
V0, which control the gradient, curvature, and volume at zero pressure. Both the ESPVR and EDPVR 
are plotted on Figure 3.5. The use of time varying elastance (E(t)) allows the dynamic ventricular 
chambers to increase (and decrease) pressure even when there is no change in volume, consistent 
with the contraction (and relaxation) phase of the cardiac cycle.  Hence, E(t) provides a means to 
simulate the pumping action of the heart and acts as the driving function for the CVS model.  
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Ventricle volumeV0 = Volume at zero pressure 
Vd = Unstressed chamber volume
 
Figure 3.5: A standard pressure volume loop showing the four stages of the cardiac cycle and the 
end systolic (es) and end diastolic (ed) pressure volume relationships (ESPVR and EDPVR). Qav and 
Qmt are the flows in and out of the ventricle.  Stroke volume (SV) is the difference between the end 
diastolic and end systolic volumes (EDV –ESV). Afterload is represented by Ea in the diagram. 
 
Segers et al. (Segers et al., 2000b, Segers et al., 2000a) experimentally showed in a canine study that 
pressure and volume could be linearly related to each other using a non-constant E(t).  
 
 ( )dVtVtEtP −= )()()(  (3.7) 
 
where P(t) and V(t) are the pressure and volume in the cardiac chamber. A more useful approach 
incorporates the ESPVR and EDPVR (Smith, 2004) of Equations (3.5) and (3.6). To apply this method a 
cardiac driver function (e(t)), normalised between 0 and 1, is used to relate ESPVR and EDPVR. At 
end systole, e(t) = 1, its maximum value, and at end diastole e(t) = 0, its minimum value. Figure 3.6 
shows an example of a driver function (also known as time varying elastance) of a healthy pig that 
illustrates how e(t) varies between 0 and 1 over one heartbeat. Therefore, the pressure in a 
dynamically elastic chamber can be related using a weighted sum of Equations (3.5) and (3.6), where 
the weighting is defined by the value of e(t). 
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 ( ) 1)(0)()(1)()(),( ≤≤−+= teVPteVPtetVP edes  (3.8) 
∴  ( ) ( ) ( )( )1exp)(1)(),( 0V-V0 −−+−= λPteVVEtetVP des  (3.9) 
 
Equation (3.9) is the governing equation used for relating pressure to volume in dynamically elastic 
chambers, such as in the ventricular chambers.  
 
Figure 3.6: Example of a normalised left ventricular driver function (elv(t)) for a healthy pig. 
 
Figure 3.7 shows a schematic of a ventricular chamber with heart valves. P2(t) and V2(t) represent 
the ventricular pressure and volume. Q12(t) and Q23(t) describe the inlet and outlet flow through 
their corresponding heart valves. 
P2(t)
V2(t)
Q12(t)
R12 L12
Q23(t)
R23 L23
P1(t) P3(t)
Ees, Vd, 
P0, λ, V0
e(t)
 
Figure 3.7: Schematic of a dynamically elastic chamber, where P2(t) represents the ventricular 
pressure. 
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3.3.5 VENTRICULAR INTERACTION 
Inter-ventricular communication plays a significant part in defining cardiovascular dynamics, where 
interaction between the two ventricles occurs through the inter-ventricular septum and via the 
pericardium, as discussed earlier in Section 2.7.2. Hence, it is important to model this 
interdependence between the ventricles. Figure 3.8 shows schematically how ventricular interaction 
can be incorporated in a CVS model. The two bold lines connecting the ventricles symbolise the 
septum and the dash-lined rectangle represents the pericardium. The volume displaced by the 
septum and the pressure produced by the pericardium are symbolised by the time-varying variables 
Vspt and Ppcd. The flows, Qlv,in, Qrv,in, Qlv,out, and Qrv,out represent the time-varying inlet and outlet flows 
of the ventricles. 
Plv(t)
Vlv(t)
Qlv,in(t) Qlv,out(t)
Ees,lv, Vd,lv, 
P0,lv, λlv, 
V0,lv
elv(t)
Prv(t)
Vrv(t)
Qrv,out(t) Qrv,in(t)
Ees,rv, 
Vd,rv, P0,rv, 
λrv, V0,rv
erv(t)
Pericardium
Vspt(t)
Ppcd(t)
 
Figure 3.8: Adding ventricular interaction, via septum and pericardium dynamics (Vspt, Ppcd), to the 
left and right ventricular chambers (lv, rv).  
 
The equations used to describe septum and pericardium dynamics in this research have been 
previously described in detail by Smith et al (Smith et al., 2004, Smith, 2004). Hence, in this section, 
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the development of these equations is only briefly reiterated. The volume definitions required to 
define the volumes used in the ventricular model are shown in Figure 3.9. The left ventricular, right 
ventricular, and septal free wall volumes (Vlvf, Vrvf, Vspt) are theoretical volumes (not physical 
volumes) which represent portions of the overall true ventricular volumes (Vlv and Vrv). These free 
walled definitions are used to relate deflection in the cardiac free walls to the actual ventricular 
volumes. 
As seen in Figure 3.9, the left and right ventricular free wall volumes are defined: 
 sptlvlvf VVV −=  (3.10) 
 sptrvrvf VVV +=  (3.11) 
 
The septum in a relaxed state normally deflects slightly into the right ventricle. Hence, the sign 
convention used in the CVS model is that a positive septal volume (Vspt) indicates deflection into the 
right ventricle, as shown in Figure 3.9.  
The pericardium volume is defined as the sum of the ventricular volumes: 
 rvflvfrvlvpcd VVVVV +=+=  (3.12) 
 
The pericardium volume used in the CVS model excludes the volume of the atria and myocardium, 
although these details can be easily added if desired.  
 
 
Figure 3.9: Cross-section of the left and right ventricles showing the volume definitions used to 
calculate the septum volume (Vspt) and pericardium pressure (Ppcd) (Smith, 2004). 
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The non-linear pressure-volume relationship defined in Equation (3.8) is used to relate the chamber 
volumes to pressures. All cardiac related pressures are shown in Figure 3.10. These pressures are 
defined:  
 perilvflv PPP +=  (3.13) 
 perirvfrv PPP +=  (3.14) 
 thpcdperi PPP +=  (3.15) 
 
where Plvf, Prvf, and Ppcd represent the pressure differences across the walls of the left ventricle, right 
ventricle, and pericardium. Pth defines the pressure in the thoracic cavity. Note that, in the CVS 
model Pth is added to the pressure in every chamber except for the aortic, as shown in Figure 3.1.  
 
Figure 3.10: Cross-section of the ventricles and pericardium showing the definitions of all the cardiac 
pressures (Smith, 2004). 
 
Subtracting Equation (3.14) from Equation (3.13) gives the septal pressure (Pspt) defined as the 
pressure difference across the septum. 
 
 rvflvfrvlvspt PPPPP −=−=  (3.16) 
 
These transmural pressures (Plvf, Prvf, Pspt, Ppcd) represent the force or stretch applied to each free 
wall. Plvf, Prvf, and Pspt are related to their corresponding ESPVR and EDPVR relationships by Equation 
(3.8), giving: 
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 lvfedlvlvfeslvlvf PePeP ,, )1( −+=  (3.17) 
 rvfedrvrvfesrvrvf PePeP ,, )1( −+=  (3.18) 
 sptedsptsptessptspt PePeP ,, )1( −+=  (3.19) 
 
The pressure across the pericardium (Ppcd) passively reacts to changes in volume, whereas the other 
pressures are actively changing with respect to volume. Hence, a different relationship is used to 
define Ppcd, similar to the EDPVR of Equation (3.6). 
 
( )( )1exp)( ,0
,0 −=
− pcdpcdpcd VV
pcdpcdpcd PVP
λ
 (3.20) 
 
where P0,pcd,  λpcd, and V0,pcd, define the gradient, curvature, and volume at zero pericardial pressure. 
Finally, combining Equations (3.9)-(3.11) and (3.16)-(3.19) gives an equation relating Vspt to Vlv and 
Vrv: 
 
( ) ( ) ( )( )
( ) ( ) ( )( )
( ) ( ) ( )( )1exp1
1exp1
1exp1
,0
,0
,0
,0,,
,0,,
,0,,
−−−−+−
−−+−−=
−−+−
−+
−−
−
rvfsptrvrv
lvfsptlvlvf
sptsptspt
VVV
rvfrvrvfdsptrvrvfesrv
VVV
lvflvlvfdsptlvlvfeslv
VV
sptsptsptdsptsptesspt
PeVVVEe
PeVVVEe
PeVVEe
λ
λ
λ
 (3.21) 
 
Through the use of Equations (3.10)-(3.21) the effects of parallel interaction between the ventricles 
can be quantified. This outcome allows the important effects of ventricular interaction to be 
captured in the CVS model. 
 
3.4 MODEL EQUATIONS 
The governing equations, Equations (3.1), (3.2), (3.3), (3.4), and (3.9), developed in Section 3.3, are 
used to define the specific equations for the pressures, volumes, and flows in a closed-loop model of 
the CVS (Starfinger, 2008, Smith et al., 2004, Smith, 2004). A list and description of the model 
outputs are shown in Table 3.1. Table 3.2 defines the parameters of the CVS model. The 
discretisation of the governing equations is shown below. 
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A simple mass balance, described by Equation (3.1), is used to define the change in volume in each 
of the six CVS chambers. 
  avmtlv QQV −=&  (3.22) 
 sysavao QQV −=&  (3.23) 
 tcsysvc QQV −=&  (3.24) 
 pvtcrv QQV −=&  (3.25) 
 pulpvpa QQV −=&  (3.26) 
 mtpulpu QQV −=&  (3.27) 
 
Equation (3.3) is used calculate non-valvular flow through the systemic and pulmonary capillary 
beds. 
 
sys
vcao
sys R
PPQ −=  
(3.28) 
 
pul
pupa
pul R
PPQ −=  (3.29) 
 
Applying Equation (3.4), non-linear DEs can be derived for flow through each of the valves (mitral, 
aortic, tricuspid, and pulmonary): 
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The pressures volume relationships of the non-cardiac chambers, including the aorta, vena cava, 
pulmonary artery, and pulmonary vein, are characterised by a linear relationship, defined by 
Equation (3.2).  
 ( )aodaoaoao VVEP ,−=  (3.34) 
 ( ) thvcdvcvcvc PVVEP +−= ,  (3.35) 
 ( ) thpadpapapa PVVEP +−= ,  (3.36) 
 ( ) thpudpupupu PVVEP +−= ,  (3.37) 
 
Note that thoracic pressure is added to the vena cava, pulmonary artery, and pulmonary artery 
chambers, as these chambers are assumed to reside inside the thoracic cavity. 
The pressures in the cardiac chamber are modelled using Equation (3.9).  
 ( ) ( ) ( )( )1exp1 ,0,0,, −−+−= − lvflvflvf VVlvflvlvfdlvflvfeslvlvf PeVVEeP λ  (3.38) 
 ( ) ( ) ( )( )1exp1 ,0,0,, −−+−= − rvfrvfrvf VVrvfrvrvfdrvfrvfesrvrvf PeVVEeP λ  (3.39) 
 
The free-wall volumes in these equations, Vlvf and Vrvf, are calculated taking septum interaction into 
account. 
 sptlvlvf VVV −=  (3.40) 
 sptrvrvf VVV +=  (3.41) 
 
The actual left and right ventricular pressures are related to free-wall pressures through 
consideration of pericardium dynamics: 
 perilvflv PPP +=  (3.42) 
 perirvfrv PPP +=  (3.43) 
where, 
 thpcdperi PPP +=  (3.44) 
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Finally, both septal and pericardial dynamics (as previously described by Equations (3.20) and (3.21)) 
are calculated using the following equations: 
 
( ) ( ) ( )( )
( ) ( ) ( )( )
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PeVVEe
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 (3.45) 
 
 
( )( )1exp)( ,0
,0 −=
− pcdpcdpcd VV
pcdpcdpcd PVP
λ
 (3.46) 
 
These 25 equations (Equations (3.22)-(3.46)) define a closed loop model of the CVS. The model 
represents all the major dynamics of the CVS, including one-way heart valves, ventricular 
interaction, and time varying myocardium activation. Thus, the CVS model can be used to accurately 
represent important hemodynamics resulting from a healthy or compromised cardiovascular state.  
Table 3.2 and Table 3.1 define the parameters and outputs of the CVS model. The parameter values 
listed in Table 3.2 representative of a healthy human. 
 
Table 3.1: List of CVS model outputs (* denotes output is a state variable). 
Symbol Name Value 
Plv Left ventricular pressure mmHg 
Pao Aortic pressure mmHg 
Pvc Vena cava pressure mmHg 
Prv Right ventricular pressure mmHg 
Ppa Pulmonary artery pressure mmHg 
Ppu Pulmonary vein pressure mmHg 
Vlv* Left ventricular volume ml 
Vao* Aortic volume ml 
Vvc* Vena cava volume ml 
Vrv* Right ventricular volume ml 
Vpa* Pulmonary artery volume ml 
Vpu* Pulmonary vein volume ml 
Qmt* Mitral valve flow ml/s 
Qav* Aortic valve flow ml/s 
Qsys Systemic vascular flow ml/s 
Qtc* Tricuspid valve flow ml/s 
Qpv* Pulmonary artery flow ml/s 
Qpul Pulmonary vascular flow ml/s 
Vspt Septum volume ml 
Ppcd Pericardium pressure mmHg 
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Table 3.2: List of CVS model parameters and their corresponding value for a healthy human.  
Symbol Name Units Value 
Ees,lvf Left ventricular end systolic elastance mmHg/ml 2.8798 
Eao Aortic elastance mmHg/ml 0.6913 
Evc Vena Cava elastance mmHg/ml 0.0059 
Ees,rvf Right ventricular end systolic elastance mmHg/ml 0.5850 
Epa Pulmonary artery elastance mmHg/ml 0.369 
Epu Pulmonary vein elastance mmHg/ml 0.0073 
Rmt Mitral valve resistance mmHg.s/ml 0.0158 
Rav Aortic valve resistance mmHg.s/ml 0.018 
Rsys Systemic vascular resistance mmHg.s/ml 1.0889 
Rtc Tricuspid valve resistance mmHg.s/ml 0.0237 
Rpv Pulmonary vein resistance mmHg.s/ml 0.0055 
Rpul Pulmonary vascular resistance mmHg.s/ml 0.1552 
Lmt Mitral valve inertia mmHg.s
2/ml 7.6968e-5 
Lav Aortic valve inertia mmHg.s
2/ml 1.2189e-4 
Ltc Tricuspid valve inertia mmHg.s
2/ml 8.0093e-5 
Lpv Pulmonary valve inertia mmHg.s
2/ml 1.4868e-4 
Vd,lvf Unstressed left ventricular volume ml 0 
Vd,ao Unstressed aortic volume ml 0 
Vd,vc Unstressed vena cava volume ml 0 
Vd,rvf Unstressed right ventricular volume ml 0 
Vd,pa Unstressed pulmonary artery volume ml 0 
Vd,pu Unstressed pulmonary vein volume ml 0 
P0,lvf Left ventricular EDPVR gradient parameter mmHg 0.1203 
P0,rvf Right ventricular EDPVR gradient parameter mmHg 0.2157 
λlvf Left ventricular EDPVR curvature parameter 1/ml 0.033 
λrvf Right ventricular EDPVR curvature parameter 1/ml 0.023 
Ees,spt End systolic septum elastance mmHg/ml 48.754 
V0,lvf Zero-pressure left ventricular volume ml 0 
V0,rvf Zero-pressure right ventricular volume ml 0 
P0,spt Zero-volume septum pressure mmHg 1.1101 
P0,pcd Zero-volume pericardium pressure mmHg 0.5003 
V0,spt Zero-pressure septum volume ml 2 
V0,pcd Zero-pressure pericardium pressure ml 200 
λspt Septum lambda 1/ml 0.435 
λpcd Pericardium lambda 1/ml 0.03 
Vd,spt Unstressed septum volume ml 2 
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3.5 SIMULATION 
The CVS model is simulated by solving the system of DEs. The program ODE45 from the software 
package, Matlab, is used to solve for the state variables. The state vector (x) is defined: 
 [ ]pupapvrvtcvcaoavlvmt VVQVQVVQVQx ,,,,,,,,,=  (3.47) 
 
Left and right ventricular time varying elastances (elv and erv) act as the driver functions for this 
system of equations. These functions can be derived on a patient-specific basis using the method of 
Stevenson et al. (Stevenson et al., 2012a, Stevenson et al., 2012b) or can be calculated directly from 
measured data. Both these methods produce a discrete signal representation of the driver function. 
The following equations are used to calculate elv and erv from measured data: 
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These equations are derived from Equation (3.50), where Vd is assumed to be zero and E(t) is 
normalised to be between 0 and 1, giving elv(t) for the left ventricle and erv(t) for the right ventricle. 
When a personalised driver function cannot be created, a general analytical equation can be used to 
describe the driver functions of both ventricles (Hann et al., 2005, Hann et al., 2006): 
 
( )22/80exp)( Ttte −−=  (3.51) 
 
where T is the period of a heartbeat. The driver function for the septum is calculated as the average 
of elv and erv: 
 2
)()()( tetete rvlvspt
+
=  (3.52) 
 
  Cardiovascular System Model 
52 | P a g e  
 
A function can also be used to model the effects of respiration to the CVS model, by making the 
thoracic pressure (Pth) some function of time. 
 )(tfPth =  (3.53) 
 
Parameter values used to simulate a healthy cardiovascular state are shown in Table 3.2. To run the 
CVS model a set of initial conditions are required for the state vector (x0):  
[ ]5.808,0.43,0,7.90,1.190,8.329,3.133,0,7.94,5.2450 =x  (3.54) 
 
These values were used for the initial conditions in this example as they were found to be close to 
the steady state values for healthy human parameters. 
Before simulation of the CVS model the ODE solver options are optimised to ensure accurate and 
timely convergence. Relative and absolute tolerances are set to 1x10-6 for ODE45. Two different 
maximum step size limits are used during the simulations. When Equation (3.51) is used to produce 
the driver functions a maximum step size of 0.01s is implemented. However, when Equation (3.48) 
and (3.49) are utilised 0.001s is used for this setting because the ODE solver requires a smaller time 
step to accurately solve regions of sharp curvature in the solution that are introduced by the 
measured driver functions. Once these ODE solver options have been set the model is simulated for 
a time span of 20 heartbeats to ensure steady state conditions are reached. The model is then re-
simulated for another three heartbeats, using the outputs of the previous simulation as initial 
conditions, to enforce a steady state simulation. The remaining outputs, which are not state 
variables, are calculated post simulation, using Equations (3.28) - (3.46), to conclude the complete 
simulation of the closed loop CVS model defined for a given parameter set. 
Healthy human parameters, as seen in Table 3.2, and the analytical driver function of Equation 
(3.51), were used to simulate the model. An example of some of the important model outputs are 
shown in Figure 3.11. The values shown in Equation (3.54) were used as initial conditions. The 
thoracic pressure (Pth) is set to -4mmHg, which is a typical value for a healthy human (Levitzky, 
2007). 
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Figure 3.11: Example of some of the simulated CVS model outputs for healthy human parameters 
and analytically derived driver functions (elv and erv). These outputs include left ventricular pressure 
(Plv), aortic pressure (Pao), left ventricular volume (Vlv), right ventricular pressure (Prv), pulmonary 
artery pressure (Ppa), and right ventricular volume (Vrv). 
 
3.6 DISCUSSION 
3.6.1 VALIDITY OF ASSUMPTIONS AND MODELLING CONCEPTS 
All models, by definition, are imperfect approximations. In this work, several assumptions were 
made to simplify the modelling approach, as outlined in Section 3.2. The main assumptions include 
linear pressure-volume and linear pressure-flow relationships for peripheral flow, exclusion of atria, 
and that the chambers represent large sections of the CVS. It is important to be aware of these 
assumptions, as they impact on the physiological accuracy of the simulated outputs of the CVS 
model. 
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Physiologically, in the model, each chamber simulates a larger section of the circulation than 
indicated by the specific name of each chamber. The non-cardiac chambers actually represent whole 
regions of the circulation. For example, the aortic chamber models the effects of all the large elastic 
arteries. Thus, the parameters of the model define the lumped or average effects of each of the six 
modelled regions of the CVS. 
Flow is modelled assuming a Poiseuille profile, which represents incompressible, Newtonian, 
laminar, axi-symmetric, fully developed flow through a rigid tube of constant cross-section. Hence, 
the following standard assumptions are applied to all equations governing flow: 
• Blood is assumed incompressible (White, 1991). 
• Although flow is not continuous in the capillaries, blood in the larger vessels is assumed to 
behave in a continuous Newtonian manner (Fung, 1993). 
• The blood vessels are assumed to be rigid with constant cross-sectional area. This 
assumption is consistent with windkessel theory involving a rigid pipe and elastic chamber. 
The rigid pipe component simulates the fluid dynamics and the elastic chamber models the 
compliance of the artery walls (Tsitlik et al., 1992, Melchior et al., 1992). 
• Laminar uni-directional axi symmetric flow is assumed. Although there is some flow 
turbulence, especially around the heart valves, it is assumed not to affect the flow profile 
significantly. 
• Flow is assumed to be fully developed meaning the velocity profile is invariant along the 
vessels (Fung, 1993). 
Through the use of these assumptions, vascular flow is commonly modelled using a simple electrical 
circuit analogy (Beyar et al., 1987, Burkhoff and Tyberg, 1993, Chung et al., 1997, Olansen et al., 
2000, Smith et al., 2004), as shown by Equation (3.3).  
Conversely, flow through the heart valves is pulsatile. Hence, it is not fully developed. To 
compensate for this issue an inertial component is added to account for the effects of the time 
varying flow. Thus, the inertia due to the acceleration of blood can be modelled, as defined by 
Equation (3.4).  
All elastance, resistance, and inertance parameters in the CVS model are considered as constants. 
This is a commonly made assumption for this type of lumped parameter modelling (Beyar et al., 
1987, Olansen et al., 2000, Ursino, 1999, Wang et al., 2003). First, elastance, which is the inverse of 
compliance, stays relatively constant over a physiological range of venous pressures in the venous 
system (Batzel and Bachar, 2010). Moreover, although it is widely accepted that lumped arterial 
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compliance/elastance is non-linear with respect to pressure (Batzel and Bachar, 2010, Li et al., 1990, 
Westerhof et al., 2009), Fogliardi et al. showed there was no advantage in using non-linear arterial 
compliance over linear arterial compliance in their analysis of different windkessel models (Fogliardi 
et al., 1996). Hence, we are justified in using a linear elastance to represent the lumped pressure 
volume relationship in the arterial and venous chambers in the CVS model. 
Second, heart valve resistance has been suggested to be a more clinically useful than other indices of 
valve function (Antonini-Canterin et al., 1999). It represents a more functional index of valve 
impairment than the anatomical index of valve area (Antonini-Canterin et al., 1999) and has been 
shown to be less flow dependent in several studies (Antonini-Canterin et al., 1999) (Ford et al., 1994, 
Casale et al., 1992, Blitz and Herrmann, 1996, Bermejo et al., 1996, Ford et al., 1990), although these 
findings have been questioned (Blais et al., 2001, Mascherbauer et al., 2004). The formulation of 
valve resistance has the advantage that it can be easily combined with other hemodynamic 
calculations (Ford et al., 1994), as seen in the CVS model. Hence, the lumped valve resistance, which 
assumes a linear relationship between pressure difference and flow, has been used to represent 
valve function in the CVS model.  
Third, as flow through the systemic and pulmonary capillaries is relatively steady, the resistance to 
flow in these regions can be considered constant, as explained above for poiseuille flow. Finally, the 
effects of inertia are only small in the model. Thus, calculating a variable inertance would add 
substantial complexity with little benefit for the model. Therefore, the elastances, resistances, and 
inertances of the heart valves are set as constants in the CVS model.  
The ventricular pressure-volume relationship is defined by the ESPVR and EDPVR. Experimental and 
clinical studies have shown that the ESPVR is linear over a physiological range of loading conditions 
(Sagawa, 1981) (Kass et al., 1987, Grossman et al., 1977, Kass and Maughan, 1988, Kass et al., 1988, 
Suga et al., 1973). Therefore, ESPVR can be modelled as a linear function, as shown by Equation (3.5) 
and Figure 3.5. The EDPVR is most commonly modelled using an exponential function in the 
literature (Guyton and Hall, 2000), which provides a good approximation for the relationship over a 
wide range of loading conditions. Therefore, an exponential equation (Equation (3.6)) was used to 
model the EDPVR, as shown in Figure 3.5 
The effects of the atria have been ignored in the model as they have only a small influence on 
cardiac and circulatory trends. In the model, the vena cava and pulmonary vein chambers represent 
the lumped effects of the large veins leading to the heart and atria. So, in effect, the atria are partly 
represented in the CVS model. However, separate atria chambers can be added to the model if the 
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need arises for the atria to be independently modelled, as done by Pironet et al. (Pironet et al., 
2012). 
 
3.6.2 SIMULATION 
To run a simulation of the CVS model, analytical equations with respect to time are required for the 
driver functions, as ODE45 is a variable time-step solver. However, discrete signals are produced 
when the driver functions are calculated from measured data using Equations (3.48) and (3.49). 
Hence, when analytical formulas for the driver functions are not used, Fourier series approximations 
for the driver functions are created from the available discrete signals to approximate a pseudo-
analytical driver function. This Fourier series function can be continuously evaluated during 
simulation avoiding the need for slow interpolation when evaluating the system of DEs and greatly 
decreasing simulation time. 
 
3.6.3 LIMITATIONS 
The main limitation of the CVS model is its lumped parameter structural definition. Due to the 
relative simplicity of the model it is unable to capture the micro-dynamics of the CVS. For example, 
the aortic notch in the aortic pressure waveform, caused by reflected pressure waves from the 
arterial system, is not modelled. However, the model does capture all the major dynamics of the 
CVS, such as changes in ventricular preload, afterload, and inotropy, which are all clinically important 
in managing major cardiac dysfunction and controllable with current clinical therapies. 
Currently, the six-chamber model assumes that flow through the heart valves only occurs in the 
forward direction. However, during valvular insufficiency, backwards flow is possible through the 
effected valve of the patient, which fails to prevent this backward flow. Therefore, the model at its 
present state is unable to represent certain valvular dysfunctions, such as mitral (Paeme et al., 2011) 
and aortic regurgitation, without further modification. 
 
3.7 SUMMARY 
A lumped parameter model of the CVS has been created previously by Smith et al (Smith, 2004, 
Smith et al., 2004). The model splits the cardiovascular system into 6 sections or chambers 
representing the main dynamic regions which contribute to cardiovascular flow. A variety of 
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assumptions were used to simplify the model equations, minimising the number of parameters 
required.  Using this minimal parameter set the model defines all the main hemodynamics of the 
cardiovascular system, including serial flow through the system, one-way heart valves, time-varying 
ventricular elastance, and parallel ventricular interaction. 
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CHAPTER 4:  CVS MODEL PARAMETER IDENTIFICATION 
For the CVS model to be clinically useful it must be personalised to each patient to accurately reflect 
that patient’s unique cardiac and circulatory state. To do this, a parameter identification process has 
been created to match the dynamics of the CVS model to measurements that are easily available or 
inferable in an ICU setting (Hann et al., 2010, Revie et al., 2011b). This chapter presents the theory 
and development of the parameter identification method, used in this research, to identify patient-
specific CVS models. 
 
4.1 INTRODUCTION 
The goal of this chapter is to develop a parameter identification process to match the CVS model 
outputs to known clinical data. The main aim is to produce a parameter identification method that 
can identify physiologically accurate patient-specific models of that cardiovascular system. These 
patient-specific models must: 
• be identifiable from common ICU measurements, 
• accurately reflect the patient’s hemodynamics, 
• provide real time feedback, 
• be easy to interpret by medical staff, 
• and provide additional, useful circulatory information. 
In fulfilling these requirements, the parameter identification method and associated patient-specific 
CVS models can be used to track acute disease-dependent changes occurring in patients, and assist 
medical staff with monitoring the effectiveness of treatment. Hence, the goal is to combine typical 
clinical measurements into a clear physiological and clinically relevant picture of a patient’s cardiac 
and circulatory status.   
The starting point for the model identification method was based on the earlier method of Starfinger 
et al. (Starfinger, 2008, Starfinger et al., 2008a, Starfinger et al., 2008b, Starfinger et al., 2007). This 
integral-based parameter identification method relied on knowledge of the left and right ventricular 
waveforms, along with either population-based assumptions or knowledge of left and right 
ventricular pressures. The use of population-based assumptions limited the patient-specificity of the 
method. Moreover, the left and right ventricular pressure and volume waveforms are rarely 
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measured in the ICU. When they are, they are only measured intermittently using echocardiography, 
limiting the real-time ability and clinical usefulness of this earlier work (Boldt, 2002). Hence, the 
identification method must not rely on direct ventricular pressure or volume measurements, for the 
approach to be practically applied in the ICU 
The improved method presented here requires only measurements that are commonly available or 
inferred in a typical ICU setting. These measurements include: features from the aortic and 
pulmonary artery pressure waveforms (Pao, Ppa), stroke volume (SV), heart rate (HR), global end 
diastolic volume (GEDV), and mitral and tricuspid valve closure times (tmt, ttc). This measurement set 
is smaller than that of (Starfinger et al., 2007) as it does not require full waveforms, and is far less 
intensive and invasive to obtain and utilise, as these measures are typically available already.  
The new model identification process has also been broken into parts, utilising smaller systemic and 
pulmonary circulatory models. Hence, only a sub-set of parameters are identified at any one time, 
leading to increased convergence stability. Thus, this research makes a significant step toward 
making this type of model-based approach more stable and clinically applicable without added 
clinical effort or burden on the patient. 
The following sections outline the basic concepts and assumptions of the new identification method. 
The specific details of how the method is applied and works are described, and the validity and 
justification of the method’s assumptions will be discussed.  
 
4.2 PARAMETER IDENTIFICATION ASSUMPTIONS AND MEASUREMENTS 
This section briefly outlines the main assumptions used and measurements available to identify the 
parameters of the six-chamber CVS model.  
 
4.2.1 ASSUMPTIONS 
Several assumptions were made to enable identification of the CVS model from the limited data set 
available in the ICU. These assumptions include: 
• the model is at steady state 
• left and right ventricular SVs are equal 
• inertial effects are negligible, Lmt = Lav = Ltc = Lpv = 0 
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• Plv = Ppu, at mitral valve closure 
• Prv = Pvc, at tricuspid valve closure 
• changes in Elv are proportional to changes in Erv when related by the ratio of the afterloads 
• GEDV ∝ LVEDV + RVEDV 
• V0,lv = V0,rv = Vd,ao = Vd,pa = Vd,vc = Vd,pa = 0 
• Vd,lvf = Vd,rvf = 23  for swine (Desaive et al., 2008) and 0 for humans 
• P0,lvf = P0,rvf = 0 
• heart valve resistances stay relatively constant over short time periods (<1 day) 
The validity and justification of these assumptions are discussed in Section 4.6. 
 
4.2.2 AVAILABLE AND INFERABLE ICU MEASUREMENTS 
Clinically, GEDV and CO, can be measured via thermodilution techniques (Michard et al., 2003, Sakka 
et al., 2000, Stetz et al., 1982, Ganz et al., 1971). The aortic pressure can be estimated from radial 
artery pressure using one of the several transfer function methods (Westerhof et al., 2008, 
O'Rourke, 2004, Hope et al., 2004, Cloud et al., 2003, Pauca et al., 2001, Chen et al., 1997). 
Pulmonary artery indices are determined using a PAC catheter. Furthermore, the modelled Pvc is 
assumed to be equivalent to CVP, which is normally measured in the ICU. Finally, tmt can be 
estimated from ECG. This measurement set represents all the clinically observable model outputs 
that can be used to identify the parameters of the six-chamber CVS model. These measurements are 
listed in Table 4.1 along with their equivalent or inferred model output. 
Table 4.1: Typically available hemodynamic measurements in the ICU and their corresponding 
equivalent in the CVS model. tmt, mitral valve closure time; Pao, aortic pressure; Ppa, pulmonary artery 
pressure; Pvc, vena cava pressure; Qsys, systemic flow; Vlv, left ventricular volume; Vrv, right 
ventricular volume. 
Measurement Description Measured using Equivalent or inferred 
model output 
HR (=1/T) Heart rate (T=period) Electrocardiogram tmt 
AP Arterial pressure Radial artery catheter Pao 
PAP Pulmonary artery pressure Pulmonary artery catheter Ppa 
CVP Central venous pressure Central line catheter Pvc 
CO (=SVxHR) Cardiac output Thermodilution ∫ dtQsys  
GEDV Global end diastolic 
volume 
Thermodilution max[Vlv(t)] + max[Vrv(t)] 
 
  CVS Model Parameter Identification 
61 | P a g e  
 
4.3 STRUCTURAL IDENTIFIABILITY  
A structural identifiability analysis was used to provide an ‘a priori’ indication of whether it was 
theoretically possible to uniquely identify the parameters of the CVS model from the available ICU 
measurements. The publicly available software package DAISY was used to perform this analysis on 
the six-chamber CVS model. This software tool uses a differential algebraic algorithm to examine 
global identifiability for non-linear (and linear) dynamic models with respect to 
observable/measurable model outputs (Bellu et al., 2007). However, please note that this purely 
theoretical analysis does not ensure practical identifiability as it assumes the observed 
measurements are noise free (Bellu et al., 2007). In reality, measurement noise is an unavoidable by-
product in physiological monitoring, and thus, would have a significant effect on the identifiability of 
the model parameters. 
Hemodynamic measurements typically available in an ICU are shown in Table 4.1. These were 
assumed to represent the observable measurements in the structural identification analysis. Hence, 
they were assigned as model outputs in DAISY. 
Due to the limitations of DAISY only a simplified version of the six-chamber CVS model was analysed. 
The Heaviside formulation, representing the heart valve dynamics (in Equations (3.30)-(3.33)), and 
the equations describing ventricular interaction (Equations (3.45)-(3.46)) were removed from this 
simplified model description. Given these assumptions, the assumptions listed in Section 4.2.1, and 
list of observable measurements from Table 4.1, the following set of differential equations and 
model outputs were algebraically derived from Equations (3.22)-(3.39): 
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(4.1) 
 
The rearranged equations of (4.1) were used to describe the simplified six-chamber CVS model in 
DAISY. The period of a heartbeat was set to an arbitrary value of 1. The left and right ventricular time 
varying elastances (elv, erv) represent the inputs of the model. GEDV, Pao, Ppa, Pvc, and CO are the 
observable outputs of the model and volumes (Vlv, Vao, Vrv, Vpa, and Vpu) are the state variables. 
These model variables (inputs, outputs, and state variables) need to be ranked to apply the pseudo-
division algorithm used in Daisy to calculate a characteristic set of the differential ideal. The standard 
ranking for system identification declares that the system inputs and outputs, as known variables in 
this case, are the lowest ranked variables and the state variables are the highest ranking (Bellu et al., 
2007). Hence, the following ranking, as denoted by ‘<’, for the model inputs, outputs, and state 
variables, was used: 
 puparvvcaolvvcpaaorvlv VVVVVVPPPCOGEDVee <<<<<<<<<<<<  (4.2) 
 
And the unknown parameter set (P) was defined as: 
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 { }pupulpapvrvfestcvcsysaoavlvfesmt ERERERERERER ,,,,,,,,,,, ,,=p  (4.3) 
 
Thus, with (4.1), (4.2), and (4.3) the input file for DAISY was created, as shown in Appendix A.   
Using a pseudo-division algorithm DAISY calculated the input-output relationship of the model. 
These relations were evaluated using a pseudo-randomly chosen set of integers, over the range of 1 
to 100, for the unknown parameters. For example: 
 { }49,35,5,30,88,83,67,75,20,28,91,8=p  (4.4) 
 
These values were inserted into the coefficients of the input-output relations which produced a set 
of non-linear algebraic equations (see Appendix A for details). This set of equations was solved using 
the Buchberger algorithm, providing the following Grobner basis for the parameter values of (4.4): 
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 (4.5) 
 
The Grobner basis shows that all the model parameters can be uniquely identified, as they are not 
functions of the other model parameters. Therefore, in theory, the simplified six-chamber CVS 
model is globally identifiable given the clinically observable measurement set listed in Table 4.1. 
Hence, in the following sections, a parameter identification method has been developed to uniquely 
fit subject-specific CVS models to available ICU measurement, as outlined in the following sections. A 
full description of the structural identification results are shown in the output file in Appendix A. 
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4.4 PARAMETER IDENTIFICATION CONCEPTS 
Two main concepts were used to develop the parameter identification method. The first was to split 
the larger problem of identifying the full six-chamber model into several smaller problems using 
simplified models, where only sub-sets of parameters are identified at any one time. The second was 
the use of a proportional gain control approach to match outputs from the CVS model to known 
measurements, and thus, iteratively identify model parameters.  
 
4.4.1 SIMPLIFIED MODELS 
The model identification was split into pieces using smaller, simple models of the systemic and 
pulmonary circulations (Figure 4.1).  Within each model the parameter identification was split up 
even further with a maximum of three parameters identified at a time. This breakdown was done to 
increase convergence stability. Thus, parameters that were related to each other, or trade off with 
each other, were identified at separate times. 
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Figure 4.1: Decoupled simplified models of (a) the systemic and (b) pulmonary circulations with 
inertia and ventricular interaction removed. Note for comparison the orientation of the pulmonary 
circulation has been reversed with respect to Figure 3.1. 
The systemic and pulmonary models were joined together once all parameters had converged. 
Ventricular coupling between the models was calculated though septum and pericardium dynamics 
(Hann et al., 2010, Revie et al., 2011b, Smith et al., 2004), and the vena cava and pulmonary vein 
chambers were identified to create a full six-chamber subject-specific CVS model. A general 
description of this process is shown in Figure 4.2. 
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ID systemic model
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ID pulmonary model
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Figure 4.2: General outline of the parameter identification process. C and NC stand for if converged 
and if not converged. 
 
4.4.2 PROPORTIONAL GAIN CONTROL 
Most of the CVS model parameters were identified by comparing the ratio of a model output to a 
known measurement. To apply this method, the model output used to identify the chosen 
parameter must:  
• be directly or inversely proportional to the parameter, 
• be measureable in a clinical setting, 
• and not be used already to identify another parameter. 
  CVS Model Parameter Identification 
67 | P a g e  
 
Hence, great consideration must be taken when deciding which model output should be used to 
identify which parameter. 
The proportional gain control method was applied once it had been decided which observable 
model outputs would be used to identify each specific parameter. Parameters directly proportional 
to a dependent model output (Dmodel) and measurement (Dmeas) were iteratively identified using: 
 
Similarly, inversely proportional parameters were iteratively identified with: 
 
In the identification method, Equations (4.6) and (4.7) were used to iteratively calculate new 
approximations for the desired parameter from old estimates. The following steps were used to 
apply this iterative proportional gain approach: 
1) Simulate model with initial parameter estimates. 
2) Apply Equations (4.6) and (4.7) to calculate new model parameters. 
3) Re-simulate model with new model parameters. 
4) Repeat steps 2) and 3) until the model outputs match the measured data within tolerance. 
This approach was used to simultaneously identify up to three parameters. An example of how the 
aortic chamber parameters are identified is shown in Section 4.4.2.1. 
4.4.2.1 Aortic chamber example 
In this example, the model parameters Eao and Rsys in the systemic simplified model are identified 
from initial approximations. Eao was found to be proportional to the amplitude of the modelled 
aortic pressure waveform (PPao) and Rsys is proportional to the mean aortic pressure (Pao,mean). Hence, 
the systemic model is fitted to the mean and amplitude of the measured aortic pressure to identify 
these parameters. Two iterations of the proportional gain control process are shown in Figure 4.3. 
Note that for the demonstrative purposes of this example the other parameters of the model have 
been previously identified and are held constant through the iterative process. Poor initial 
approximations have been used for Rsys and Eao to show the effectiveness of the method. 
 old
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Figure 4.3: Example of the proportional gain control process iteratively fitting the mean and 
amplitude of the aortic pressure (Pao,mean, PPao). The grey line in the plots represent the measured 
aortic pressure and the black line represents the modelled aortic pressure. Superscripts stand for 
iteration number. The top panel shows aortic pressure simulated from the aortic model using initial 
guesses for aortic elastance (Eao) and systemic resistance (Rsys). The second and third panels show 
the re-simulated aortic pressure after the first and second iterations of the proportional gain control 
process. 
 
As seen in Figure 4.3, the mean and amplitude of the modelled aortic pressure quickly converge to 
their measured counterparts. Within two iterations the error is less 1% for the mean aortic pressure 
and 7% for the aortic amplitude. In practice this process would be repeated until the percentage 
error is less than 0.5% for both measurements, and, as a result of this process, Rsys and Eao would 
converge to their patient-specific value. 
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4.5 SPECIFICS OF PARAMETER IDENTIFICATION 
The parameter identification process was split up into parts, as illustrated by Figure 4.2. The 
identification process used in each of these parts is shown below. 
 
4.5.1 SYSTEMIC MODEL IDENTIFICATION 
The first step in identifying the systemic model was to approximate the left ventricle driver function, 
elv(t). The method of Stevenson et al. (Stevenson et al., 2012a, Stevenson et al., 2012b) was used to 
estimate erv(t) from features in the measured aortic pressure waveform, Pao,true. The systemic model 
parameters were then identified using a proportional gain controller that compares ratios of discrete 
values calculated from the model outputs (SO) to a set of discrete measured data (SM) to optimise 
the model parameters (SI), where S stands for systemic model and O = outputs, M = measured, and I 
= identified model parameters, as outlined by Equations (4.8)-(4.10). The initial parameter values 
used to simulate the systemic model, based off previous analysis of porcine data, are shown in Table 
4.2. 
 { }vcsysaoavlvfesmtpu PRERERPSI ,,,,,, ,≡  (4.8) 
 { }sysaoaoavlvlvmt QVPQVPQSO ,, ,,,,≡  (4.9) 
 






≡ mttrue
trueao
trueaotruemeanao tSVdt
dP
PPPSM ,,,, max,,
,,,
 (4.10) 
   
Table 4.2: Initial systemic model parameter inputs. 
Parameter Ppu Rmt Ees,lvf Rav Eao Rsys Pvc 
Initial Value 5 0.05 2 0.04 2.5 2.5 5 
 
To start the identification algorithm, the systemic model was simulated using an initial estimate for 
the parameter set, SI, as seen in Table 4.2.  At this stage, only Ppu, Eao, Rmt, Rav, and Rsys of SI were 
identified, with Pvc identified later by the pulmonary model, and Ees,lvf identified once the rest of the 
parameters of the simplified models have been fitted. Therefore, both Ees,lvf and Pvc remained at their 
initial value, as shown in Table 4, during identification of the other systemic model parameters.  
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First, the mitral valve resistance (Rmt), aortic elastance (Eao) and systemic resistance (Rsys) were 
identified by comparing the model outputs to the measured SVtrue, PPao,true, and Pao,mean,true to find 
better approximations for the parameters, as shown by:  
 oldmt
true
approxlv
newmt RSV
SV
R
,
,
, 





=  (4.11) 
 oldao
approxao
trueao
newao EPP
PP
E
,
,
,
, 







=  (4.12) 
 oldsys
approxmeanao
truemeanao
newsys RP
P
R
,
,,
,,
, 







=  (4.13) 
 
New model outputs (SO) were then calculated through re-simulation of the systemic model using 
the new parameter approximations for Rmt, Eao, and Rsys. These outputs were re-entered into 
Equations (4.11)-(4.13) and the process was repeated until the model outputs, SVlv,approx, PPao,approx, 
and Pao,mean,approx matched the measured data to a tolerance of 0.5%.  
Next, the aortic valve resistance, Rav, and pulmonary vein pressure, Ppu, were identified. Rav and Ppu 
were identified separately from Rmt, Eao, and Rsys because they depend on the accurate convergence 
of these parameters. Ppu directly trades off with Rmt, as seen in Equation (3.30) when inertial effects 
are ignored. Rav is dependent on Qav (Equation (3.31)) which itself is a function of stroke volume, a 
measured output that is matched previously through identification of Eao. Hence, the reason Rav and 
Ppu are identified separately to Rmt, Eao, and Rsys.  
To calculate Ppu the mitral valve closure time, tmt was used:  
 )( mtlvpu tPP =  (4.14) 
 
It is assumed that at the time of mitral valve closure there is no pressure difference across the valve, 
as shown on Figure 2.6. Therefore, at this time, Ppu is equal to the left ventricle pressure.  
Another important feature available from the measured data was the maximum gradient or 
inflection point of the ascending section of the aortic pressure waveform, dPao,max,true/dt. In the 
systemic and six-chamber models, the parameter Rav has a significant effect on the gradient of the 
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ascending aortic pressure inflection point. With all other parameters held constant, changes in Rav 
cause inversely proportional changes in the maximum aortic pressure gradient.  
For example, as Rav decreases, flow into the aorta (Qav) increases, as shown by Equation (3.30). The 
increased Qav causes the aortic volume to increase at a faster rate (Equation (3.23)) especially at the 
start of ejection, resulting in a sharper increase in the aortic pressure (Equation (3.34)). Hence, 
identification of Rav was achieved using the formula: 
 oldav
trueaoapproxao
newav Rdt
dP
dt
dP
R
,
max,,max,,
, 











=  (4.15) 
 
where dPao,max,approx/dt  is the maximum ascending gradient of the model output Pao. In practice, 
dPao,max/dt is calculated by finding the first local minimum that occurs before a large ascent in the 
aortic pressure waveform, representing the start of ejection. The following inflection point is tehn 
found, representing the point of maximum gradient in the aortic pressure waveform. The change in 
pressure and time difference between these point (ΔP / Δt) is used to approximate dPao,max,approx/dt  
and dPao,max,true/dt   
With the new approximations for Ppu and Rav, the parameters Rmt, Eao, and Rsys were re-identified, 
using Equations (4.11)-(4.13) to ensure conformity. This overall, added iterative process was 
repeated until dPao,max,approx/dt  converged to the measured data and Ppu stops changing between 
iterations, in both cases to a set tolerance of 0.5%. 
Throughout identification of the systemic model, an estimate was used for the left ventricle end 
systolic elastance (Ees,lvf), as seen in Table 4.2, as this parameter could not be identified at this stage. 
However, this parameter was approximated at a later point, along with the right ventricle end 
systolic contractility (Ees,rvf), once the other parameters of the pulmonary model had been identified.  
 
4.5.2 PULMONARY MODEL IDENTIFICATION 
The model inputs, model outputs, and discrete measurements (calculated from the measured 
waveforms), which were used to identify the pulmonary model, are defined by PI, PO, and PM, 
where P stands for pulmonary model, as outlined by Equations (4.16)-(4.18). Table 4.3 shows the 
initial parameter inputs for the pulmonary model. 
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 { }pusyspapvrvfestcvc PRERERPPI ,,,,,, ,≡  (4.16) 
 { },,,,,,, pulaopapvrvrvtc QVPQVPQPO ≡  (4.17) 
 






≡ tctrue
truepa
truepatruemeanpa tSVdt
dP
PPPPM ,,,, max,,
,,,
 (4.18) 
 
Table 4.3: Initial pulmonary model parameter inputs. 
Parameter Pvc Rtc Ees,rvf Rpv Epa Rpul Ppu 
Initial Value 5 0.04 0.8 0.03 2.1 0.4 From SI 
 
Identification of the pulmonary model was achieved in a similar fashion to the systemic model so 
only a brief description is given here. During this process, Ees,rvf was held constant at its initial value 
(see Table 4.2), and was identified, along with Ees,lvf, once the other parameters of the simplified 
models had been identified.  
First, the right ventricle driver function, erv(t), was identified using the method of (Stevenson et al., 
2012a, Stevenson et al., 2012b). Then Equations (4.19)-(4.21), analogous to Equations (4.8)-(4.10), 
were used to identify Rtc, Epa, and Rpul:  
 oldtc
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Once these parameters converged, Pvc and Rpv were calculated using: 
 )( tcrvvc tPP =  (4.22) 
 oldpv
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max,,max,,
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where dPao,max,approx/dt is the maximum ascending gradient of the model output Ppa, and these 
equations are analogous to Equations (4.14) and (4.15). 
 
4.5.3 IDENTIFY VENTRICULAR CHAMBERS 
The final parameters identified for the systemic and pulmonary models were Ees,lvf and Ees,rvf. In 
estimating Ees,lvf it was assumed that: the parameter Rav had been identified; the model output Pao 
matched the measured data; and the systemic model stroke volume (SVlv,approx) had converged to the 
measured stroke volume (SVtrue). By analysing ohms law for fluid flow (pressure = flow·resistance or 
P=Q·R), the flow through valve (Q), a function of SVlv,approx, multiplied by the resistance (Rav) will give 
a good approximation of the pressure drop across the aortic valve, ΔPav. Therefore, the model 
should intrinsically output a relatively accurate systolic Plv profile, independent of Ees,lvf, as Plv ≈ Pao + 
ΔPav.  
Given that Plv was already known, changes in Ees,lvf must trade off with left ventricle volume, as 
constrained by Equation (3.39), when the passive elastic recoil effects of the ventricle are ignored. 
Therefore, if the identified Ees,lvf was too low then the modelled left ventricle volume, Vlv will be too 
large. Hence, knowledge of the true left ventricle volume can be used to pinpoint the correct Ees,lvf.  
However, left ventricle volume is rarely measured, as it is extremely invasive to measure directly. 
Instead, global end diastolic volume (GEDV), which can be readily measured via thermodilution 
techniques (Michard et al., 2003, Sakka et al., 2000), was used to identify the sum of the ventricular 
elastances (Ees,sum = Ees,lvf + Ees,rvf):  
 oldsumes
true
approx
newsumes EGEDV
GEDV
E
,,,,
=  (4.24) 
 
where GEDV was assumed to approximately equal the sum of the left and right ventricle end 
diastolic volumes.  
Inotropes indiscriminately affect both sides of the heart. To approximate the individual left and right 
ventricular contractilities (Ees,lvf and Ees,rvf) it was assumed that  any inotropic effects act evenly over 
the whole myocardium so the ratio of the contractilities stays constant over time. In other words, 
the percentage change in left ventricle elastance (ΔEes,lvf/Ees,lvf) is equal to the percentage change of 
the right ventricle elastance (ΔEes,rvf/Ees,rvf)  over the same time period. Using this assumption, Ees,lvf 
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was split from Ees,sum using a ratio of the elastances, CE, which stays constant for each individual. The 
ratio CE was identified and averaged from measurements from each patient using a ratio of the 
afterloads and modelled vena cava pressure, Pvc: 
 
const
EE
E
PP
PP
C
rvfeslvfes
lvfes
truemeanpatruemeanao
vctruemeanao
E =
+
≈
+
−
=
,,
,
,,,,
,,  
(4.25) 
 
This relationship is based on the Anrep effect (Anrep, 1912, Knowlton and Starling, 1912, Sarnoff and 
Mitchell, 1961) where increases in myocardial contractility are related to increases in afterload 
represented by Pao,mean,true on the left heart and Ppa,mean,true on the right heart. A mean elastance ratio, 
CE,mean, was averaged from the set of CE’s found for a patient. In calculating CE,mean, only CE’s greater 
than 0.6 (Ees,lvf/Ees,rvf  > 1.5) were used to find the mean. This physiological bound ensures that the 
contractility of the left ventricle is always greater than the right ventricle contractility (Hosenpud and 
Greenberg, 2007, Konstam et al., 1985).  Once CE,mean was calculated Ees,lvf and Ees,rvf were derived 
from Ees,sum. 
 sumesmeanElvfes ECE ,,, =  (4.26) 
 lvfesnewsumesrvfes EEE ,,,, −=  (4.27) 
 
The method for identifying the end systolic ventricle elastances is iterative and starts with initial 
guesses for Ees,lvf and Ees,rvf,  as shown in Table 4.2 and Table 4.3, which were used to identify the 
systemic and pulmonary models. Once both values had converged, the modelled ventricular 
volumes (Vlv, Vrv) were used to calculate GEDVapprox. The parameters Ees,lvf and Ees,rvf were then 
updated using Equations (4.24), (4.26), and (4.27) and the parameters for the systemic and 
pulmonary models were re-identified, as described in Sections 4.5.1 - 4.5.3. This process was 
repeated until GEDVapprox had converged to the measured value. 
Ventricular interaction was calculated at the same time Ees,lvf and Ees,rvf were identified. Initially, 
septum (Vspt) and pericardium dynamics (Ppcd) were set to zero in the systemic and pulmonary 
models. However, as new approximations for Ees,lvf and Ees,rvf were identified, Vspt and Ppcd were 
calculated using Equations (3.45) and (3.46). Vspt and Ppcd were then added to the simplified models 
during the next iterative step in the identification process, thus introducing ventricular interaction 
between the models. An in depth description on the modelling and calculation of Vspt and Ppcd can be 
found at Smith et al. (Smith et al., 2004). 
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4.5.4 IDENTIFICATION OF VENOUS CHAMBERS 
The six-chamber model is the combination of the identified systemic and pulmonary models, plus 
two venous chambers representing the vena cava and the pulmonary vein. To fully define the model 
of Figure 3.1, two further parameters are required, the vena cava and pulmonary vein elastances 
(Evc, Epu). The other parameters, already identified for the systemic and pulmonary models, were 
fixed during identification of the six chamber model, and remain unchanged for the remainder of the 
identification process.   
To identify Evc and Epu the pulmonary vein pressure, Ppu, identified from the systemic model, was 
held constant in the six-chamber model while the vena cava pressure, Pvc, is allowed to vary. The six-
chamber model was simulated with initial guesses for Evc and Epu. Changes in the six-chamber model, 
output Pvc,6 were compared to the identified parameter, Pvc,simple, from the simplified models to 
calculate a better approximation for Evc using: 
 oldvc
vc
simplevc
newvc EPmean
P
E
,
6,
,
, )( 







=  (4.28) 
 
The model was re-simulated with the altered Evc to produce a new Pvc,6. A secondary effect of 
altering Evc, is that the simulated pulmonary volume waveform, Vpu, changes. This change was then 
utilised to identify Epu: 
 )(
,
,
pu
simplepu
newpu Vmean
P
E =  (4.29) 
 
This process of optimising Evc and Epu was repeated until the mean six-chamber vena cava pressure, 
Pvc,6 equalled the Pvc,simple. 
 
4.5.5 AVERAGING VALVE RESISTANCES 
One of the major problems with identifying subject-specific parameters is inter-beat variability in the 
measured data. This variability is problematic when identifying the valve resistances (Rmt, Rav, Rtc, 
Rpv), which are highly sensitive to small changes in the measured data (as shown later in Section 
5.3.2). However, physiologically, valve resistances stay constant between adjacent beats.  
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To enforce constant valve resistances, the simplified models were identified using several different 
periods of the measured data. The valve resistances identified for each set of measured data were 
stored and averaged. The medium value of the stored valve resistances was used to re-identify the 
other parameters of the simplified models for each set of the measured data. Equations (4.11), 
(4.15), (4.19), and (4.23) were no longer needed and were replaced with Equations (4.30) and (4.31):  
 oldpu
true
approxlv
newpu PSV
SV
P
,
,
,
=  (4.30) 
 newvc
true
approxrv
newvc PSV
SV
P
,
,
,
=  (4.31) 
 
Hence, the estimated tmt and ttc measurements were no longer required in the identification process. 
 
4.5.6 SUMMARY 
The parameter identification method was run using bounds to constrain the identified parameters 
within physiological limits. This helped avoid instabilities in the identification process which can 
occur if the parameters are allowed to become too big or small. A list of the parameter bounds are 
shown in Table 4.4. 
 
Table 4.4: Parameter bounds used in the parameter identification method 
Parameter Lower Bound Upper Bound 
Rmt 0.005 0.5 
Ees,lvf 0.1 10 
Rav 0.005 0.5 
Eao 0.1 10 
Rsys 0.1 10 
Evc - - 
Pvc 1 minimum of 15 or (Pao,min,true – 2) 
Rtc 0.005 0.5 
Ees,rvf 0.1 10 
Rpv 0.005 0.5 
Epa 0.1 10 
Rpul 0.05 10 
Epu - - 
Ppu 1 minimum of 15 or (Ppa,min,true – 2) 
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A highly iterative process, involving six feedback loops was used to identify the parameters of the 
six-chamber model. This model identification system was run on a 2.13 GHz dual core machine with 
3GB of ram. Since this research is still in the development stages the model identification had been 
run using the development-orientated but relatively slow Matlab software (MathWorks, Natwick, 
MA, USA). Using one processor the identification method took on average 6 minutes and 24 seconds 
to identify a subject-specific model of the CVS. Preliminary tests using the C programming language, 
which is better suited for real time applications, have suggested the simulation time of the six-
chamber model  can be reduced by a factor of 100, to approximately 3 seconds per identified model, 
which is an acceptable run time in a clinical environment. 
The approach presented has been changed dramatically from that in Starfinger et al. (Starfinger et 
al., 2007), as the method now only requires a minimal set of measurements that are typically 
available in the ICU. In contrast, Starfinger et al. (Starfinger et al., 2007) required a larger set of 
invasive measurements and assumptions based on population trends.  Hence, this approach is far 
more general. The step-wise process, including iterative feedback loops, of the new algorithm is 
summarised in Table 4.5. 
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Table 4.5:  Step-wise parameter identification process of the six-chamber cardiovascular system 
model. 
 
Step 1: Input set of measured data. 
 
Step 2: Approximate left and right ventricle driver functions. 
 
Step 3:  Estimate an initial set of input parameters for systemic and pulmonary 
models as shown in Table 4 and 5. 
 
Step 4:  Identify systemic model of Figure 2 (a). 
Step 4.1:  Simulate systemic model. 
Step 4.2: Identify Rmt, Eao, and Rsys with Equations (4.11) - (4.13). 
Step 4.3:  Re-simulate the systemic model with new parameters. 
Step 4.4: If SVlv,approx, PPao,approx, and Pao,mean,approx have converged within a 
tolerance of 0.5% go to Step 4.5 otherwise go back to Step 4.2. 
Step 4.5: Identify Ppu and Rav with Equations (4.14) and (4.15).  
Step 4.6: If Ppu and dtdP approxao /max,.
 
have converged within a tolerance of 0.5% 
go to Step 5 otherwise go back to Step 4.2. 
 
Step 5: Identify pulmonary model. 
Step 5.1:  Simulate pulmonary model. 
Step 5.2: Identify Rtc, Epa, and Rpul for the Equations (4.19) - (4.21). 
Step 5.3: Re-simulate the pulmonary model with new parameters. 
Step 5.4: If SVrv,approx, PPpa,approx, and Ppa,mean,approx have converged within a 
tolerance of 0.5% go to Step 5.5 otherwise go back to Step 5.2. 
Step 5.5: Identify Pvc and Rpv with Equations (4.22) and (4.23).  
Step 5.6: If Pvc and 
dtdP approxpa /max,  have converged within a tolerance of 0.5% 
go to Step 6 otherwise go back to Step 5.2. 
 
Step 6: Identify Ees,lvf and Ees,rvf with Equations (4.24), (4.26), and (4.27) and calculate 
Vspt and Ppcd with Equations (3.45) and (3.46). If GEDVapprox, Vspt, and Ppcd have 
converged within a tolerance of 0.5% go to Step 6 otherwise go back to Step 
4. 
 
Step 7: Repeat Steps 1 to 6 with different sets of the measured data and store and 
average the identified valve resistance. 
 
Step 8: Repeat Steps 1 to 6 using the averaged/fixed valve resistances (ie without 
identifying Rmt, Rav, Rtc and Rpv) and Equations (4.30) - (4.31). 
 
Step 9: Identify six-chamber model. 
Step 9.1: Simulate six-chamber model. 
Step 9.2: Identify Evc and Epu with Equations (4.28) - (4.29). 
Step 9.3: Re-simulate six-chamber model with new parameters. 
Step 9.4: If Pvc has converged within a tolerance of 0.5% go to Step 10 
otherwise go back to Step 9.2. 
 
Step 10: Output six-chamber parameters and model outputs 
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4.6 DISCUSSION 
4.6.1 VALIDITY AND JUSTICATION OF ASSUMPTIONS 
The first assumption made by the identification method is that the measurement set used in the 
identification process represent steady state hemodynamics. Hence, it is assumed the SVs of the left 
and the right ventricles are the same. This assumption is physiologically reasonable as serial 
interaction between the ventricles, due to the Frank Starling mechanism, maintains the balance of 
ejected volume from both pumps. 
Second, inertial effects of the blood were ignored. Inertia, represented by the inertance parameters 
in the model, was found to contribute less than 1% to the outputs of the CVS model. Hence, it was 
removed from Equations (3.30)-(3.33), simplifying these equations, and decreasing the number of 
parameters required for identification. 
Third, it was assumed that the venous filling pressures, Ppu and Pvc, were equal to the pressures in 
the left and right ventricles, Plv and Prv, at the time of mitral and tricuspid valve closure. In the CVS 
model, Ppu and Pvc act as the filling pressures to ventricles, as the left and right atrium are not 
modelled. Since inertia of blood is ignored, the heart valves close when there is a negative pressure 
gradient, which prevents backwards flow through the valve. Hence, the valves close as soon as 
ventricular pressure rises above the venous press and at this point Ppu ≈ Plv and Pvc ≈ Prv. This 
assumption is used to identify Ppu and Pvc in the identification process.  
In the ICU, few measurements are taken directly from the heart. There are not enough available 
measurements to directly identify Ees,lvf and Ees,rvf. Hence, in the identification process an empirical 
coefficient (CE), based on Equation (4.25), was used as added piece of information to calculate Ees,lvf 
and Ees,rvf. Equation (4.26), which uses CE, is based off a strong relationship (R
2 = 0.80) between Ees,lvf 
and the sum contractilities, Ees,sum, where Ees,sum is identified beforehand using GEDV. This 
relationship was discovered during preliminary development of the model identification process 
where left and right ventricular volume measurements from porcine studies (Ghuysen et al., 2008, 
Lambermont et al., 2006) were used to fit subject-specific CVS models. The relationship is shown in 
Figure 4.4. Although applying the empirical relation requires extra iterations during the identification 
process it enables accurate approximation of left and right ventricular function without the need for 
highly invasive measures. In practice, measurement of Ees,lvf and Ees,rvf require highly invasive cardiac 
catheterisation combined with a vena cava occlusion manoeuvre or expensive equipment needed 
for echocardiography. Importantly, these latter methods, while accurate, do not provide continuous 
measurements and are clinically impractical, limiting their utility.  
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Figure 4.4: Relationship used to separate the end systolic left ventricular elastance (Ees,lvf) from the 
sum of the ventricular elastances (Ees,sum). The coefficient CE is calculated from the mean aortic, mean 
pulmonary artery, and vena cava pressures using Equation (4.25). 
 
The fifth assumption assumes the maximum heart volume (GEDV) is directly proportional to the sum 
of the maximum left and right ventricles. In the ICU GEDV is normally calculated from thermodilution 
measurements. The assumption of proportionality is logical because at the end of filling most of the 
volume from the left and right atriums has been ejected into the ventricles. This assumption is also 
backed up by experimental evidence (Sakka et al., 2000). Therefore, the main determinant of GEDV 
will be LVEDV and RVEDV, and the small amount of volume left in the atriums at the end of filling will 
generally be proportional to these volumes.  
The less important model parameters are not identified during the identification process. This choice 
is simply due to the lack of available unique ICU measurements. These parameters, such as 
unstressed volumes of the six model chamber (Vd,lvf, Vd,rvf, Vd,ao, Vd,pa, Vd,vc, and Vd,pu) and the zero 
volume left and right ventricular pressures, are set as constants in the CVS model so the 
identification method can focus on identifying the more important metrics which define the main 
dynamics of the cardiovascular flow. In general, this choice ensures identifiability of the more 
physiologically and clinically relevant parameters. 
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The final assumption made by the identification process is that the valve resistances stay relatively 
constant. Calcification of the heart valves, the main cause of stenosis, normally develops slowly. 
Hence, it is assumed that the resistant state of the heart valves do not change over short time 
periods (<1 day). In the identification method several patient-specific models are identified from 
different sets of data and the heart valve resistances are averaged. The CVS models are then re-
identified using these averaged and now constant valve resistances. The use of this process removes 
the inter-beat variability in the identified valve resistances, which are highly sensitive to noise in the 
measured data. Thus, facilitating identification of more accurate CVS models. 
 
4.6.2 SIMPLIFIED MODELS 
Before the identification process, the systemic and pulmonary side of the six-chamber CVS model 
are separated from each other. These simplified models are mathematically decoupled by removing 
the ventricular interaction and replacing the vena cava and pulmonary vein chambers with constant 
pressure sources, Pvc and Ppu. Although the models are mathematical decoupled there still remains 
an intrinsic coupling between the models as they both share the same upstream and downstream 
pressure, Pvc and Ppu, and they are identified using the same SV. 
The use of the simplified models increases the convergence stability of the identification process, as 
only subsets of the total number of parameters need to be identified at any one time. This results in 
less interaction between parameters during identification, smoothing convergence. The setup with 
the simplified models also makes the identification process easy to program, as the larger problem 
of identifying the full six-chamber model is broken into smaller and easier to understand modules. 
 
4.6.3 PARAMETER IDENTIFICATION LIMITATIONS 
The main limitation of model identification method is its reliance on knowing the pulmonary artery 
pressure, which is not widely measured. The use of the pulmonary artery catheter (PAC) has gone 
out of fashion in recent times (Johnston et al., 2008b, Wiener and Welch, 2007) as it has been 
associated with little or even deleterious effects on mortality rates (Binanay et al., 2005, Shah et al., 
2005). Some investigators (Shah et al., 2005) have suggested the use of the PAC by itself may not be 
the problem. Instead, incorrect interpretation of the waveform and the use of sub-optimal therapies 
triggered from data obtained from the PAC may be the cause of these poor results. In such cases, 
patient-specific models could be used to standardise interpretation of the measurement.  
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Features of the pulmonary artery waveform in conjunction with other measurements can be 
converted into easy to understand metrics representing ventricular contractility, preload, vascular 
stiffness and resistance which are directly controllable with current clinical treatments (fluid 
resuscitation, inotropes, vasopressors, and vasodilators), providing a better platform for therapy to 
be based from. Given the potential, and only small added risks associated with the PAC (Berenholtz 
et al., 2004, Johnston et al., 2008a, Mermel et al., 1991, Ramritu et al., 2008, Safdar et al., 2002, 
Weil, 1998), this compromise favours improved patient outcome, as well as ease of use. 
Alternatively, the model identification method could easily be adapted to use echocardiography 
measurements to identify parameters of the pulmonary circulation, although, this approach would 
reduce the frequency at which the CVS models could be identified. 
The model also assumes Vd,lvf  = Vd,rvf = 0, though in most cases this assumption is not accurate. When 
the true Vd,lvf or Vd,rvf ≠ 0, Ees,lvf and Ees,rvf will not quantitatively represent the gold standard definition 
of ventricular contractility as defined by Sugawa et al. (Sagawa et al., 1977), as represented by 
Equation (3.7). However, physiologically Vd,lvf and Vd,rvf stay relatively constant over the range of 
normal loading conditions and short time periods. Therefore, as the CVS model is a lumped 
parameter model the effects of a non-zero Vd,lvf or Vd,rvf will be taken into account during the 
identification of Ees,lvf and Ees,rvf. In other words, if there is a sharp increase in the contractile state of 
the heart, a sharp increase will be noticed in the identified Ees,lvf and Ees,rvf. Thus, importantly, 
although the value of modelled Ees,lvf and Ees,rvf may differ from the gold standard measurement the 
qualitative trends of these parameters should still represent the changes in the patient’s state. 
Preliminary testing has indicated that changes in the estimated driver function may be used to 
identify Vd,lvf, which could be incorporated in future versions of the modelling identification method.  
Further limitations in identifying the ventricular contractilities arise from the assumption that the 
ratio of the contractilities, CE, stays constant over the duration of the trial. It would seem logical that 
if one side of the heart was badly damaged or highly distended then the relationship between Ees,lvf 
and Ees,sum may no longer be linear and the ratio may not stay greater than 0.6.  It should be noted 
that such patients might well be close to death. No useful literature was found comparing inotropic 
effects on both the left and right ventricle simultaneously. Hence, the assumption of a constant CE 
was based off measurements from the nine pigs with induced pulmonary embolism (N=5) or induced 
septic shock (N=4) where CE was found to stay relatively constant in this range for each animal over a 
wide range of inotropic states and loading conditions (see Figure 4.4). For use in humans, this ratio 
will have to be further confirmed in trends that controllably change the inotropic state of the heart 
with dobutamine or a similar infusion. 
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4.7 SUMMARY 
A parameter identification method for identifying patient-specific models cardiovascular models has 
been created. The models can be identified from readily ICU measurements through the use 
simplified models and proportional gain control. This work is an improvement on previous work as 
this process now enables real-time monitoring of cardiovascular dynamics in a clinical setting.
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CHAPTER 5:  PARAMETER IDENTIFICATION VALIDATION 
The parameter identification method outlined in Chapter 4 must now be tested and validated. In this 
chapter, subject-specific CVS models are identified using porcine data from animal trials. The 
convergence, sensitivity, repeatability, and accuracy of these models is tested and analysed to 
validate the method and its performance and limitations.  
 
5.1 INTRODUCTION 
This chapter examines the ability of the parameter identification method to accurately identify 
subject-specific CVS models from realistically available clinical data. Verification and validation of the 
identified models was done by analysing: 
1) model convergence, 
2) parameter sensitivity, 
3) repeatability of model identification, 
4) and accuracy of the model outputs against independent measurements not used in the 
identification method. 
These analyses provide quantitative information on the strengths and weaknesses of the parameter 
identification method. 
These verification and validation analyses were tested using measurements from two porcine 
studies on acute pulmonary embolism (PE) and septic shock (SS). The convergence, parameter 
sensitivity, and repeatability of the model identification process were tested using measurements 
from the PE study. Validation against independent measurements was analysed using identified 
models for both PE and SS. The details and results of the validation analyses are outlined in the 
following sections.  
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5.2 METHODS 
5.2.1 PORCINE MEASUREMENTS 
To validate of the model identification method, subject-specific CVS models were identified 
retrospectively from measurements recorded in experimental pig studies on PE and SS. In the PE 
study, autologous blood clots were inserted into 5 pigs to induce pulmonary embolism (Ghuysen et 
al., 2008). Continuous measurements over 6 - 12 heartbeats of aortic pressure, pulmonary artery 
pressure, and left and right ventricular pressures and volumes were measured. Measurements were 
recorded at 30 minute intervals up to 4.5 hours with an extra set of measurements taken 5 minutes 
before the end of the trials (T0, T30,....,T210, T240, T265, T270).  
In the SS study, an endotoxin infusion over the first 30 minutes was used to induce septic shock in 4 
pigs (Lambermont et al., 2006). The same measurements as in the porcine study were recorded. 
However, in this study measurements were only recorded up to 4 hours (T0, T30,..., T210, T240). 
Further details on the experimental protocol used in both these studies can be found in the Sections 
6.2.1 and 7.2.1 or in (Ghuysen et al., 2008, Lambermont et al., 2006).  
 
5.2.2 MODEL IDENTIFICATION ANALYSES 
First, model convergence was checked to ensure the model outputs correctly converged to the 
convergence set points. These set points represent measurements of hemodynamic vital signs 
recorded for one heartbeat (ie, MAP and SV), as shown in Table 4.1, Section 4.2.2. The convergence 
of the identified CVS models was analysed by observing whether or not the model outputs 
converged to their corresponding set points to within the desired tolerance (normally +/- 0.5%) for 
the systemic and pulmonary sub models and for the full six chamber model identified in the PE 
study. 
Second, the sensitivity of the model parameters to changes in the convergence set points used in the 
identification method was analysed. Each convergence set point was changed by +/-10%, while the 
other set points were left at their measured value. CVS models were identified for every 
combination of the altered convergence set points, and the effect on the identified parameters was 
analysed for Pig 1, in the PE study, in a healthy (at T0) and diseased state (at T150). 
Third, the repeatability of the model identification method was examined. In the porcine studies, the 
subject-specific CVS models were identified from hemodynamic measurements recorded over one 
heartbeat. Hence, to test the repeatability of the identification method, subject-specific CVS models 
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were identified from measurements obtained from three adjacent heartbeats. The change in the 
subject-specific models was analysed to see how the identified parameters varied between 
heartbeats. Thus, this analysis provides an indication of the repeatability of the parameter 
identification process. 
Finally, the ability of the subject-specific models to accurately identify cardiac measurements not 
used as convergence set points in the model identification process was explored. Modelled left and 
right ventricular pressures and volume outputs were compared to measured values. Hence, the 
ability of the subject-specific CVS models to predict dynamics of the CVS that were assumed 
unknown beforehand is tested. This independent measurement validation assesses the ability of the 
identified subject-specific CVS models to interpolate cardiac dynamics from the available circulatory 
measurements.   
 
5.2.3 DATA ANALYSIS 
In the convergence and repeatability analyses data is presented as mean bias plus or minus two 
standard deviations (mean +/- 2SD) of the percentage error. In the sensitivity analysis data is 
presented in pairs showing the percentage deviation in the parameter due to changing  the 
convergence setting input by +/- 10% (or +/-0.005s for temporal inputs). To analyse the repeatability 
of the model identification method the percentage change in the identified parameters between 
beats was analysed. Bland-Altman analysis (Bland and Altman, 1986) was used to illustrate the 
accuracy of the identification method against independent measurements. Median, 5th, and 95th 
percentile percentage errors are also used to quantify accuracy against the independent 
measurements. A percentage error less than 20% was regarded as an acceptable result, because the 
clinical measurement of physiological variables often lack precision, with errors of +/- 10 to 20% not 
uncommon (Clancy et al., 1991, Critchley and Critchley, 1999, Salandin et al., 1988). 
 
5.3 RESULTS 
5.3.1 CONVERGENCE 
The convergence of the identified models was verified for the PE data by checking whether or not 
the model outputs matched the convergence criteria within the given tolerance. Table 5.1 shows the 
bias and spread (mean +/- 2 SD) of the errors in the model outputs used in the identification process.  
In 93% of the subject-specific models all the model outputs converged to the measured value within 
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the tolerance range. However, the model outputs of 4 of the identified systemic sub-models, 3 of 
the pulmonary sub-models, and 4 of the six-chamber models did not converge within their set 
tolerances. The larger errors seen in Table 5.1 are solely due to four (of 51) identified models that 
had not fully converged during the identification process. For all the other models, the model 
outputs converged to within 0.5% of the convergence criteria. 
 
Table 5.1: Convergence analysis of the parameters of the systemic and pulmonary sub-models and 
six-chamber model for the PE case. Data presented for 51 subject-specific CVS models compares the 
model output to measured data to a bias +/- 2SD. 
 Bias +/- 2SD 
Systemic Pulmonary Six 
Pao,mean -0.03 +/- 0.62% - -0.00 +/- 0.66% 
PPao -0.09 +/- 1.60% - -0.07 +/- 1.55% 
max dPao/dt -0.33 +/- 4.39% - -0.04 +/- 3.75% 
SVlv 0.00 +/- 0.32% - -0.03 +/- 0.42% 
Ppa,mean - 0.08 +/- 0.65% -0.01 +/- 1.05% 
PPpa - -0.41 +/- 1.37% -0.54 +/- 1.98% 
max dPpa/dt - -0.59 +/- 7.98% -0.18 +/- 10.3% 
SVrv - 0.00 +/- 0.10% -0.04 +/- 0.97% 
GEDV - - -0.08 +/- 0.70% 
Erat - - -0.02 +/- 0.35% 
Ppu,mean - - 0.02 +/- 0.18% 
Pvc,mean - - 0.00 +/- 0.05% 
 
5.3.2 SENSITIVITY ANALYSIS 
A sensitivity analysis was done using one heartbeat’s worth of pig measurements, for Pig 1 in a 
healthy state (at T0) and diseased state (at T150 after 2 injected emboli). The measurement of mean 
arterial pressure (Pao,mean,true) used in the identification process was altered by +/- 10%, while the 
other measurements were kept at their normal values. A subject-specific CVS model was identified, 
and the effect of changing Pao,mean,true on the identified parameters was observed. This process was 
repeated for the other measurements used to identify subject-specific CVS models. All pressure, 
pressure gradient, and volume measurements were changed by +/- 10%, and time measurements 
were altered by +/- 0.005s. Please note that during the identification process the valve resistances 
were not averaged, as described in Section 4.4.5, so that the sensitivity of these parameters could 
also be analysed.  The results of the sensitivity analysis are shown in Table 5.2 and Table 5.3 for Pig 1 
in a healthy state at T0 and Pig 1 in a diseased state at T150 during the trial. 
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Table 5.2 shows that the parameters on the pulmonary side of the model are insensitive to 
convergence inputs relating to the other side of the circulation, i.e. Rtc, Erv, Rpv, Epa, and Rpul only 
change by a small amount when PPao is altered. A parameter was considered highly sensitive if it 
changed by greater than 25%. The valve resistances, Evc, and Epu were the most sensitive parameters, 
with the parameter changing as much as 50%. Rmt was highly sensitive to tmt; Rav was highly sensitive 
to PPao, SV, and GEDV; Rtc was highly sensitive to ttc; Rpv was highly sensitive PPpa, and moderately 
sensitive to max dPpa/dt and GEDV; Evc was highly sensitive to ttc; and Epu was highly sensitive to tmt. 
The results for the diseased state at T150, as shown in Table 5.3, are similar to the healthy state 
results. The valve resistance and venous chamber elastances were again the most sensitive 
parameters. In the diseased state, maximum changes of up to 180% were noticed for some of the 
parameters, although Rav and Rpv were a lot less sensitive to SV and GEDV. The results shown in Table 
5.2 and Table 5.3 indicate the need for accurate measurements and averaging when identifying 
valve resistances in the CVS model. 
 
5.3.3 REPEATABILITY OF MODEL IDENTIFICATION ANALYSIS 
The repeatability of the model identification process was tested by identifying subject-specific CVS 
models for three adjacent heartbeats. The analysis was performed for the same pig (Pig 1) and at the 
same times (T0 and T150) as the sensitivity analysis, although, different heartbeats from the 
recorded measurements were used. The adjacent heartbeats reflect steady state hemodynamics, 
and thus, there are only minor differences due to the natural variability between the measurements 
of each beat.  The identified parameters for the different heartbeats and their percentage change 
from the first heartbeat are shown in Table 5.4. Again, the heart valve resistances were not 
averaged, to allow analysis of their inter-beat sensitivity.   
The results in Table 5.4 are similar to the sensitivity analysis in that the valve resistances,  Evc, and Epu 
seem to be the most sensitive to small changes in the measurements. All the other parameters 
change by less than 9% between beats. A maximum change of 105% is seen for the Rmt identified 
from the 3rd beat at T150. These results indicate that the measurements used as convergence 
criteria in the parameter identification process should be averaged to reduce inter beat variability in 
the identified parameters. 
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Table 5.2:  Parameter sensitivity analysis of Pig 1 at T0 showing identified parameters for +/-10% (or -/+ 0.005s for tmt and ttc) change in the measured input 
value used in the identification method. ‘ID value’ indicates the parameter value identified when the inputs of the identification process were not altered. 
R mt 
[mmHg.s/ml]
E lv 
[mmHg/ml]
R av 
[mmHg.s/ml]
E ao 
[mmHg/ml]
R sys 
[mmHg.s/ml]
E vc 
[mmHg/ml]
R tc 
[mmHg.s/ml]
E rv 
[mmHg/ml]
R pv 
[mmHg.s/ml]
E pa 
[mmHg/ml]
R pul 
[mmHg.s/ml]
E pu 
[mmHg/ml]
ID value 0.025 2.572 0.058 2.662 3.467 0.005 0.065 0.478 0.010 0.741 0.429 0.015
P ao,mean -9.6|7.9 -10.1|8.6 15.6|-16.4 1.9|-0.6 -10.9|9.5 0.5|0.4 0.3|-0.2 1.4|-1 0.6|-0.3 -0.2|0.2 2.2|-2.2 -15.4|8.5
PP ao -1.7|1.7 -0.9|1.1 -55|32.1 -12.4|10.6 0.2|0.2 0.4|0 -0.4|0.4 -1|1.3 -1.5|1.4 -0.1|0 0.4|-0.4 -3.1|1.7
max dP ao /dt 0.3|-0.1 0.2|-0.1 16|-11.4 0.7|0.6 0|0.3 0.4|0.8 0.1|0 0.2|-0.1 0.2|-0.2 0|0 -0.1|0.1 -1.3|-4.7
t mt -50.8|32.1 0.1|0.1 0.9|1.3 0.4|0.4 0.4|0.1 0.6|0.4 0|0 0.1|0.1 -1|1.6 -0.7|1.2 6.6|-10.4 -53.3|29.2
P pa,mean 0.3|-0.6 1.3|-0.9 6.3|0.7 0.5|0.4 0.4|-0.1 -8.8|8.5 -8.8|7.3 -9.7|8.3 4.6|-4 1.9|-2 -13.5|10.7 -3.8|-2.3
PP pa -0.2|0 -0.9|1 -2|5.8 0.3|0.6 0.2|0 -1.9|2.8 -2.2|2 -1.5|1.6 -42.4|26.6-13.4|10.3 -0.2|0.2 -1.2|-3.2
max dP pa /dt -0.1|-0.1 0.2|0 3.8|0.4 0.6|0.2 0.1|0.2 0.5|-0.2 0.3|-0.3 0.3|-0.1 17.1|-21 -0.1|0 -0.1|0.2 -0.8|-0.6
t tc 1.1|-1.5 3.9|-4.4 11.4|-11 1.1|0.3 1.5|-1.3 -42.9|27.9-44.1|28.7 -4.3|5.2 -5.1|6.1 -0.4|-0.1 -0.3|0.6 0.5|-4.4
SV 6.1|-5.2 -3.9|3.8 -40.9|20.6 8.7|-8.5 9.7|-9.7 -5.9|6.7 5.3|-4.3 -5.3|5.2 -10.3|9.2 8.8|-9.6 10.5|-10.7 -3.4|-1
GEDV 4.3|-3.6 13.8|-13.830.8|-49.9 1.7|-1.1 0.3|0.2 5.7|-3.1 5.8|-4.3 15.2|-14.9 19.8|-18 0.4|-1.2 -0.6|0.2 -3.9|2.3
%
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Table 5.3:  Parameter sensitivity analysis of Pig 1 at T150 showing identified parameters for +/-10% (or -/+ 0.005s for tmt and ttc) change in the measured 
input value used in the identification method. ‘ID value’ indicates the parameter value identified when the inputs of the identification process were not 
altered. 
R mt 
[mmHg.s/ml]
E lv 
[mmHg/ml]
R av 
[mmHg.s/ml]
E ao 
[mmHg/ml]
R sys 
[mmHg.s/ml]
E vc 
[mmHg/ml]
R tc 
[mmHg.s/ml]
E rv 
[mmHg/ml]
R pv 
[mmHg.s/ml]
E pa 
[mmHg/ml]
R pul 
[mmHg.s/ml]
E pu 
[mmHg/ml]
ID value 0.075 2.307 0.027 2.821 2.158 0.013 0.051 1.239 0.240 3.841 0.611 0.063
P ao,mean 1.5|-3.4 -5.1|9.4 -5.9|9.3 2.5|1.2 -12.4|9.4 -4.3|-1.3 -1.9|0.2 -4.8|-0.8 -3.7|-0.9 0.1|-0.1 -0.1|-0.1 9.5|8
PP ao -0.4|-1.2 -0.4|0.7 -41.6|25 -10.7|10.4 -0.4|-0.4 -1.1|-1.8 -0.2|0.3 -0.5|0.8 -0.5|0.6 0|0 0|0 5.9|7.6
max dP ao /dt -0.9|-0.3 0.2|-0.2 12.1|-36.9 0.8|0.4 -0.6|-0.1 -1.5|-0.8 0.1|-0.1 0.2|-0.2 0.2|-0.2 0|0 0|0 7.2|3.2
t mt -193.1|0 -1.3|0 -8.6|0 0|0 -0.1|0 -4.4|0 -3|0 -2.5|0 -12.6|0 -3.8|0 21.1|0 -126.4|0
P pa,mean 0.6|0.2 1.6|1.6 -1.4|-5.4 -1.3|0.3 0.4|-0.1 -6.4|3.7 -7|3.3 -9.4|1.8 -2.5|-10.1 4.3|-3.3 -16.2|12.1 -4.1|-0.9
PP pa -0.3|-1 -3.6|4.3 -4.3|-5.2 0.3|2 0.8|-1.6 -11.2|6 -10|7.6 -7.1|4.6 -48.5|22.2 -15.8|13 -0.2|0.4 3.7|8.5
max dP pa /dt -0.3|-1 3.9|-1.6 -1.8|-5 1.1|1.2 -0.5|0 6.8|-7.5 7|-5.1 4.1|-3.5 22.7|-25.1 2|-1.1 -0.6|0.4 1.9|8.9
t tc -0.3|-0.7 9.8|-0.1 5.1|-0.8 0.3|0.8 6.8|-1.4 -130.2|7 -180.7|10.6 -11|0.1 -7.3|-0.7 -0.2|0 -0.3|0 -0.4|6.2
SV 9.8|-11.3 -2.5|3.2 -7.6|-3.9 10.9|-7 10.2|-10.6 -5.5|2.4 6.1|-5.2 -4|3.5 1.6|-2.4 9.7|-9.6 9.6|-9.8 4.6|8.3
GEDV 0.3|-0.9 12.9|-12.6 7.7|-13.7 -0.2|0.5 0.1|-0.2 4.8|-4.8 5.2|-4.6 13.2|-14 7.7|-7.7 0.2|0 0.1|-0.2 -8.1|11.2
%
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Table 5.4: Identified parameters of the CVS model from measurements obtained from three adjacent beats. The table shows the parameter values and the 
percentage change in brackets for beats 2 and 3 in the parameter value in comparison to beat 1.  
R mt 
[mmHg.s/ml]
E lv 
[mmHg/ml]
R av 
[mmHg.s/ml]
E ao 
[mmHg/ml]
R sys 
[mmHg.s/ml]
E vc 
[mmHg/ml]
R tc 
[mmHg.s/ml]
E rv 
[mmHg/ml]
R pv 
[mmHg.s/ml]
E pa 
[mmHg/ml]
R pul 
[mmHg.s/ml]
E pu 
[mmHg/ml]
Beat 1 0.033 2.6 0.22 2.6 3.4 0.003 0.038 0.41 0.008 0.56 0.26 0.025
Beat 2 0.035 (6.5) 2.6 (-1.4) 0.18 (-17) 2.7 (1.9) 3.4 (1.3) 0.003 (5.6) 0.041 (7.8) 0.40 (-1.7) 0.006 (-23) 0.54 (-2.5) 0.24 (-6.5) 0.028 (8.2)
Beat 3 0.034 (3.0) 2.6 (0.4) 0.2 (-7.1) 2.7 (2.2) 3.4 (0.8) 0.003 (0.1) 0.037 (-1.2)0.40 (-1.4) 0.005 (-35) 0.56 (-1.0) 0.25 (-4.0) 0.026 (1.8)
Beat 1 0.018 2.3 0.11 2.3 2.3 0.008 0.047 1.0 0.11 2.6 0.75 0.024
Beat 2 0.029 (55) 2.3 (-0.0) 0.12 (7.1) 2.5 (4.9) 2.4 (1.9) 0.009 (16) 0.060 (28) 1.1 (3.3) 0.12 (18) 2.7 (3.6) 0.73 (-2.8) 0.032 (34)
Beat 3 0.037 (105) 2.3 (0.0) 0.09 (-11) 2.4 (2.9) 2.3 (-1.0) 0.011 (41) 0.071 (53) 1.1 (8.6) 0.17 (60) 2.6 (2.9) 0.68 (-9.0) 0.039 (64)
t150
t000
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5.3.4 VALIDATION AGAINST INDEPENDENT MEASUREMENTS 
Validation was achieved by comparing the other model outputs to measurements that were not 
used in the identification process (left and right ventricular end diastolic volumes [LVEDV, RVEDV] 
and maximum left and right ventricular pressures [Plv,max, Prv,max]). Bias, precision, absolute 
percentage errors and correlation metrics were used to analyse accuracy. These metrics were 
analysed in both the pulmonary (PE) and septic shock (SS) studies. 
 
5.3.4.1 Pulmonary embolism 
Table 5.5 shows that the modelled outputs, LVEDV, RVEDV, Plv,max, and Prv,max correlated well with 
their corresponding independent measurements, with R2 > 0.84 in all cases.  All percentage errors 
were less than 15% except for those for Prv,max. Modelled LVEDV, RVEDV, and Plv,max all had a small 
bias (-1.1 ml, 1.0 ml, and -0.6 mmHg). However, a larger bias of 6 mmHg was seen for Prv,max.  Two 
standard deviations of the modelled LVEDV and RVEDV fell with 6ml of the measured values. 
Whereas, two standard deviations of Plv,max and Prv,max fell within a larger range of 18.5 mmHg and 
23.4 mmHg, respectively. Figure 5.1 and Figure 5.2 show the regression and Bland-Altman plots for 
LVEDV and RVEDV. 
 
Table 5.5: Mean, bias and precision metrics, median absolute percentage errors with 5th and 95th 
percentile bounds, and correlation coefficients of the measurements used for validation of the 
model identification process in the pulmonary embolism pig study. 
 Mean Bias +/- 2SD   % Error (5th - 95th percentile) R2 
LVEDV 79.6 ml -1.1 +/- 5.4 ml   1.6% (0.1% - 8.6%) 0.96 
RVEDV 71.8 ml 1.0 +/- 5.7 ml  1.7% (0.1% - 10.4%) 0.89 
Plv,max 127.7 mmHg -0.6 +/- 18.5 mmHg 3.6% (0.3% - 14.6%) 0.86 
Prv,max 47.4 mmHg  6.6 +/- 23.4 mmHg 16.0% (2.4% - 54.1%) 0.84 
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Figure 5.1: Regression (top) and Bland-Altman analysis showing 2 standard deviation limits (bottom) 
of the modelled and measured left ventricular end diastolic volume (LVEDV) in the pulmonary 
embolism study.  
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Figure 5.2: Regression (top) and Bland-Altman analysis showing 2 standard deviation limits (bottom) 
of the modelled and measured right ventricular end diastolic volume (RVEDV) in the pulmonary 
embolism study.  
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5.3.4.2 Septic shock 
In the septic shock study all four modelled outputs (LVEDV, REVDV, Plv,max, Prv,max ) correlated well 
with the measured data (R2  ≥ 0.78), as seen in Table 5.6.   Modelled left ventricular outputs (LVEDV, 
Plv,max) had a small negative bias (-5.4 ml, and -1.4 mmHg) whereas right ventricular outputs (RVEDV, 
Prv,max) tended to slightly overestimate (4.9 ml, and 0.5 mmHg) the true measurement. The precision 
(2 standard deviations) of the LVEDV and RVEDV predictions were 13.9ml and 14.1ml,  and 10.6 
mmHg and 10.1 mmHg for Plv,max and Prv,max. All percentage errors were within an acceptable range 
(<20%), except for the 95th percentile error in the modelled maximum right ventricular pressure. 
Figure 5.3 and Figure 5.4 show regression and Bland-Altman plots for LVEDV and RVEDV. 
 
Table 5.6: Mean, bias and precision metrics, median absolute percentage errors with 5th and 95th 
percentile bounds, and correlation coefficients of the measurements used for validation of the 
model identification process in the septic shock pig study. 
 Mean Bias +/- 2SD   % Error (5th - 95th percentile) R2 
LVEDV 93.7 ml -5.4 +/- 13.9 ml    7.5% (0.5% - 13.8%) 0.94 
RVEDV 84.4 ml   4.9 +/- 14.1 ml   7.4% (0.5% - 18.1%) 0.91 
Plv,max 87.8 mmHg -1.4 +/- 10.6 mmHg   4.5% (0.3% - 15.2% ) 0.93 
Prv,max 39.7 mmHg  0.5 +/- 10.1 mmHg    6.2% (0.6% - 26.6%) 0.78 
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Figure 5.3: Regression (top) and Bland-Altman analysis showing 2 standard deviation limits (bottom) 
of the modelled and measured left ventricular end diastolic volume (LVEDV) in the septic shock 
study.  
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Figure 5.4: Regression (top) and Bland-Altman analysis showing 2 standard deviation limits (bottom)  
of the modelled and measured right ventricular end diastolic volume (RVEDV) in the septic shock 
study.  
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5.4 DISCUSSION 
5.4.1 CONVERGENCE 
All the controlled outputs of the systemic and pulmonary sub-models converged towards their 
measured values during the identification process. However, in a few cases (three systemic and four 
pulmonary sub-models) some of the outputs did not converge to within the desired tolerance. These 
cases occurred because: 1) the parameter being identified had reached its upper or lower limit, 
causing the output to stop converging closer to its target value; or 2) the simulation of the CVS 
model was not run for enough time to reach steady state for the given parameter set, which is 
required for correct parameter identification.  
Scenario 1) was mostly a problem when identifying Rav and Rpv using the measurements of maximum 
dPao/dt and maximum dPpa/dt. Rav and Rpv are highly interdependent on Ees,lvf and Ees,rvf  being 
accurate. However, at first, when identifying the simplified sub-models only initial estimates for Ees,lvf 
and Ees,lvf are used. Thus, in some cases large errors in Ees,lvf and Ees,rvf, used to initially identify the 
sub-models, can cause Rav and Rpv to converge to unphysiological values that are below the 
allowable limits set in the identification method (see Table 4.4, Section 4.7). In such cases the 
identification method tries to reduce Rav and Rpv so the model matches the measured maximum 
aortic and pulmonary artery pressure gradients. However, the imposed lower limits for Rav and Rpv in 
the identification method stop the maximum dPao/dt and dPpa/dt outputs reaching their measured 
value. Thus, these outputs do not converge to within the set tolerance during parameter 
identification. However, this is generally not a problem when identifying the six-chamber model 
because Ees,lvf and Ees,rvf are identified. 
Scenario 2) occurs when the initial estimates of the model outputs, as shown in Table 4.2 and Table 
4.3, in Sections 4.5.1 and 4.5.2 (different to the initial parameter estimates for the parameter 
identification method), are vastly different to the steady state model outputs. During simulation of 
the CVS model, the poor initial conditions cause there to be a long transient period before steady 
state conditions are reached. However, in the parameter identification method a maximum time 
limit is set to limit the amount of computational time spent on any one simulation of CVS model. 
Thus, sometimes, the maximum time limit of the simulation is reached before steady state 
conditions in the simulation are achieved. In such cases, the model outputs taken from the 
simulation do not reflect steady state conditions which are required for identifying subject-specific 
models. Therefore, the parameters identified for the systemic and pulmonary sub-models may not 
reflect steady state, and when used to simulate six-chamber model may cause errors in the model 
outputs. To reduce this problem, when simulating the CVS models, it is checked if the models have 
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reached steady state over the set time span in the ODE solver. If the models have not reached the 
steady state, the models are re-simulated using the end conditions of the previous simulation as the 
initial conditions for the new simulation, to allow more time for steady-state solution to be reached.   
For 93% of the 51 identified model cases in the PE analysis all of the parameters converged to their 
set points within the desired tolerance. In the 7% of models that did not converge most of the model 
outputs had converged to set points and the model outputs that had not fully converged were still 
close to their measured value with errors < 10% most of the time. These results are acceptable and 
still good for this type of physiological monitoring (Clancy et al., 1991, Critchley and Critchley, 1999, 
Salandin et al., 1988). Hence, these identified models could still be used to base therapy decisions 
from.  
 
5.4.2 PARAMETER SENSITIVITY 
The most sensitive parameters to changes in the measured inputs were the valve resistance (Rmt, Rav, 
Rtc, and Rpv) and the venous elastances (Evc and Epu). Rmt was highly sensitive to the mitral valve 
closure times (tmt).  A change in the mitral valve closure time can significantly change Ppu. Identified 
Rmt is a function of pressure difference between the Ppu and the diastolic left ventricular pressure 
during filling of the left heart. Hence, a change in the mitral valve closure time causes a large change 
in Ppu which consequentially causes a large change in Rmt. The same logic holds true for the 
sensitivity of Rtc in relation to ttc. 
Rav was very sensitive to changes in the measured maximum dPao/dt, PPao, SV, and GEDV. Once 
inertial effects are ignored, Rav is defined by a rearranged version of Equation (3.31): 
 )(
)()(
tQ
tPtP
R
av
aolv
av
−
=  (5.1) 
 
The difference between Plv and Pao is only small during left ventricular ejection, resulting in the 
numerator of Equation (5.1) being substantially smaller than the magnitude of Qav. Hence, small 
changes in the features of the aortic pressure waveform (maximum dPao/dt and PPao) can cause 
relatively large changes in this numerator and consequentially cause large changes in Rav. Qav and Pao 
are both products of SV, and SV is a function of Plv in the model. Hence, Rav is also highly sensitive to 
SV. Finally, Plv is defined by Ees,lvf (Equation (3.38)), which is identified using GEDV in the parameter 
identification method. As mentioned earlier Rav is interdependent with Ees,lvf and small changes in 
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Ees,lvf can cause large changes in Rav. Thus, Rav is also highly sensitive to changes in GEDV. The same 
principles can be used to explain why identified Rpv is sensitive to dPpa/dt, PPpa, SV, and GEDV. 
Lastly, Evc and Epu are very sensitive to changes in tmt and ttc. This result occurs because Evc and Epu are 
fitted using Pvc and Ppu, which are identified from the systemic and pulmonary sub-models. Small 
changes in tmt and ttc can cause large changes in the identified Ppu and Pvc in the sub-models. Hence, 
Evc and Epu vary a lot when tmt and ttc are changed in the parameter identification method. 
To minimise the variance in the identified parameters due to perturbations in the measurements, 
the highly sensitive parameters can be averaged over several identified models. By averaging the 
parameters, over several identifications in a given period, the negative flow-on effects of 
measurement noise, or other irregularities due to sensor issues, on these highly sensitive 
parameters would be reduced.  Thus, this approach would produce more physiologically accurate 
subject-specific models of the CVS. For example, averaging valve resistances, as done in Chapters  6, 
7, and 8 and in (Revie et al., 2011b), and averaging Evc and Epu over several identified models can be 
done using the approach. 
 
5.4.3 INTER-BEAT REPEATABILITY 
The ability of the identification method to repeatedly identify subject-specific CVS models from sets 
of data from adjacent heartbeats, was also analysed. This analysis represents a more realistic 
sensitivity analysis than the previous section as: 1) there are slight changes in all the measurements 
between heartbeats, not just a change in one measurement as there was in Section 5.4.2; and 2) 
these changes represent realistic inter-beat variability in the measurements and hemodynamics, 
rather than an arbitrary potentially unrealistic change of +/- 10% used in Section 5.4.2. Moreover, 
the measurements used to identify the subject-specific CVS models were taken in steady state. 
Therefore, it can be assumed that there is very little beat-to-beat change in hemodynamics and that 
most of the inter-beat variability in the measurements is thus due to measurement noise. Hence, 
this analysis also shows how repeatable the model identification method in response to 
measurement noise. 
The results of this repeatability analysis were similar to the previous parameter sensitivity analysis. 
The identified heart valve resistances (Rmt, Rav, Rtc, Rpv) and the elastance of the venous chambers 
(Evc, Epu) were the most variable parameters between heartbeats. Inter-beat variability is in the 
identified model parameters was noticeably smaller for Pig 1 in a healthy state, whereas larger 
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errors were seen at T150 after pulmonary embolism was induced. The largest change of 105% was 
seen for the identified Rmt between beat 1 and beat 3 for Pig 1 at T150. 
To eliminate the effects of measurement noise, the subject-specific CVS models could be identified 
from a set of averaged measurements. The measurements used as the convergence criteria in the 
identification method could be averaged over several heartbeats to reduce the effects of 
measurement noise, increasing the repeatability of the model identification process between 
heartbeats. This recommendation is implemented in Chapter 8, where the measurements used to 
identify patient-specific CVS models were averaged over two breathing cycles (approximately 6-12 
heartbeats). 
 
5.4.4 VALIDATION AGAINST INDEPENDENT METRICS 
Modelled cardiac metrics of LVEDV, RVEDV, Plv,max, and Prv,max, for both PE and SS, correlated well 
against their measured values, with all but Prv,max of 0.78 with R
2 value greater than 0.9. LVEDV and 
RVEDV were modelled accurately in both studies with averaged absolute percentage errors less than 
8%. Plv,max was also modelled accurately in both studies with median absolute percentage errors less 
than 6.5%. Modelled Prv,max was the least accurate metric, especially in PE, with median absolute 
percentage errors of 16%, although there was only an average error of 6.2% in the SS study. In the 
PE study, LVEDV and RVEDV were identified more accurately. However, the maximum pressures 
were more accurate in the SS study. These results indicate that there appears to be a trade off in the 
accuracy of the maximum ventricular volumes (LVEDV, RVEDV) and the maximum ventricular 
pressures (Plv,max, Prv,max) in the identified models. Most errors were less than 10% and the majority 
were less than 20% which is acceptable for this type of physiological monitoring (Clancy et al., 1991, 
Critchley and Critchley, 1999, Salandin et al., 1988). 
A primary cause of some of the larger errors and difference in polarity of the modelled bias between 
the left and right ventricle measurements, as seen in Table 5.5 and Table 5.6, is due to the difficulties 
in measuring and calculating the right ventricular volume experimentally with a conductance 
catheter. Due to the right ventricle’s complex shape the volume measurements were 
underestimated in most of the pigs, where the left ventricular SV was greater than two times the 
right ventricular SV, which is not physiologically accurate for steady state hemodynamics.  
The SV of both ventricles in the CVS model is assumed to be equal, so an average of the measured 
left and right ventricular stoke volumes was used in the identification process. Therefore, once 
converged, the identified models generally underestimated the measured left ventricular stroke 
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volume and overestimated the measured right ventricular stroke volume. This issue caused the 
LVEDV and, consequentially, the left ventricular pressure in the model to be underestimated relative 
to the measurements taken in the experiment, with the opposite occurring in the right ventricle. 
However, more importantly, these errors were generally systematic so the trends associated with 
these measurements are still clearly identified and accurate, as indicated by the good correlations 
seen in Table 5.5 and Table 5.6.  
 
5.5 SUMMARY 
In 93% of cases the outputs of the identified models converged to their set-points. In the remaining 
cases the models still converged towards their set points but did not reach them due to parameter 
limits in the parameter identification method or because the CVS models were not simulated over a 
long  enough time span to reach steady state. The heart valve resistances and venous elastances 
were found to be the most sensitive parameters to changes in the model identification set points. 
However, these parameters could be averaged over several identified CVS models and averaged 
measurements could be used to fit the subject specific models to reduce the sensitivity of these 
parameters and improve the repeatability of the identification method. Finally, the subject-specific 
models could generally predict cardiac volume and pressure measurements to percentage errors 
less than 20%, which is acceptable for this type physiological monitoring. 
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CHAPTER 6: MODEL-BASED MONITORING OF PULMONARY EMBOLISM 
The subject-specific models have been shown to robustly and accurately represent cardiovascular 
dynamics. Now, the ability of these models to monitor and track the cardiac and circulatory 
response to common cardiovascular diseases is tested. In this chapter, the clinical potential of the 
approach to monitor hemodynamic changes due to acute pulmonary embolism in porcine trials is 
examined (Revie et al., 2011a). 
 
6.1 INTRODUCTION 
Pulmonary embolism (PE) is an acute, life threatening disease thought to be responsible for around 
15% of all sudden deaths (Kasper and Harrison, 2005).  In one study, untreated mortality was found 
to be 26% (Barritt and Jordan, 1960). Other studies have shown that pulmonary embolism is 
responsible for, or contributes to, around 15% of in-hospital deaths (Smulders, 2000, Dalen and 
Alpert, 1975, Morrell and Dunnill, 1968, Uhland and Goldberg, 1964). In particular, the dysfunction is 
a major problem in intensive care due to factors such as: the insertion of catheters, admission of 
post cardiac surgery patients, prolonged bed rest, and compromised anticoagulant state of the 
typical ICU patient (Cook et al., 2005, Heit et al., 2000, Anderson and Spencer, 2003) . Further 
exacerbating the problem is the fact that PE often goes unrecognised, with studies showing that only 
around one third of all patients that died from this dysfunction were correctly diagnosed before 
death (Goldhaber et al., 1982, Stein and Henry, 1995).  
Due to the fast acting and deadly nature of PE it is important to diagnose and treat as soon as 
possible. Mortality increases if diagnosis is delayed and/or if correct treatment is not administered in 
a timely fashion. When pulmonary embolism is diagnosed and treated correctly, mortality rates drop 
from around 30%, in untreated patients, to 2.5% (Carson et al., 1992, Smulders, 2000). Hence, real 
time monitoring is required to ensure symptoms of pulmonary embolism are identified before 
irreversible damage is done.  
This chapter analyses the monitoring ability of subject-specific CVS models to track the onset and 
evaluation of pulmonary embolism. The parameter identification method, outlined in Chapter 4, was 
retrospectively tested using measurements from a porcine study on pulmonary embolism (Ghuysen 
et al., 2008). In this animal study, a wide range of hemodynamic measurements were recorded and 
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autologous blood clots were used to induce PE. Subject-specific CVS models were identified from 
clinically available data derived from the porcine measurements. The performance of the model 
identification method in PE was assessed against independent measurements not used for 
identification (Chapter 5), experimentally derived metrics (Ghuysen et al., 2008), and clinically 
expected trends from the literature (Elliott, 1992, Wauthy et al., 2004). Hence, the overall goal of 
this work was to demonstrate the clinical relevance and prove the concept (and potential) of 
computer-based clinical monitoring of CVS status for the acute CVS dysfunction. 
 
6.1.1 PATHO-PHYSIOLOGY AND TREATMENT OF PULMONARY EMBOLISM  
Pulmonary embolism is the blockage of the pulmonary artery or one of its distal branches due to an 
embolism. Emboli are generally blood clots (thrombus) originating from the deep veins of the legs 
and pelvis. The thrombi break off from the walls of the deep veins, travel through the right heart, 
and get stuck in the pulmonary circulation.  The main cause of pulmonary embolism is deep vein 
thrombosis (DVT). Other causes of pulmonary embolism include air bubbles, fat deposits, talc, or 
amniotic fluid. The severity of pulmonary embolism depends on the size of these emboli, as well as, 
coexistent cardiopulmonary disease, and the magnitude of counterproductive neural and humoral 
reflex responses (Goldhaber, 2002). 
Pulmonary embolism symptoms result from the obstruction to blood flow in the lungs which causes 
pressure to build up in the right ventricle (Wauthy et al., 2004). Clinical signs of PE include low blood 
oxygen saturation, rapid breathing, and a rapid heart rate.  Diagnosis is based off these findings, 
which may lead to a D-dimer test and/or chest CT scan for confirmation (Goldhaber and Elliott, 
2003a). Treatment generally consists of anticoagulant medication, and, in severe cases, thrombolysis 
or surgical intervention (pulmonary thrombectomy) (Goldhaber and Elliott, 2003b). 
From a hemodynamic perspective, the obstruction in the pulmonary vasculature initiates the release 
of vasoactive agents, such as serotonin and platelets, which increase pulmonary arterial tone 
(Goldhaber and Elliott, 2003a). As a result, pulmonary vascular resistance increases due to the 
mechanical obstruction of the emboli and pulmonary vasoconstriction (Goldhaber and Elliott, 
2003a). Systemic vascular resistance also increases as a reflex response (Klabunde, 2004) to maintain 
mean arterial pressure and preload on the left ventricle. Alveolar dead space increases in the lungs 
due to under-perfused alveoli capillaries. Bronchoconstriction reflexes cause elevated airway 
resistance and pulmonary edema decreases pulmonary compliance. The combinations of these 
factors result in increased right ventricular afterload and subsequent dilation of the right ventricle 
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with excess volume (Goldhaber, 1998). Follow on effects include: decreased venous return, a 
subsequent drop in left ventricle preload, and ischemia due to compromised cardiovascular and 
pulmonary function (Goldhaber and Elliott, 2003a). 
This hemodynamic profile summarises the causes and effects of pulmonary embolism: 
• Thrombotic 
o Clots form in deep veins and embolise to pulmonary arteries (Goldhaber, 1998) 
• Obstructive 
o Mechanical obstruction of blood flow to the lungs from blood clots (Goldhaber, 
1998) 
o Pulmonary vascular vasoconstriction (reflex response) due to release of vasoactive 
agents (Goldhaber and Elliott, 2003a) 
o Increased pulmonary vascular resistance (reflex response and physical obstruction) 
(Goldhaber and Elliott, 2003a) 
o Initial increase in systemic vascular resistance increases (reflex response) to 
maintain MAP and left ventricle preload (Klabunde, 2004) 
• Distributive 
o Right ventricle dilation (Goldhaber and Elliott, 2003a, Gan et al., 2006, Lualdi and 
Goldhaber, 1995) 
o Decreased left ventricle filling  due to reduced return from pulmonary circulation 
(Goldhaber and Elliott, 2003a) 
o Decreased left ventricle preload (Goldhaber and Elliott, 2003a, Gan et al., 2006, 
Lualdi and Goldhaber, 1995) 
• Cardiogenic 
o Initial increase in contractility (reflex response) to maintain CO (Burkhoff and Tyberg, 
1993, Klabunde, 2004) 
o Eventual decrease in contractility due to decreased oxygen supply to heart 
(Goldhaber and Elliott, 2003a) 
o Leftward shift in intra-ventricular septum due to right ventricule dilation and 
decreased left ventricle preload (Goldhaber and Elliott, 2003a, Gan et al., 2006, 
Lualdi and Goldhaber, 1995) 
• Chronotropic 
o Increased heart rate (reflex response) to increase CO and maintain tissue perfusion 
(Goldhaber and Morrison, 2002) 
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6.2 METHODS 
6.2.1 PORCINE EXPERIMENTS AND DATA 
All procedures and protocols used in the porcine experiments were reviewed and approved by the 
Ethics Committee of the Medical Faculty at the University of Liege (Belgium). Six pure Pietrain pigs 
were pre-medicated and anesthetised as explained in (Ghuysen et al., 2008). 10 ml/kg volume-cycle 
ventilation was provided after endotracheal intubation through a cervical tracheostomy at a 
respiratory rate of 20 breaths per minute. Inspired oxygen fraction was set to 40% and the 
respiratory settings were adjusted to maintain CO2 between 30 and 35 mmHg. Access to the cardiac 
chambers and pulmonary truck was achieved via median sternotomy. A micromanometer-tipped 
catheter was inserted into the pulmonary artery through an incision in the right ventricle outflow 
track and was adjusted to be 2cm downstream from the pulmonary valve. Another 
micromanometer-tipped catheter was descended into the thoracic aorta through the femoral artery.  
Furthermore, 7F, 12 electrode conductance micromanometer-tipped catheters were positioned in 
the left and right ventricle so that all electrodes were within these cavities.  
To simulate PE three autologous blood clots of decreasing size (0.25, 0.125, and 0.0625 g  kg-1) were 
inserted into the external jugular vein at 0, 120 and 240 minutes into the trials. From the catheters, 
continuous waveforms over 6 to 12 heartbeats were obtained every 30 minutes (T0 to T270) of left 
and right ventricular pressures and volumes (Plv, Prv, Vlv, Vrv), aortic pressure (Pao), and pulmonary 
artery pressure (Ppa). This research uses 51 sets of data from five of the pigs (Pig 1, Pig 2, Pig 3, Pig 4, 
and Pig 5) from the study (Ghuysen et al., 2008). Measurements from the sixth pig were omitted as 
it died very early in the trial and only a partial set of measurements were available for Pig 2 as it died 
at T180. 
 
6.2.2 MODEL IDENTIFICATION 
The model identification method outlined in Chapter 4 was used to identify the subject-specific 
models of pulmonary embolism. In this study GEDV was assumed to be equal to the sum of the 
maximum left and right ventricular volumes (GEDV = max(Vlv) + max(Vrv) = LVEDV + RVEDV). The 
mitral and tricuspid valve closure times were estimated from the approximated left and right 
ventricular functions (elv(t) and erv(t) ) from (Stevenson et al., 2012a, Stevenson et al., 2012b) as 
central venous pressure and ECG were not measured in this study. 
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6.2.3 DATA AND STATISTICAL ANALYSIS 
 Data is presented as mean +/- standard deviation (SD) unless stated otherwise. A paired-sample t-
test was used to check temporal variance over T0 – T60, T120 – T150, and T240 - T265 to analyse the 
effect of the injected emboli. A value of p < 0.05 was considered a statistically significant result. 
Percentage errors, and bias and precision metrics were used to compare the relationship of the 
modelled to experimentally derived metrics. A percentage error less than 20% was regarded as an 
acceptable result as measurement of physiological variables often lack similar precision, with errors 
of +/- 10-20% not uncommon (Clancy et al., 1991, Critchley and Critchley, 1999, Salandin et al., 
1988). 
 
6.3 RESULTS 
Data sets were recorded every 30 minutes, and once 5 minutes before the end of the experiments 
(T0, T30, T60,... , T240, T265, T270) in each of the four and half hour long trials. From each of the 
data sets, subject-specific models were retrospectively fitted for each of the pigs. Hence, a total 51 
subject-specific CVS models were identified and analysed.  
In this study each animal acts as its own control with baseline measurements taken at T0 reflecting 
the undiseased state of the pig, prior to the injection of the autologous blood clots. Statistically 
significant changes (p<0.05) were seen in the measured systolic and diastolic aortic and pulmonary 
artery pressures, and left and right ventricular end diastolic volume over T0-T60, showing the 
deviation from baseline circulatory dynamics due to the insertion of the initial blood clot after T0. 
Further changes were also noted after insertion of later blood clots at T120 and T1240. A summary 
of these main hemodynamic measurements is seen in Figure 6.1. 
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Figure 6.1: Evolution of the averaged hemodynamic measurements recorded during the trials. * 
indicates P<0.05 for indicating a significant temporal change over T0-T60, T120-T150, or T240-T265 
after the insertion of emboli. The data is presented as mean +/- SD.  
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6.3.1 COMPARISON TO EXPERIMENTALLY DERIVED METRICS 
For further validation, on top of the validations shown in Chapter 5, the identified pulmonary 
afterload, right ventricular end systolic elastance, and right ventricular vascular coupling (RVVC) 
from the model were compared to corresponding metrics (Ea, Ees, Ees/Ea) derived experimentally 
using pressure-volume loop analysis from the same measurements (Ghuysen et al., 2008). The 
afterload on the right ventricle in the model is the pulmonary vascular resistance divided by the 
period of one heartbeat (Ea,model = Rpvl/T).   
Bias, precision, and correlation indices for pulmonary afterload and coupling are shown in Table 6.1 
and the temporal trends for these indices are shown in Figure 6.2, Figure 6.3, and Figure 6.4. The 
model matched pulmonary afterload closely with a bias and precision (2 SD) of -0.06 +/- 0.68 
mmHg/ml and correlation of R2 = 0.86. The model parameter Ees,rvf is directly comparable to 
experimentally derived right ventricular end systolic elastance and was found to have bias of and 
precision of -0.87+/-1.00  mmHg/ml (R2=0.51). Furthermore, a bias and spread of -0.73 +/- 0.83 was 
observed for the RVVC with correlation of R2 = 0.83 as seen in Figure 6.4.  
 
Table 6.1: Bias, precision, and correlation metrics comparing the modelled to experimentally derived 
indices of afterload, contractility, and right ventricular vascular coupling (RVVC). 
Metric Bias Precision (2SD) R
2
 
Afterload (Ea) -0.06 mmHg/ml 0.68 mmHg/ml 0.86 
Contractility (Ees) -0.87 mmHg/ml 1.00 mmHg/ml 0.51 
RVVC (Ees/Ea) -0.73 0.83 0.83 
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Figure 6.2: Comparison of the experimentally derived (Ghuysen et al., 2008) and modelled 
pulmonary afterload. The data is presented as mean +/- SD. 
 
Figure 6.3: Comparison of the experimentally derived (Ghuysen et al., 2008) and modelled right 
ventricular end systolic elastance (Ees,rvf). The data is presented as mean +/- SD. 
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Figure 6.4: Comparison of the experimentally derived (Ghuysen et al., 2008) and modelled right 
ventricular-vascular coupling (RVVC or Ees/Ea). The data is presented as mean +/- SD. 
 
6.3.2 PULMONARY EMBOLISM TRENDS 
6.3.2.1 Afterload 
The model parameters for systemic and pulmonary vascular resistance (Rsys, Rpul) represent the main 
components of afterload on the left and right ventricles, respectively. The averaged time varying 
trends for these parameters are shown in Figure 6.5. Average Rsys stays relatively constant 
throughout the study, ranging between 2.5 and 3 mmHg.s/ml, except for a drop at T180, which is 
largely influenced by the near death state of Pig 2. In contrast, the averaged Rpul value steadily 
increases to 243% above the baseline value by the end of the study, with noticeable increases seen 
after T0, T120, and T240 when the autologous blood clots were introduced to the circulation. These 
results match clinically expected trends (Goldhaber and Elliott, 2003a). 
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Figure 6.5: Modelled left and right ventricular afterload. The data is presented as mean +/- SD. 
 
6.3.2.2 Preload 
Ventricular preload in the model is represented by ventricular end diastolic volume (LVEDV, RVEDV). 
Averaged LVEDV and RVEDV over all the pigs are seen in Figure 6.6. The averaged RVEDV increases 
slightly above baseline throughout the study indicating right ventricular distension. On the other 
hand, LVEDV decreases dramatically most likely due to a decrease in venous return (Gan et al., 2006, 
Goldhaber and Elliott, 2003a). 
0 30 60 90 120 150 180 210 240 265 270
0
0.5
1
1.5
2
2.5
3
3.5
4
Va
sc
u
la
r 
re
si
st
an
ce
 
(m
m
Hg
.
s/
m
l)
Time (min)
 
 
Systemic
Pulmonary
  Model-Based Monitoring of Pulmonary Embolism 
113 | P a g e  
 
 
Figure 6.6: Modelled left and right ventricular end diastolic volume (LVEDV, RVEDV). The data is 
presented as mean +/- SS. 
 
6.3.2.3 Contractility 
Parameters of left and right ventricular end systolic elastances define the inotropic state of the 
ventricles in the CVS model. The evolution of model parameters, Ees,lvf and Ees,rvf, through time is 
shown in Figure 6.7. Both parameters increase for most of the study. However, large drops are seen 
after T265 when the pigs are near death. As with Rpul, large increases in Ees,rvf are seen after T0, T120, 
and T240 indicating a reflex response in the pigs to counteract the increased resistance of the 
pulmonary system (Klabunde, 2004).  
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Figure 6.7: Modelled left and right ventricular end systolic elastance (Ees,lvf, Ees,rvf). The data is 
presented as mean +/- SD. 
 
6.3.3 SUBJECT-SPECIFIC RESPONSE 
Although the average results seen in the previous section show that the model is capable of 
identifying the hemodynamic trends of the induced disease over a cohort, inter-patient variability 
can be significant. It is important to know how each subject responds to the disorder. Hence, it is 
essential to analyse the individual time varying trends for each pig, not just the averaged trends of 
the disease. 
The time varying profile of some of the measurements used to identified the subject-specific CVS 
models are shown in Figure 6.8. The subject-specific parameters identified from these 
measurements can be seen in Figure 6.9. For all the pigs an increase in pulmonary vascular 
resistance was noticed at T0, the main consequence of PE. This increase in pulmonary resistance 
would have been responsible for the increase in mean pulmonary artery pressures observed in the 
pigs. The identified increases in Rpul indicate that PE was successfully induced in each pig. 
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Figure 6.8: Temporal evolution of the subject-specific hemodynamic measurement recorded during the porcine trials and used to identify the subject-
specific CVS models. 
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Figure 6.9: Identified subject-specific metrics of preload (LEVDV, RVEDV), afterload (Rsys, Rpul), contractility (Ees,lvf, Ees,rvf), and right ventricular vascular index 
(RVEDV/LVEDV). 
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To counteract the increased resistance of the pulmonary circulation the right ventricle contracts 
with greater force to maintain cardiac output. This result is captured by monitoring the modelled 
Ees,rvf, which represents the contractile state of the right ventricle Figure 6.9 shows the time varying 
trend of the modelled Ees,rvf in each pig. In all the pigs, except Pig 1, the change Ees,rvf closely matches 
the change in Rpul, indicating that increasing contractility is a internal reflex response to increased 
afterload. 
The pigs’ conditions begin to deteriorate when the response of the cardiovascular (such as increased 
Ees,rvf) can no longer adequately compensate for the effects PE. The obstruction in the pulmonary 
circulation cause decreased venous return to the left heart and a rise in pressure and volume in the 
right heart (Goldhaber and Elliott, 2003a). To analyse the magnitude of these effects the right 
ventricle expansion index (RVEI) is used, which is the ratio of the right to left end diastolic volumes 
(RVEDV/LVEDV). The individual response of the modelled RVEI for each pig is shown in Figure 6.9. 
RVEI increases for each pig throughout the study. The largest increases are noticed for Pigs 1 and 2, 
which both die during the study. Hence, RVEI can be used as an indicator of the severity of PE and 
the ability of the pig’s internal reflexes to respond to the disorder.  
 
6.4 DISCUSSION 
6.4.1 COMPARISON WITH CLINICALLY DERIVED METRICS 
Modelled pulmonary afterload closely matched the clinically derived metric with an R2 = 0.86 and 
bias of -0.06 mmHg/ml. The trends for the modelled right ventricle contractility and right ventricular 
vascular coupling also followed the trends of the clinically derived metrics (R2 = 0.51, R2 = 0.83) 
although a large negative bias was observed (-0.87 mmHg/ml and -0.73 mmHg/ml). The main reason 
for this bias was due to the use of the constant Vd,rvf = 23 ml to define the pressure volume 
relationship in the right ventricle (Equation (3.39)), as recommended for pigs in (Desaive et al., 
2008). However, this value was deduced from a porcine model of septic shock and may not optimally 
represent right ventricle dynamics in pulmonary embolism. Though, more importantly, this bias from 
the use of Vd,rvf = 23 ml represents a relatively systematic error in the modelled metrics meaning that 
disease-dependent trends in these indices were still captured. Hence, the identified model 
parameters can still be used to monitor the progression (trends) of disease in the subjects. 
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6.4.2 DETECTING ACUTE PULMONARY EMBOLISM 
The subject-specific CVS models captured the main hemodynamic trends of PE. Increased pulmonary 
vascular resistance, a main sign of PE (Goldhaber, 1998, Goldhaber and Elliott, 2003a, Lualdi and 
Goldhaber, 1995), was observed in this study, indicating the presence of pulmonary emboli. The 
increased resistance in the pulmonary vasculature caused the pressure and volume in the right heart 
to increase (Goldhaber and Elliott, 2003a, Lualdi and Goldhaber, 1995, Wauthy et al., 2004), as 
shown in Figure 6.1. The obstruction also resulted in less blood returning to the left ventricle. Hence, 
the volume (or preload) of the left ventricle decreased (Figure 6.1). Right ventricular contractility 
increased, as Rpul increased, in an attempt to expel a build up of volume in the right ventricle and to 
maintain stroke volume (Figure 6.1).  These trends were tracked well by the subject-specific models 
as shown by the validation analysis performed in Chapter 5 and the results in Section 6.3.1.  
Left and right end diastolic ventricular volume and pressure, pulmonary vascular resistance, and end 
systolic elastance are rarely measured in intensive care as they are highly invasive to measure. 
However, the use of these metrics can provide great insight into cardiac and circulatory status during 
PE. To calculate these metrics the model-based approach only utilises measurements that are 
already taken in the ICU. Thus, this method provides a means of identifying these parameters 
without the need for direct cardiac measurement. Therefore, identified subject-specific models can 
be used to provide important information on a patient’s cardiovascular health without any added 
risk.   
 
6.4.3 SUBJECT-SPECIFIC MODELLING 
The averaged results show that the model is capable of identifying the hemodynamic trends of PE. 
However, it is important to know how each subject (or patient) responds to the disorder to optimise 
treatment for the individual. Hence, in this research the time varying trends for each pig were also 
analysed. 
Pulmonary vascular resistance (Rpul) increased in all the pigs (Figure 6.9), as expected, indicating that 
the PE was successfully induced in each of the subjects in this study. An increase in right ventricular 
contractility (Ees,rvf), reflecting one of the CVS compensatory reflex mechanisms to the pulmonary 
blockage, was also detected by the identification process.  These results, as shown in Figure 6.9, 
illustrate how the subject-specific models were able to monitor the effect of the obtrusive blood 
clots, and identify the magnitude of each pig’s compensatory reflex response to PE. 
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When the reflex responses of the pigs can no longer handle the effects of the pulmonary embolism 
the right ventricle begins to distend and the preload of the left ventricle begins to decrease quickly.  
Thus, the right ventricle expansion index in the model was used as an indicator of the severity of PE. 
Large increases in RVEI were seen near death in Pigs 1 and 2, as shown on Figure 6.9, indicating that 
the subject-specific models are capable of identifying the severity of the PE. 
 
6.4.4 LIMITATIONS 
Most of the limitations are the same as stated in Section 4.6.3. One major limitation of this type of 
research is the uncertainty regarding whether the animal model of the PE reflects the true disease. 
However, it is pretty obvious from the measurements recorded in this animal study and 
corresponding identified CVS models that pulmonary vascular resistance increased after the 
insertion of blood clots. Indicating that the blood clots most likely did embolise from their insertion 
point in jugular vein to the pulmonary circulation where they obstructed blood flow. Thus, the 
effects of the induced PE in the animal study closely matched the known effects of the actual 
disease. 
One assumption used in the parameter identification method in this chapter was that the global end 
diastolic volume (GEDV) is equal to the sum of the left and right end diastolic volumes 
(LEVDV+RVEDV). This is not true in reality as GEDV represents the volume of the whole heart and not 
just the ventricles. When measured in practice GEDV also represents the volume of the initial part of 
the arterial system. However, GEDV has been found to be highly related to cardiac preload (Michard 
et al., 2003), which is primarily dominated by the left ventricle and right ventricle. Changes in GEDV 
mostly reflect changes in LVEDV and RVEDV, and hence, if required, a simple relationship can be 
used to relate the measured GEDV to the GEDV used in the parameter identification process. 
 
6.5 SUMMARY 
The identified subject-specific CVS models correctly estimated the known physiological responses to 
PE. An increase in right ventricle afterload (Rpul), the main hemodynamic consequence of PE, related 
well to the experimentally derived pulmonary vascular resistance. The individualised models also 
captured a loss of autonomous control of important reflex responses, Rsys and Ees,rvf, in Pigs 1 and 2 
leading to cardiovascular failure. Furthermore, the identified RVEI increased as emboli were inserted 
into the pigs, indicating a leftward shift in the intra-ventricular septum, which accurately matched 
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the changes in the measured RVEI.  These results clearly show that subject-specific models can be 
used to identify clinically useful and relevant cardiac and circulatory information in PE by accurate 
regular assessment of (model-based) subject-specific CVS status. Hence, this research demonstrates 
and proves the clinical relevance, concept and potential of this model-based approach to CVS 
monitoring and diagnosis of PE. 
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CHAPTER 7:  MODEL-BASED MONITORING OF SEPTIC SHOCK 
Septic shock is a common and serious dysfunction in the ICU affecting the heart and circulation. 
Thus, it is important to test the ability of the parameter identification method to track the 
hemodynamic changes due to septic shock. This chapter examines the ability of subject-specific CVS 
models to monitor the effects of septic shock in pigs (Revie et al., 2012). 
 
7.1 INTRODUCTION 
Sepsis is one of the most prevalent diseases in the ICU contributing to 10.4% of ICU admissions in the 
United States (Martin et al., 2003). Septic shock is the more severe form of sepsis accounting for 9% 
of ICU patients, with mortality rates ranging between 25-80% (Brun-Buisson, 2000, Angus et al., 
2001). The disease is caused by a harmful systemic inflammatory response to an infection. Its effects 
are wide reaching due to decreased oxygen delivery, which can result in multiple organ failure 
(Dellinger, 2003). The mortality rates are high, especially for the acute form of the disease, which is 
most prevalent in elderly (Girard et al., 2005) or immune-compromised individuals. In such patients, 
a weakened immune system cannot deal with the underlying infection as effectively as a healthy 
person.  Hence, these patients usually die unless the underlying infection is controlled.  
To increase the chances of survival it is important to diagnose, monitor, and treat septic shock, as 
early as possible. In recent times, it has been shown that early detection and application of goal 
directed therapy can help improve outcomes in response to the disease (Rivers et al., 2001). The use 
of an automated model-based monitoring system could help track more direct and controllable 
targets for treatment. Hence, the combination of a model-based monitoring and goal directed 
therapy could provide a means to further standardise therapy and improve patient outcomes. 
This chapter analyses the ability of subject-specific CVS models to track metrics of cardiovascular 
health during septic shock. The model identification method, outlined in Chapter 4, is retrospectively 
tested using measurements from a porcine study on septic shock (Lambermont et al., 2006). In this 
animal study, endotoxin infusions were used to induce septic shock and the pigs were then treated 
with a newly developed large pore hemofiltration therapy (LPHF). A range of hemodynamic 
measurements were recorded, and it was hypothesised that the filtration of small to medium sized 
water soluble cytokine molecules from the blood stream would reduce the systemic inflammatory 
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effects of septic shock resulting in improved circulatory dynamics. However, the aim of this study is 
not to test the effectiveness of the LPHF, but to assess the ability of the system to track the disease 
dependent hemodynamic changes resulting from endotoxin infusion and the resulting LPHF 
treatment.  
Subject-specific CVS models are again identified from clinically available data derived from the 
porcine measurements. The performance of the model identification method in septic shock is 
assessed against independent measurements not used for identification (Chapter 5), experimentally 
derived metrics (Lambermont et al., 2006), and clinically expected trends from the literature (Chan 
and Klinger, 2008, Dellinger, 2003, Merx and Weber, 2007, Parker et al., 1984, Schneider et al., 1988, 
Vincent et al., 1992, Groeneveld et al., 1988). Hence, the overall goal of this work is to demonstrate 
the clinical relevance and prove the concept (and potential) of computer-based clinical monitoring 
of: 1) CVS status; 2) septic shock; and 3) the effect of treatment. 
 
7.1.1 PATHO-PHYSIOLOGY AND TREATMENT OF SEPTIC SHOCK 
Septic shock is commonly caused by a Gram-negative bacterial infection which produces endotoxins 
(Werdan, 2001). High levels of endotoxins in the blood activate a systemic inflammatory response 
leading to systemic vasodilation (Werdan, 2001),  myocardial depression (Vincent et al., 1992), 
widespread endothelial injury (Mutunga et al., 2001), and disseminated intravascular coagulation 
(Fourrier et al., 1992).  The combination of these effects causes hypoperfusion leading to multiple 
organ dysfunction syndrome (Werdan, 2001). Treatment normally consists of aggressive fluid 
resuscitation, antibiotic administration, early goal directed therapy, and organ support (positive 
pressure ventilation, dialysis, etc) (Dellinger, 2003, Rivers et al., 2001). Vasopressors, such as 
norepinephrine or dopamine, are commonly used to increase blood pressure, and inotropes (e.g. 
dobutamine) may be used to assist cardiac function (Dellinger, 2003).  
Figure 7.1 from Dellinger (Dellinger, 2003) outlines the main effects of septic shock from a 
hemodynamic perspective. In untreated septic shock (Figure 7.1, A) left ventricular venous return 
decreases due to capillary leakage, increased venous capacitance, and increased pulmonary vascular 
resistance. Stroke volume is further compromised by decreased left and right ventricular 
contractility. HR and left ventricular compliance increase to partially restore CO and left ventricle 
preload. However, CO and LVEDV may remain below normal levels. Finally, systemic vascular 
resistance decreases to enables a higher SV at the cost of lower blood pressure, and thus, can lead 
to severe hypotension.  
  Model-Based Monitoring of Septic Shock 
123 | P a g e  
 
Aggressive fluid loading (Figure 7.1, C) increases venous return by counteracting the effects of 
capillary leak, increased venous compliance, and increased pulmonary vascular resistance. Cardiac 
function improves as left ventricular preload increases. Due to the combination of these factors, 
most patients exhibit a hyperdynamic state, after fluid resuscitation, with high CO and low systemic 
resistance. 
 
Figure 7.1: Illustration of the effects of septic shock before and after fluid resuscitation, from 
Dellinger (Dellinger, 2003). VR, venous return; VC, venous capacitance; AO, aorta; AR, arteriolar 
resistance; RA, right atrium; LA, left atrium; RV, right ventricle; LV, left ventricle;  PA, pulmonary 
artery. 
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The hemodynamic profile of the effects of septic shock is summarised below: 
• Hypovolemic 
o Capillary leak (Dellinger, 2003) 
o Venous dilation (Dellinger, 2003) 
o Decreased venous return (Chan and Klinger, 2008) 
• Cardiogenic 
o Decreased ventricular contractility (Chan and Klinger, 2008, Dellinger, 2003, Vincent 
et al., 1992, Merx and Weber, 2007) 
o Left-ward shift in inter ventricular septum (Chan and Klinger, 2008) 
• Hypoperfusion (despite adequate CO) 
o Decreased systemic resistance (Chan and Klinger, 2008, Parrillo et al., 1990) 
• Obstructive 
o Increased pulmonary vascular resistance (Chan and Klinger, 2008) 
o Activation of coagulation mechanisms (Chan and Klinger, 2008, Fourrier et al., 1992) 
• Distributive  
o Right ventricle dilation (Chan and Klinger, 2008) 
o Shunting (Dellinger, 2003) 
o Decreased splanchic blood flow (Dellinger, 2003) 
• Cytoxic 
o Inability of tissues to utilise O2 despite sufficient supply (Dellinger, 2003) 
 
7.2 METHODS 
7.2.1 PORCINE EXPERIMENTS AND DATA 
All procedures and protocols used in the porcine experiments were reviewed and approved by the 
Ethics Committee of the Medical Faculty at the University of Liege (Belgium). Four pure Pietrain pigs 
weighing 20-30kg were premedicated and anesthetised as described in (Lambermont et al., 2003, 
Lambermont et al., 2006). After endotracheal intubation, through a cervical tracheostomy, the pigs 
were connected to a volume cycle ventilator (Evita 2, Drager, Lubeck, Germany) set to deliver a tidal 
volume of 10ml/kg, with a fraction of inspired oxygen (FiO2) of 0.4, at a respiratory rate of 20 
breaths/min.  Respiratory settings were adjusted so the end tidal CO2 pressure ranged between 30 
and 35 mmHg. The animals received a 0.5-mg/kg endotoxin infusion (lipopolysaccharide from 
Escherichia coli serotype 0127:B8; Sigma Chemical, St. Louis, MO, U.S.A) over 30 minutes from T0 to 
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T30. From T60 onwards the pigs underwent a zero balance continuous veno-venous hemofiltration 
at a rate of 45 ml/kg/h with a 0.7 m2 large-pore (78 Å) membrane with a cutoff of 80 kDa (Sureflux 
FH 70, Nipro, Osaka, Japan) and a BaxterBM 25-BM 14 hemofiltration device (Baxter Health Care, 
Munich, Germany). Ultrafiltrate was replaced in the post dilution mode by a bicarbonate-buffered 
hemofiltration fluid (Na+: 150 mM; K+: 3 mM; bicarbonate: 30 mM) at a temperature of 37°C. 
Anticoagulation of the extracorporeal circuit was achieved using a loading dose of 5000 IU of heparin 
followed by an anticoagulation regimen based on the activated clotting time (100 - 200s). 
The pulmonary trunk was accessed via medial sternotomy and a micromanometer-tipped catheter 
(Sentron, Cordis, Miami, FL) was inserted into the main pulmonary artery through a stab wound in 
the RV outflow tract and positioned approximately 2 cm downstream of the pulmonary valve. Aortic 
pressure was measured using a micromanometer-tipped catheter inserted into the descending 
thoracic aorta through the right femoral artery. 7F, 12 electrode conductance micromanometer-
tipped catheters (CD Leycom,  Zoetermeer, Holland) were positioned in the left and right ventricles 
so that all electrodes were in their respective cavities. From these four catheters continuous 
measurements over 6 to 12 heartbeats were recorded every 30 minutes (T0 to T240) of the aortic 
and pulmonary pressure waveforms (Pao, Ppa), and the left and right ventricular pressure and volume 
waveforms (Plv, Vlv, Prv, Vrv) at a sampling rate of 200 Hz.  In this study, 34 sets of measurements from 
the four pigs were used. Further details on the trials can be found in (Lambermont et al., 2006).  
 
7.2.2 MODEL IDENTIFICATION 
The model identification method outlined in Chapter 4 was used to identify the subject-specific 
models of septic shock. In this study GEDV was assumed to be equal to the sum of the maximum left 
and right ventricular volumes. A left and right ventricle deadspace volume of 23 ml (Vd,lvf = Vd,rvf = 23 
ml) was used to simulate the CVS model as suggested by Desaive et al. (Desaive et al., 2008) . The 
mitral and tricuspid valve closure times were estimated from the approximated left and right 
ventricular functions (elv(t) and erv(t) ) from (Stevenson et al., 2012a, Stevenson et al., 2012b), as 
central venous pressure and ECG were not measured in this study. 
 
7.2.3 DATA AND STATISTICAL ANALYSIS 
Data is presented as mean +/- 1 standard deviation (SD) unless stated otherwise. A paired-sample t-
test was used to check temporal variance over T0 - T60 to analyse the effect of the endotoxin 
intervention. P < 0.05 was considered a statistically significant result. Percentage errors, and bias 
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and precision metrics were used to compare the relationship of the modelled to experimentally 
derived metrics.  A percentage error less than 20% was regarded as an acceptable result as 
measurement of physiological variables often lack precision, with errors of +/- 10-20% not 
uncommon (Clancy et al., 1991, Critchley and Critchley, 1999, Salandin et al., 1988). 
 
7.3 RESULTS 
Data sets were recorded every 30 minutes (T0, T30, T60,... ...,T240) in each of the four hour long 
trials. From each of the data sets, subject-specific models were retrospectively fitted for each of the 
pigs. Hence, a total 34 subject-specific CVS models were identified and analysed.  
In this study, each animal acts as their own control with baseline (T0) measurements reflecting the 
undiseased state of the pig. The temporal variance in the measurements of the cohort were 
analysed between T0-T30, as well as T0-T60 and T30-T60. The reason temporal variance was 
analysed over T0-T60 and T30-T60 is because sometimes the symptoms of septic shock do not 
manifest immediately after the endotoxin infusion at T30. Statistically significant temporal changes 
(P<0.005) were noticed in the measured systolic and diastolic aortic and pulmonary artery pressures, 
left and ventricular end diastolic volume (LVEDV, RVEDV), heart rate (HR), and maximum left 
ventricular pressure (Plv,max) over the first hour, underlining the pathological changes occurring in the 
animals due to the endotoxin infusion. A summary of the main hemodynamic measurements is seen 
in Figure 7.2.  
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Figure 7.2: Evolution of the averaged hemodynamic measurements recorded during the trials. * 
indicates P<0.05 for expected temporal changes over T0-T60 due to the induction of septic shock. 
The data is presented as mean +/- SD.  
 
7.3.1 COMPARISON TO EXPERIMENTALLY DERIVED METRICS 
For further validation (on top of the validations shown in Chapter 5), the identified pulmonary 
afterload, right ventricular end systolic elastance, and right ventricular vascular coupling (RVVC) 
from the model were compared to corresponding metrics (Ea, Ees, Ees/Ea) derived experimentally 
using pressure-volume loop analysis from the same measurements (Lambermont et al., 2006). The 
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afterload on the right ventricle in the model is the pulmonary vascular resistance divided by the 
period of one heartbeat (Ea,model = Rpul/T).  Bias, precision, and correlation indices for pulmonary 
afterload and coupling are shown in Table 7.1 and the temporal trends for these indices are shown 
in Figure 7.3, Figure 7.4, and Figure 7.5 . The model matched the changes in pulmonary afterload 
accurately (R2 = 0.86) although there was a noticeable bias of -0.06 mmHg/ml. The model parameter 
Ees,rvf is directly comparable to experimentally derived right ventricular end systolic elastance and 
was found to have bias of and precision of -0.48 +/- 0.40 mmHg/ml (R2= 0.66). Furthermore, a 
relatively small bias and spread of -0.73 +/- 0.83 was observed for the RVVC with correlation of R2 = 
0.83 as seen in Figure 7. 
 
Table 7.1: Bias, precision, and correlation metrics comparing the modelled to experimentally derived 
indices of afterload, contractility, and right ventricular vascular coupling (RVVC). 
Metric Bias Precision (2SD) R
2
 
Afterload (Ea) -0.27mmHg/ml 0.48 mmHg/ml 0.94 
Contractility (Ees) -0.48 mmHg/ml 0.40 mmHg/ml 0.66 
RVVC (Ees/Ea) -0.14 0.67 0.71 
 
 
Figure 7.3: Comparison of the experimentally derived (Lambermont et al., 2006) and modelled 
pulmonary afterload. The data is presented as mean +/- SD. 
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Figure 7.4:  Comparison of the experimentally derived (Lambermont et al., 2006) and modelled right 
ventricular end systolic elastance (Ees,rvf). The data is presented as mean +/- SD. 
 
 
Figure 7.5: Comparison of the experimentally derived (Lambermont et al., 2006) and modelled right 
ventricular-vascular coupling (RVVC). The data is presented as mean +/- SD. 
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7.3.2 SEPTIC SHOCK TRENDS 
Global hemodynamic trends during septic shock were examined through analysis using identified 
metrics of preload, afterload and contractility from the subject-specific CVS models. 
 
7.3.2.1 Preload 
Ventricular preload in the model is represented by ventricular end diastolic volume (LVEDV, RVEDV). 
Averaged LVEDV and RVEDV over all the pigs are seen in Figure 7.6. The averaged RVEDV increases 
throughout the study indicating right ventricular distension. LVEDV remains 10 ml to 15 ml below its 
baseline (T0) durind the trial, as expected (Chan and Klinger, 2008, Schneider et al., 1988). 
 
Figure 7.6: Modelled left and right ventricular end diastolic volume (LVEDV, RVEDV). The data is 
presented as mean +/- SD. 
 
7.3.2.2 Afterload 
The model parameters for systemic and pulmonary vascular resistance (Rsys, Rpul) represent the main 
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baseline value by the end of the study after an initial spike at T30. These results match clinically 
expected trends (Dellinger, 2003, Groeneveld et al., 1988, Vincent et al., 1992). 
 
Figure 7.7: Modelled left and right ventricular afterload. The data is presented as mean +/- SD. 
 
7.3.2.3 Contractility 
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ventricles. The evolution of model parameters, Ees,lvf and Ees,rvf, through time is shown in Figure 7.8. 
An initial spike in both parameters is seen at T30, where afterwards the parameters increase and 
then start decreasing at the end of study (T150 onwards). 
0 30 60 90 120 150 180 210 240
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
Va
sc
ul
ar
 
re
si
st
an
ce
 
(m
m
Hg
.
s/
m
l)
Time (min)
 
 
Systemic
Pulmonary
  Model-Based Monitoring of Septic Shock 
132 | P a g e  
 
 
Figure 7.8: Modelled left and right ventricular end systolic elastance (Ees,lvf, Ees,rvf). The data is 
presented as mean +/- SD. 
 
7.3.3 SUBJECT-SPECIFIC RESPONSE 
Although the averaged results, seen previously, show that the model is capable of identifying the 
hemodynamic trends of the induced disease over a cohort, inter-patient variability can be 
significant. It is important to know how each subject responds to the disorder and corresponding 
treatment. Hence, it is essential to analyse the individual time varying trends for each pig, not just 
the averaged trends of the disease.  
Figure 7.9 shows the subject-specific trends in the measured data for the pigs. The mean aortic 
pressure decreases initially in all the pigs, consistent with the known signs of septic shock. However, 
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whereas aortic pressure remains well below the baseline value in Pigs 3 and 4 at the end of the 
experiment. Mean pulmonary artery pressure increases during the trials in Pigs 1, 2, and 3 and 
hyperdynamic cardiac states are observed in Pigs 3 and 4 with large increases in cardiac output.   
The identified model parameters are shown in Figure 7.10. In the identified models, the main reason 
mean aortic pressures is restored in Pigs 1 and 2 is due to an increase is systemic vascular resistance, 
as there is no significant change in cardiac output. However, this result appears to come at the cost 
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of higher pulmonary resistances and pressures and may lead to decoupling of the right ventricle and 
pulmonary circulation.    
In the CVS models, the hyperdynamic states observed in Pigs 3 and 4 are caused by an initial increase 
in left ventricle contractility and a decrease in systemic resistance. In the absence of fluid 
resuscitation, cardiac output decreases at the end of the trials along with the identified left 
ventricular end systolic elastance, indicating the onset of myocardial depression. These results 
represent the known pathophysiological state of septic shock (Dellinger, 2003, Vincent et al., 1992). 
These findings, as expected, show there is significant inter-patient variability in response to the 
endotoxin and corresponding large-pore hemofiltration therapy. On average, systemic resistance 
drops by 20.3% across the four pigs over the duration of the trials. However, when analysing the 
individual response of each of the pigs, it is seen that the Rsys returns to baseline for Pig 2, and a 
substantial improvement is observed in Pig 1 after LPHF treatment (T60 onwards). Whereas, there 
are large drops in Rsys with no apparent improvement with treatment in Pigs 3 and 4, indicating the 
difference response to septic shock and therapy between the pigs. 
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Figure 7.9: Temporal evolution of the subject-specific hemodynamic measurement recorded during the porcine trials and used to identify the subject-
specific CVS models. 
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Figure 7.10: Identified subject-specific metrics of preload (LEVDV, RVEDV), afterload (Rsys, Rpul), and contractility (Ees,lvf, Ees,rvf). 
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7.4 DISCUSSION 
7.4.1 DETECTING SEPTIC SHOCK 
The subject-specific models of the CVS captured the main hemodynamic trends of septic shock. A 
drop in systemic vascular resistance, corresponding to a loss of vascular tone in the arterial system 
(Parrillo et al., 1990, Dellinger, 2003, Chan and Klinger, 2008), and an increase in pulmonary vascular 
resistance were noticed, a known result of the disease (Chan and Klinger, 2008, Dellinger, 2003). 
Initially, for Pigs 3 and 4 a decrease in Rsys leads to an increase in cardiac output, reflective of warm 
septic shock. Later in the trials, the decreasing ratio of the left to right ventricular afterload caused 
dilation of the right ventricle and a decrease in left ventricular preload (LVEDV).  These two factors 
would have resulted in a flattening of the intra-ventricular septum and a decrease in the left 
ventricular function (Chan and Klinger, 2008). This point is reinforced through analysis of left 
ventricular contractility, Ees,lvf, which increases initially, but starts to drop in the later stage of the 
trials. Hence, the model appears to be accurately capturing the expected trends of septic shock in 
the pigs. 
 
7.4.2 COMPARISON TO EXPERIMENTALLY DERIVED METRICS 
The modelled metric of afterload (Rpul/T) underestimated the experimentally derived value, as seen 
on Figure 7.3. This result is expected as Rpul/T only represents the averaged steady state resistive 
component of afterload and does not take into account the pulsatile component of afterload due to 
the dynamic impact of stiffness in the circuit (Hunter et al., 2008). However, despite these 
limitations, the modelled afterload still captured the changes in afterload observed in the pigs with 
correlation of R2 = 0.86.    
Similarly, the modelled right ventricular contractility (Ees,rvf) underestimated the experimentally 
derived value calculated from regressive pressure volume loops. This finding is most likely the result 
of using a constant right ventricle deadspace volume (Vd,rvf) of 23 ml for the ESPVR in the model. In 
reality the deadspace volume would change as inotropic state changes in the pigs. However, due to 
the lack of available measurements it cannot be identified and is kept as a constant in the fitting 
process. However, by keeping Vd,rvf constant, changes in modelled Ees,rvf were accurately identified as 
shown by the good correlation of R2 = 0.66 with the true value, which is of greater importance 
clinically. 
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In the calculation of modelled right ventricular vascular coupling the systematic errors observed in 
Ees,rvf and Rpul/T  are cancelled out. Hence, there is only an average bias of -0.73 in the modelled right 
ventricular vascular coupling metric. Because the trends the modelled Ees,rvf and Rpul/T are the 
calculated trend in RVVC is also good with R2 = 0.83. These examples illustrate how the subject-
specific CVS models can accurately monitor disease-dependent changes in right ventricular function.   
 
7.4.3 HEMODYNAMIC EFFECTS OF LARGE PORE HEMOFILTRATION 
Systemic vascular resistance began to increase one hour after the treatment was started (T120) in 
Pigs 1 and 2.  As a result, mean aortic pressure increased in these two pigs independent of changes 
in cardiac output. These results tentatively suggest that LPHF was responsible for increasing systemic 
vascular resistance through the removal of inflammatory molecules in Pigs 1 and 2. Thus, the 
treatment helped maintain coupling between the left ventricle and arterial system. Although, the 
treatment appeared to have little effect on the other two pigs. Larger trials would be required 
before a more substantiated conclusion on this therapy could be made, which was not the goal of 
this research. However, it is clear the model has accurately segregated those subjects who did (and 
did not) respond positively to the endotoxin insult, due either to internal cardiovascular reflexes or 
because of the effects of this therapy. 
 
7.4.4 SUBJECT-SPECIFIC MODELLING 
Section 7.3.2 shows that personalised CVS models can be used to accurately match and predict 
important hemodynamic markers of  afterload (Rsys, Rpul), preload (LVEDV, RVEDV), and inotropy 
(Ees,lvf , Ees,rvf).  The subject-specific models were also able to track the main hemodynamic changes in 
resulting from induced septic shock. The results show that the new model identification method 
utilised is capable of accurately identifying markers of cardiovascular health, like the previous 
integral-based method (Starfinger et al., 2008a, Starfinger et al., 2007). However, this improved 
method is clinically more relevant, as it requires a much smaller, more clinically available set of 
measurements including features from the aortic and pulmonary artery pressures, SV, GEDV, and 
the mitral and tricuspid valve closure times.   Hence, the method is a significant improvement on 
previous work (Starfinger et al., 2008a, Starfinger et al., 2007), especially with respect to clinical 
feasibility.  
Although the measurements in this study were only taken intermittently every 30 minutes, the 
system has the potential to provide continuous real time information to medical staff. Accurate 
  Model-Based Monitoring of Septic Shock 
138 | P a g e  
 
model identification can be achieved using low fidelity pressure measurements, as only the main 
features of the aortic and pulmonary artery pressure are required such as the mean, amplitude and 
maximum gradient. In practice, the aortic pressure could be inferred from the radial artery pressure 
using several possible methods (Chen et al., 1997, Hope et al., 2004, Pauca et al., 2001, Westerhof et 
al., 2008). The method could also be implemented in the ICU at little extra cost as it only uses 
measurements already taken in the ICU. Thus, adding no further invasive burden to the patient or 
staff. In addition, the system can be easily automated so that a full picture of a patient’s 
hemodynamic state is available to clinicians with little extra effort required from medical staff. 
 
7.4.5 LIMITATIONS 
Most of the limitations are the same as stated in Section 4.6.3. In this chapter, subject-specific CVS 
models were matched to measurements from an experimental animal model of septic shock with 
LPHF. It is difficult to known if this animal model accurately represents the same dynamics that are 
seen in a septic shock patient. However, the measurements shown in Figure 7.2 are consistent with 
known trends of the disease. It is also difficult to separate the effects of the hemofiltration therapy 
from the subject’s internal recuperative response to septic shock. Though, it is clear, through 
analysis of the results, that the method can track if the patient is getting better (or not), which is of 
greater importance. 
Systemic and pulmonary vascular resistance were used to analyse afterload in the subject-specific 
CVS models. Although it is widely accepted the systemic vascular resistance and pulmonary vascular 
resistance are not the best measures of ventricular afterload (Tibby and Murdoch, 2003, Lang et al., 
1986, Naeije, 2003, Hunter et al., 2008) they are still the most commonly surrogates of afterloads 
(Tibby and Murdoch, 2003). Hence, the systemic and pulmonary vascular resistance were chosen for 
examination of afterload in this study. 
 
7.5 SUMMARY 
The CVS monitoring system accurately estimated the known physiological responses to septic shock 
and tracked the effectiveness of continuous veno-venous LPHF. A decrease in systemic vascular 
resistance and increase in pulmonary vascular resistance was identified by the model, both well 
known trends of septic shock. RVVC in the model related closely to the experimentally derived 
metric calculated from the same measurement. Furthermore, restoration of systematic vascular 
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resistance was observed in two of the pigs, possibly due to the LPHF treatment, with no significant 
drop in mean aortic pressure noticed in these pigs. However, large drops in systemic resistance in 
Pigs 3 and 4 resulted in hyperdynamic states with hypotension. These results clearly show that 
subject-specific models can be used to accurately identify and discriminate clinically useful and 
relevant cardiac and circulatory information in acute CVS dysfunction by accurate regular 
assessment of (model-based) subject-specific CVS status. The ability to accurately segregate 
between successful and unsuccessful response to therapy is a further significant validation of this 
model and method. Hence, this research demonstrates and proves the clinical relevance, concept 
and potential of this model-based approach for hemodynamic monitoring and diagnosis of septic 
shock. 
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CHAPTER 8: MODEL-BASED MONITORING OF RECOVERY POST MITRAL VALVE 
SURGERY 
This chapter looks at using a model-based parameter identification approach to retrospectively 
analyse the initial recovery from mitral valve repair or replacement in the ICU. The aim of this work 
is to use patient-specific CVS models to monitor hemodynamic recovery post mitral valve surgery. 
The results of this chapter provide the first clinical proof of concept of this model-based approach on 
human measurements. 
 
8.1 INTRODUCTION 
Mitral regurgitation is one of the most common forms of valvular heart disease affecting 
approximately 2% of the population (Nkomo et al., 2006). Because of this high prevalence, mitral 
valve replacement and repair are regularly-performed surgical procedures in the hospital. Operative 
mortality rates for the mitral valve replacement are estimated to be 5% in elderly patients (>75 
years) (Detaint et al., 2006) and 8% when performed in tandem with coronary artery bypass surgery 
(CABG)(Edwards et al., 2001). There are high risks of post-operation complications in patients 
undergoing mitral valve surgery. Hence, they are often admitted to the ICU during the first one-to-
two days post-surgery. During this period, it is essential to accurately monitor and track important 
signs of cardiac and circulatory health to ensure hemodynamic recovery. 
This chapter examines the ability of the parameter identification method of Chapter 4 to capture the 
state of global hemodynamic recovery post mitral valve surgery using the circulatory measurements 
taken as part of normal care. To do this, hemodynamic measurements were retrospectively 
collected from the Christchurch hospital ICU electronic patient database. These measurements 
reflect a realistic uncontrolled clinical scenario. Hence, they provide the perfect backdrop for the 
first human clinical test of this model-based monitoring method.   
The overall objective of this chapter is to test the ability of a model-based method to track clinically 
relevant signs of hemodynamic recovery. Patient-specific CVS models are identified using data 
recorded from the first 12 hours of ICU admission. Parameters and metrics derived from the patient-
specific models are examined to analyse the performance of the approach. 
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8.1.1 MITRAL REGURGITATION, REPAIR, REPLACEMENT, AND RECOVERY 
Mitral valve regurgitation occurs when the mitral valve does not close properly after left ventricular 
filling. Blood leaks backwards through the valve during left ventricular contraction and ejection due 
to the failure of the valve to fully close. This phenomenon is known as regurgitation (Stouffer, 2008).  
The most common cause of primary mitral regurgitation is mitral valve prolapse due to myxomatous 
degeneration (Hayek et al., 2005). Myxomatous degeneration causes the valve leaflets and chordae 
tendineae to stretch (Hayek et al., 2005, Devereux et al., 1976). The elongated leaflets and chordae 
tendineae prevent the valve leaflets from fully sealing when the valve is closed, causing the leaflet to 
prolapse into the left atrium, as shown in Figure 8.1. Other causes of primary mitral regurgitation 
include ischemic heart disease (Martinez-Selles et al., 2009), rheumatic fever (Martinez-Selles et al., 
2009), and Marfan Syndrome (Devereux et al., 1976). Secondary mitral regurgitation results from 
systolic left ventricular dysfunction, in the presence of normal valvular structure (Yiu et al., 2000). 
Acute mitral regurgitation is commonly caused by endocarditis (Mokadam et al., 2011). 
HeartHeart
Normal valve 
leaflet position
Prolapsed valve leaflet
Blood Flow
Blood Flow
Chordae
Tendineae
 
Figure 8.1: Illustration of a normal and prolapsed mitral valve leaflet (yalemedicalgroup.org, 2012). 
 
The patho-physiology of mitral regurgitation can be broken into three phases: the acute phase, the 
chronic compensated phase, and the chronic decompensated phase (Bonow et al., 2006, Otto, 2001, 
Carabello, 2008, Kusiak and Brest, 1986). In the acute phase, the left ventricle and atrium experience 
a volume overload (Bonow et al., 2006). The ventricle has to pump the sum of the forward flow, into 
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the aorta, and the regurgitant flow, into the atrium. Hence, the total stoke volume (combination of 
forward and backwards flow) of the ventricle is increased in the acute setting, normally due to more 
complete emptying of the heart (decreased LVESV). As a result, the ejection fraction increases. 
However, forward flow is normally decreased (Bonow et al., 2006). As the disorder progresses the 
left ventricular volume increases and contractile function deteriorates, leading to decreased ejection 
fraction. The regurgitant flow also causes a pressure and volume overload in the left atrium (Bonow 
et al., 2006). The increased atrial pressure inhibits the venous return from the lungs and causes 
pulmonary congestion (Bonow et al., 2006). 
In the chronic compensated phase, mitral regurgitation develops slowly over months to years giving 
the heart time to adapt to the disorder. The left ventricle develops eccentric hypertrophy 
(enlargement of the ventricular muscle) to compensate for the increased SV and LVEDV (Bonow et 
al., 2006). The eccentric hypertrophy and increased LVEDV help maintain cardiac output at near 
normal levels (Bonow et al., 2006). The left atrium also adapts by enlarging, allowing the filling 
pressure in the chamber to decrease (Bonow et al., 2006). This decreased filling pressure improves 
venous return from the lungs, alleviating the effects of pulmonary congestion (Bonow et al., 2006). 
Due to these compensatory mechanisms, individuals with chronic compensated mitral regurgitation 
may be asymptomatic. 
Eventually, maybe after many years, an individual in the compensated phase will develop left 
ventricular dysfunction (Bonow et al., 2006), a sign of the decompensated phase of the disease. In 
the chronic decompensated phase, the contractility of the myocardium can no longer compensate 
for the regurgitant volume, leading to a decrease in total SV (Bonow et al., 2006). Decreased total SV 
results in decreased forward flow and an increase in LVESV (Bonow et al., 2006). The increased filling 
volume translates to increased filling pressures in the ventricle and atrium, leading to increased 
pulmonary congestion (Bonow et al., 2006). The left ventricle also begins to dilate in this phase, 
resulting in dilation of the mitral annulus, further worsening the effects of mitral regurgitation. As a 
result of these factors, ejection fraction normally decreases, although it may still remain in a normal 
range (Bonow et al., 2006). 
Mitral valve surgery is the recommended treatment for severe mitral regurgitation (Bonow et al., 
2006).  This can include mitral valve repair or replacement (MVR). Valve replacement involves a 
substitution of the diseased valve with a mechanical or bioprosthetic valve, via surgery. 
Alternatively, the mitral valve can be repaired, especially if it is only minimally damaged. Advantages 
of mitral valve repair include lower surgical mortality and improved long term survival (Enriquez-
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Sarano et al., 1995). Surgical mortality rates range between 3.8% for valve replacement and 1.4% for 
valve repair (Gammie et al., 2009). 
After surgery patients are admitted to the ICU for close monitoring. Post-operative risks of mitral 
valve surgery include atrial fibrillation, pulmonary edema, ARDS, and pulmonary embolism. Hence, in 
this early stage of recovery, inotropic, fluid resuscitation, and ventilator support are normally 
required to assist respiratory and cardiac function.  
Given this information, the expected hemodynamic recovery profile post-mitral valve surgery can be 
summarised as: 
• Valvular 
o Decreased mitral valve regurgitation (Flameng et al., 2003, Foster et al., 2007, 
Bolling et al., 1998) 
• Cardiogenic 
o Increased left ventricle contractility (Starling, 1995) 
o Increased cardiac output (Bolling et al., 1998, Braunwald et al., 1965) 
• Distributive 
o Decreased left ventricle volume (although may be masked by fluid resuscitation) 
(Bolling et al., 1998) (Starling, 1995) 
o Decreased right ventricle volume (although may be masked by fluid resuscitation) 
(Grapsa et al., 2012) 
• Circulatory pressures 
o Decreased right ventricle and pulmonary artery pressure (Braunwald et al., 1965, 
Foltz et al., 1984) 
o Decreased left ventricle filling pressure (Starling, 1995, Braunwald et al., 1965, Foltz 
et al., 1984) 
• Obstructive 
o Decreased pulmonary vascular resistance (Braunwald et al., 1965, Foltz et al., 1984) 
 
The CVS model has parameters to reflect these conditions, and should thus be able to capture the 
overall broad profile, or, critically deviations from the desired profile. 
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8.2 METHODS 
8.2.1 CLINICAL STUDY 
The clinical study was a retrospective, observational, single centre study performed at the 
Christchurch Hospital mixed medical-surgical ICU. Auditing ethics was obtained for this observation 
study from the Upper South A Regional Ethics Committee (REF: URA/12/EXP/023). The study used 
data collected over a six month period from the 1st February to the 1st July 2012. 
 
8.2.2 PATIENTS 
The inclusion criteria for patients in the study included: 
• Diagnosed mitral valve regurgitation 
• Underwent mitral valve replacement or repair surgery 
• Immediate admission to the ICU post operation 
• Swan-Ganz catheterisation for > 12 hours after ICU admission 
Over the six month period four patients fulfilled these criteria. The demographics of these four 
patients are shown in Table 8.1. Overall they represent a normal range of cardiovascular disorders, 
as well as mitral valve surgeries. Hence, they should provide a suitable initial test of the model 
capability in a clinical setting.  
Table 8.1: Demographics of patients who underwent mitral valve (MV) surgery. CABG, coronary 
artery bypass surgery; AV, aortic valve; CAD, coronary artery disease; IHD, ischemic heart disease; 
AF, atrial fibrillation. Note CABGx2 or x4 refers to double or quadruple coronary artery bypass graft.  
Patient # 1 2 3 4 
Age 75 64 82 75 
Sex (M/F) M M M M 
Height (cm) 187 155 160 164 
Weight (kg) 96 56.5 65 69 
BMI (kg/m
2
) 27.5 23.5 25.3 25.6 
Surgery MV repair and 
CABG x2 
MV replacement MV repair and 
CABGx4 
MV repair and AV 
replacement 
Reason for MV 
surgery 
MV regurgitation 
and CAD 
MV regurgitation MV regurgitation 
and IHD 
MV and AV 
regurgitation 
Other diagnoses CAD, 
hypertension 
 IHD, pulmonary 
hypertension,  
hypertension, 
dyslipidaemia 
AV regurgitation,  
transient ischemic 
attack, AF, 
pneumonia, 
hypertension 
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8.2.3 MEASURED DATA 
Hemodynamic measurements from the first 12 hours of ICU admission were retrospectively 
obtained from a secure ICU database. Swan-Ganz derived measurements of cardiac output (CO) and 
the pulmonary artery pressure waveform (Ppa) were collected. Other data collected included: 
a) Hemodynamic measurements of radial arterial pressure (AP), central venous pressure (CVP) 
and ECG waveforms. 
b) Measures of respiratory function, peak inspiratory pressure (PIP), positive end expiratory 
pressure (PEEP), fraction of expired oxygen (FiO2), and oxygen saturation (SpO2). 
c) Administered vasoactive drugs and fluids, and urine output. 
d) Patient demographics. 
 
8.2.4 INFERRED DATA 
Further data required by the parameter identification method, was inferred from each patient’s 
demographics data or from the available measurements. A baseline total blood volume (TBV) 
estimation was calculated using the Nadler formula (Nadler et al., 1962).  Hence, for males, TBV was 
calculated using: 
 6041.003219.03669.0 3 +×+×= weightheightTBV  (8.1) 
 
and for females using, 
 1833.003308.03561.0 3 +×+×= weightheightTBV  (8.2) 
 
where height is in metres and weight is in kilograms. Changes in TBV from baseline were assumed to 
be equal to the balance of fluid entering and exiting the patient. The total blood volume in the heart 
(HBV) was estimated to account for 7% of the blood in the CVS (Guyton and Hall, 2000). 
Furthermore, approximately 70% of the blood in the heart resides in the ventricles. Using these 
assumptions the total volume in the ventricles (GEDV) can be calculated from TBV using: 
 TBVGEDV ××= 07.07.0  (8.3) 
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In this research GEDV is refers to the sum of the maximum left and right ventricle volumes 
(GEDV=LVEDV+RVEDV) 
Moreover, the aortic pressure waveform was derived from radial pressure using the general transfer 
function from the work of (Chen et al., 1997), and changes in intrathoracic pressure (Pth) in the 
model were estimated using a linear relationship with PEEP, as derived from the results of (Smiseth 
et al., 1996): 
 85.1
PEEPPth =  (8.4) 
 
where both PEEP and Pth are in millimetres of mercury. 
 
8.2.5 PARAMETER IDENTIFICATION 
The parameter identification method outlined in Chapter 4 was used to identify the subject-specific 
CVS models. Measurements used as convergence criteria for the parameter identification method 
were averaged over two breathing cycles. Analytical time varying elastance functions, defined by 
Equation (3.51), were used to represent elv(t) and erv(t). The tricuspid valve closure time was not 
required as CVP was measured. CVP was assumed to be equal to Pvc in the model.  The closure time 
of the mitral and tricuspid valves were assumed to be the same. Hence, the intercept between the 
modelled Pvc and right ventricle pressure (Prv) was assumed to be equal to the mitral valve closure 
time in the parameter identification.  
In the parameter identification method, Equation (4.25) was slightly modified to better match 
human data (instead of pig data). To do this, Pvc was removed from the equation as central venous 
pressure does not a significant effect on left ventricle afterload in humans, and therefore, does not 
influence left ventricle contractility. Hence, the following equation is now used to calculate CE: 
 
rvfeslvfes
lvfes
truemeanpatruemeanao
truemeanao
E EE
E
PP
P
C
,,
,
,,,,
,,
+
≈
+
=  (8.5) 
 
In this study, CE was allowed to vary with time, and thus, was not enforced as a constant for each 
patient in the parameter identification process, as had been done in the pigs studies of Chapters 6 
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and 7. This was done to allow for the possibility that CE could change over the longer 12 hour 
observational period used in the human study, as opposed to relatively short 4 hour pig trials.  
Through these assumptions, subject-specific CVS models were matched to the clinically obtained 
hemodynamic measurements. Models were identified from the clinical data at hourly intervals, from 
T0, representing admission to the ICU, to T12, 12 hours later. Hence, 52 subject-specific CVS models 
were identified for the four patients. 
 
8.3 RESULTS 
8.3.1 RECORDED DATA 
All the patients initially required ventilator support on their admission to the ICU. Heart stimulants 
(inotropes) and fluid resuscitation were used to improve cardiac and circulatory function in 
conjunction with hemodynamic monitoring. These were dosed by the attending clinician. An 
overview of the administered therapies for each patient can be seen in Appendix B  
For this research, hemodynamic measurements were recorded every hour over the first 12 hours 
(T0, T1, T2,... , T11, T12) after admission to the ICU. These measurement sets were pre-processed 
and averaged over 2 breathing cycles (approximately 6 – 12 heartbeats) before they are used in the 
parameter identification method.  Figure 8.2 summarises these main hemodynamic measurements 
for each patient. 
On average, mean aortic pressure increased from 78.0 to 89.3 mmHg, mean pulmonary artery 
pressure dropped from to 33.3 to 23.8 mmHg, stroke volume improved from 48.6 to 65.0 ml, and 
heart rate decreased from 83.2 to 73.3 bpm, over the 12 hour period.   Individually, Patients 1, 2, 
and 3 had similar trends including a relatively constant aortic pressure, decreasing pulmonary artery 
pressure, increasing stroke volume, and decreasing heart rate. In contrast, a large increase in aortic 
pressure and a drop in stroke volume are noticed for Patient 4, as seen on Figure 8.2. Hence, 
Patients 1-3 were following the clinically desired path, while Patient 4 was less stable or certain in 
recovery.  
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Figure 8.2: Evolution of the patient-specific hemodynamic vital signs recorded during the first 12 hours post mitral valve surgery. 
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8.3.2 PATIENT-SPECIFIC MODELS 
Patient-specific CVS models were fitted to the data sets at one hour intervals (T0-T12, 13 per 
patient). Modelled indices of preload (LVEDV, RVEDV), afterload, (Rsys, Rpul), and contractility (Ees,lvf, 
Ees,rvf) were analysed along with the left ventricle filling pressure (Ppu) of the left ventricle, as shown 
in Figure 8.3.   
 
8.3.2.1 Preload 
Left and right ventricle preload, as analysed through the modelled LVEDV and RVEDV, increased in 
all patients. This result was expected as all patients had been administered fluids and had a positive 
fluid balance after 12 hours of admission to the ICU (see Appendix B). The increased preload partially 
explains the average increase in measured SV seen in these patients, as shown on Figure 8.1. 
 
8.3.2.2 Afterload 
Left ventricle afterload, represented by Rsys in the model, stayed relatively constant in Patients 1, 2, 
and 3. In Patient 4, Rsys increased constantly throughout the 12 hours. The resulting increase in left 
ventricle afterload was most likely responsible for the observed increase in mean aortic pressure, 
and the decrease in SV, which is consistent with the known ventricular response to increased 
afterload (Klabunde, 2004).  
In contrast, right ventricle afterload, represented by Rpul in the model, decreased for Patients 1, 2, 
and 3. These findings are expected due to the inhibition of pulmonary arteriolar vasoconstriction 
mechanisms post surgery (Foltz et al., 1984). The decrease in Rpul is partially responsible for the 
decrease in the measured pulmonary artery pressures in these patients. No substantial change in Rpul 
was observed in Patient 4 throughout the 12 hour period. This result explains why there was only a 
minor drop in mean pulmonary artery pressure in Patient 4. 
 
8.3.2.3 Contractility 
Identified left ventricular contractility (Ees,lvf) increased in Patients 1, 2, and 3, indicating improved 
contractile state. In Patient 4, Ees,lvf decreased, signifying a depressed cardiac state. These changes in 
left ventricle contractility partially account for the increase in SV seen in Patients 1-3 and the 
decrease in SV seen in Patient 4. 
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For Patients 1, 2, and 3 no substantial change was seen in right ventricular contractility (Ees,rvf). 
However a large drop was observed in Patient 4. This result further suggests the cardiac state of 
Patient 4 is depressed post mitral valve repair. 
 
8.3.2.4 Left ventricle filling pressure 
In the model, the left ventricle filling pressure is represented by the pulmonary vein pressure (Ppu). 
Ppu is highly rated to the end systolic pressures in the left ventricle, which are elevated during mitral 
regurgitation. Thus, a drop in Ppu should occur as the cardiovascular system adapts to the cessation 
of regurgitant flow post mitral valve correction (Foltz et al., 1984). As expected, Ppu decreased in all 
patients 12 hours after admission to the ICU. This drop in pulmonary vein pressure is partially 
responsible for the decline in pulmonary artery pressures, indicating a decreased likelihood of 
pulmonary congestion in these patients 
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Figure 8.3: Evolution of the patient-specific metrics of preload (left and right end diastolic volumes), afterload (systemic and pulmonary vascular resistance), 
contractility (left and right ventricular end diastolic elastances), and ventricular filling pressures (pulmonary vein pressure) identified from the CVS model.
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8.4 DISCUSSION 
8.4.1 MODEL-BASED APPROACH 
The model-based approach used in this chapter provides a way of approximating metrics of preload 
(LVEDV, RVEDV), afterload (Rsys, Rpul), and contractility (Ees,lvf, Ees,rvf), post mitral valve operation. 
Metrics specific to mitral insufficiency could also be tracked, such as pulmonary vein pressure, an 
important metric of mitral regurgitation and pulmonary congestion. Thus, the identified CVS models 
can be used to reveal the hemodynamic reasons why the patients react differently to the mitral 
valve correction. 
The parameter identification method only used measurements that were taken as part of normal 
clinical care. Thus, these measurements reflect a realistic uncontrolled clinical scenario. Most of 
these measurements, except for the patient demographic data, can be continuously measured and 
electronically stored to a database. Hence, the approach has the potential to be automated and to 
provide real time information to make therapeutic decisions. Further potential benefits of the 
approach are that it could be implemented at little extra cost and effort as it does not require any 
additional hardware, measurements, or interventions from the medical staff. 
 
8.4.2 PATIENT-SPECIFIC MODELLING OF HEMODYNAMIC RECOVERY 
The patient-specific models observed a decrease in pulmonary vein pressure and a decrease in Rpul 
over the duration of the study. The combination of these factors explains the decrease in pulmonary 
artery pressure in the patients. These results are consistent with the findings of Foltz et al. (Foltz et 
al., 1984) whom found that mitral regurgitation-induced elevated left ventricle filling pressures and 
pulmonary vasoconstriction are rapidly reversed post mitral valve surgery. 
The patient-specific CVS models observed clinically relevant signs of cardiac recovery in 3 of the 4 
patients in the study (Patients 1, 2, and 3). Left ventricle filling pressures decreased (Braunwald et 
al., 1965, Starling, 1995) and left ventricular contractility increased (Starling, 1995), leading to 
increased cardiac output in these patients. These results indicate the cardiovascular system is 
compensating well to the alterations in mitral valve function. 
In the other patient (Patient 4), a decreased left and right ventricle contractility and increased 
systemic resistance was noticed, contributing to a decrease in stroke volume and increase in aortic 
pressure. The combination of these factors caused left ventricle dilation. This effect is symptomatic 
of patients with decompensated hearts, where an increase in left ventricle afterload after valve 
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replacement leads to a decline in ejection fraction (Goldfine et al., 1998, Zile et al., 1985). The mitral 
valve surgery has effectively removed the low resistance conduit for backwards ejected flow from 
the ventricle. Thus, the left ventricle can only eject through the high resistance conduit of the 
systemic circulation. The weakened contractile state of the left ventricle in Patient 4 does not appear 
to be able to compensate for this apparent increase in afterload (Leung et al., 1996, Zile et al., 1985, 
Goldfine et al., 1998). Hence, the CVS model of Patient 4 indicates that ventricular dilation and 
decreased left ventricular end systolic elastance are responsible for the decrease in stroke volume, 
leading to decreased ejection fraction, which is common after surgical correction of the mitral valve 
(Suri et al., 2008). The identified model parameters for Patient 4 also show a decoupling between 
the ventricular and arterial system due to decreased left ventricular function an increased left 
ventricular afterload. This decoupling indicates the transfer of blood between the ventricle and 
arterial system is becoming less efficient. These examples illustrate how patient-specific models can 
be used differentiate patients with compensated cardiac function from patients with 
decompensated cardiac function after mitral valve repair or replacement. Hence, the model can be 
used to track the progression of recovery in ICU patients post mitral valve surgery. 
 
8.4.3 LIMITATIONS 
The heart valves in the CVS model do not allow backwards flow. Hence, the model is unable to 
simulate the effects of residual mitral regurgitation post surgery. However, in most cases this is not a 
problem as the regurgitation is normally minimal or non-existent immediately after mitral valve 
replacement or repair (Bolling et al., 1998, Flameng et al., 2003, Foster et al., 2007). 
Population-based empirical equations were used to estimate the total blood volume and global end 
diastolic volume. These equations are not dependent on the cardiovascular state of the patient, and 
thus, may not precisely reflect the true value. However, they provide good initial approximations for 
the baseline (T0) convergence criteria and can be used in conjunction with the known fluid balance 
to interpret trends in the later identified CVS models (T1, T2, ...,T12). 
 
8.5 SUMMARY 
Patient-specific CVS models were retrospectively fitted to hemodynamic measurements taken from 
patients recovering from mitral valve surgery in the ICU. The model-based approach was able to 
track known trends in preload, afterload, and contractility in the patients, post mitral valve surgery. 
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A decrease in pulmonary artery pressure was observed due to a decrease in pulmonary vein 
pressure and pulmonary vascular resistance, a known response to mitral valve correction, leading to 
decreased pulmonary congestion. Furthermore, through analysis of contractility and preload, the 
approach was able to differentiate between patients with compensated and decompensated hearts. 
Thus, the method was able to discriminate between patients who responded positively against 
patients who responded negatively to the surgery during the first 12 hours of recovery. Hence, this 
chapter illustrates the clinical potential of patient-specific models in an ICU setting. 
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CHAPTER 9:  AORTA MODEL 
A model of arterial dynamics is used to describe the relationship between pressure and flow in the 
arterial system. The arterial model provides a more detailed description of arterial flow than the six-
chamber model of Chapter 3, but is a less comprehensive description of global cardiovascular 
dynamics. Hence, the arterial flow model is introduced in this chapter as an alternative modelling 
modality that can be used when modelling arterial dynamics is more important than simulating the 
hemodynamics of the whole CVS.  
 
9.1 INTRODUCTION 
A better understanding of the factors contributing to morphological changes in the aortic pressure 
waveform may help assist with analysing disease and treatment dependent hemodynamic changes 
that occur in the ICU patient (Mitchell et al., 2004, Hope et al., 2005, Thiele and Durieux, 2011).  
Model-based approaches can be used to help provide insights into the components that contribute 
to the shape of the aortic waveform. In 2003, Wang et al. (Wang et al., 2003) combined windkessel 
(Frank, 1898) and wave theories (Parker and Jones, 1990) to create a model of aortic hemodynamics 
that described the main components that make up the aortic pressure pulse. This model was able to 
account for the difference in shape between the aortic pressure and flow waveforms (Davies et al., 
2007, Wang et al., 2003), and suggested wave reflections only make a minor contribution to the 
shape of the aortic pressure waveform (Davies et al., 2010, Wang et al., 2003).  
This model was initially derived from windkessel theory (Frank, 1898), which treats the arterial 
system as an elastic reservoir. This reservoir acts as a hydraulic integrator, storing the flow going into 
the arterial system as volume. The changes in volume (ΔVwk) of the arterial reservoir are related to 
changes in pressure (ΔPwk) by the lumped compliance (C) of the arterial system, where ΔVwk is simply 
the difference between the flow in (Qin) and out (Qout) of the arterial system.   
Following the windkessel theory, Lighthill (Lighthill, 1978) suggested that the difference between the 
pressure generated by the 2-element windkessel model and the measured aortic pressure could be 
the result of pressure generated due to wave motion. He named this difference the excess pressure 
(Pex). Hence, excess pressure is defined as the difference between the aortic pressure and reservoir 
pressure (Pex = Pao – Pwk). By combining these two theories in a model, Wang et al. (Wang et al., 
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2003) found that the shape of the Pex closely matched the shape of Qin, indicating the two variables 
were related by the proximal resistance of the aorta (Rprox = Qin/Pex). Hence, through consideration of 
these findings, the following model representing flow and pressure in the aorta can be derived, as 
shown in Figure 9.1. In Figure 9.1, P∞ represents the downstream pressure to which the aortic 
diastolic pressure decays, R symbolises the peripheral systemic resistance, and C is the lumped 
compliance or capacitance of the arterial system. 
Pao Pwk P∞
Rprox
C
R
Qin Qout
 
Figure 9.1:  Schematic of the modified aortic model used in this research showing the flows in and 
out of the arterial system (Qin, Qout), the aortic pressure (Pao), reservoir pressure (Pwk). The 
parameters of the system are: Rprox, proximal resistance of the aorta; C, compliance of the arterial 
system; R, peripheral systemic resistance; and P∞ the downstream pressure of the arterial system. 
 
In this model, the excess pressure component (Pao - Pwk) describes pressure due to the dynamic 
viscous effects of the forward and backward travelling waves in the aorta. Whereas, the reservoir 
pressure simulates the ability of the arterial system to absorb flow ejected from the heart, store that 
flow as potential energy and volume, and release the volume later during the heartbeat as diastolic 
flow. Essentially, the arterial reservoir acts as means of spreading systolic flow ejected from the 
ventricle across the whole heartbeat before it reaches the capillaries. Thus, the reservoir helps 
smooth the flow of blood, oxygen, and nutrients to the organs of the body. An example of the aortic 
model splitting aortic pressure into its reservoir and excess pressure components is shown in Figure 
9.2. 
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Figure 9.2: Aortic pressure separated into reservoir (Pwk) and excess pressure (Pex) components. 
 
The aorta model can be used to provide insight into how energy and blood is transferred from the 
ventricle, through the arterial system, and into the capillaries. The following sections develop the 
equations, discuss the validity of the assumptions, and outline the limitations of this model. 
 
9.2 MODEL ASSUMPTIONS 
The assumptions used to create the arterial flow model are: 
• Conservation of mass 
• Poiseuille flow 
• Constant resistances, compliances, and downstream pressure 
• Backwards wave reflections are minimal during systole in the central aorta 
• The shape of the Pex and Qin are the same 
• Reservoir pressure is independent of position in the arterial system 
The validity of these assumptions is analysed in Section 9.5. 
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9.3 MODEL DEVELOPMENT 
The arterial flow model is based on the work of (Wang et al., 2003). It is proposed that the arterial 
pressure waveform is made of two components representing: 1) the time-varying reservoir pressure 
(Pwk), which is independent of position along the arterial tree, and 2) the excess pressure (Pex) which 
is dependent on time (t) and distance along the arterial tree (x):  
 ( ) ( ) ( )txPtPtxP exwkao ,, +=  (9.1) 
 
Frank Otto’s windkessel theory states that Pwk can be determined by assuming conservation of mass 
and a linear relation between pressure and volume: 
 
( ) ( )
( )
( ) ( ) ( )
C
tQtQ
dt
tdV
tdV
tdP
dt
tdP outinwk
wk
wkwk −
==  
(9.2) 
 
where, 
 
( )
( )tdP
tdVC
wk
wk
=  (9.3) 
 
In Equations (9.2) and (9.3), the linear relation between windkessel pressure and volume is 
represented by compliance (C). The flow out of the arterial system (Qout) is defined assuming 
poiseuille resistance (R) and a constant pressure downstream sink (P∞): 
 ( ) ( )[ ]R
PtP
tQ wkout ∞
−
=  (9.4) 
 
Hence, the driving force of the flow out of the arterial system is assumed to be pressure difference 
between Pwk and P∞. P∞ represents the asymptotic level to which diastolic pressure would decay if 
the heart stopped beating, and R symbolises the resistance of the peripheral circulation. Thus, 
substituting Equation (9.4) into Equation (9.2) gives: 
 
( ) ( ) ( )
C
tQ
RC
PtP
dt
tdP inwkwk
=
−
+ ∞  (9.5) 
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which has the general solution: 
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where t0 and P0 are the time and pressure at the beginning of ejection and τ = RC, the time decay 
constant. Equation (9.6) describes a hydraulic integrator where Pwk is related to the integral of Qin. 
When Qin = 0, as in diastole, Equation (9.6) simply describes a decaying pressure profile of decay rate 
τ. 
In this research, the reflected or backward travelling waves are assumed to be negligible in the 
central aorta. Hence, Qin is assumed to be linearly proportional to Pex, as indicated by the work of 
(Wang et al., 2003), giving: 
 ( ) ( ) proxinex RtQtP =  (9.7) 
 
where Rprox symbolises the proximal viscous resistance of flow in the aorta. Please note that Pex is 
now only a function of time. Substituting Equations (9.6) and (9.7) into Equation (9.1) gives: 
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Equation (9.8) is now analogous to a 3-element windkessel model. The inputs, outputs and 
parameters of the aorta model are outlined in Table 9.1. 
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Table 9.1: Inputs, outputs, and parameters of the aorta model. 
 Symbol Description Units 
Inputs Qin Flow into the aorta ml/s 
  
Outputs 
Pao Aortic pressure mmHg 
Pwk Reservoir/windkessel pressure mmHg 
Pex Excess pressure mmHg 
Qout Flow out of the arterial system ml/s 
 
Parameters Rprox Proximal resistance of the aorta mmHg.s/ml 
C Compliance of the arterial system ml/mmHg 
R Peripheral systemic resistance mmHg.s/ml 
P∞ Downstream pressure of arterial system mmHg 
 
9.4 SIMULATION 
The aorta model was simulated in Matlab. Qin, as the only input, was used to drive the model. The 
Matlab function ‘cumtrapz’, which uses the trapezium rule to approximate an integral, was used to 
numerically integrate Qin, as required by Equation (9.8). An example of inputs and simulated outputs 
of the aorta model for a healthy swine are shown in Figure 9.3. The parameter values used for this 
simulation are listed in Table 9.2. 
 
Table 9.2: Parameters used to simulate healthy swine hemodynamics. 
Parameter Value 
Rprox 0.1072 mmHg.s/ml 
C 0.4734 ml/mmHg 
R 1.3229 mmHg.s/ml 
P∞ 30 mmHg 
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Figure 9.3: Example of the inputs and outputs of the model used to simulate healthy aortic 
hemodynamics in a pig. The flow into the aorta (Qin) acts as the input for the model and flow out of 
the arterial system (Qout), aortic pressure (Pao), and reservoir pressures (Pwk) represent the outputs of 
the model. 
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9.5 DISCUSSION 
9.5.1 VALIDITY OF ASSUMPTIONS AND MODELLING CONCEPTS 
Many of the assumptions used in the aorta model have been previously discussed in Section 3.6.1, 
and thus will not be discussed further here. The new and most controversial assumptions used in 
this model are: 1) backward wave reflections are minimal during systole, and hence, the shape of Pex 
is the same as Qin; and 2) the reservoir pressure (Pwk) is independent of the position in the arterial 
system. 
The first assumption is based on the findings of Davies et al. (Davies et al., 2010), who found that 
backward wave reflections only make a small contribution to the augmentation index in 
hypertensive patients. Moreover, the model is only intended to model central aorta dynamics, 
where backwards travelling waves are small during systole (Aguado-Sierra et al., 2008). Therefore, 
the author feels justified in making this assumption, and that it will have minimal impact in the 
situations expected in this work, validating this assumption, particularly for examining dynamics at 
the aorta. 
The second assumption, that the reservoir pressure is independent on position in the arterial 
system, is based on the results of (Davies et al., 2007). In this study, it was shown that the shape of 
the reservoir pressure is relatively constant when calculated from measurements taken from 
different parts of the arterial system. Thus, reservoir pressure is essentially a constant of the arterial 
system. 
 
9.5.2 MODEL SIMULATION 
An example simulation of the aorta model is shown in Figure 9.3. In this simulation, the aortic 
pressure and reservoir pressure are the same during diastole. However, during systole Pao is higher 
than Pwk due to the addition of the excess pressure generated from the viscous effects of Qin. The 
difference in the shapes of Qin and Qout result from the storage capacity of the arterial reservoir, 
which absorbs some of the flow during systole and releases it during diastole. This ability helps the 
arterial system smooth the flow of blood before it hits the capillaries, ensuring that the organs of the 
body have a constant supply of oxygen and nutrients. 
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9.5.3 LIMITATIONS 
The assumption that there are no backward travelling waves augmenting the pressure during systole 
limits the ability of the model to simulate more distal parts of the arterial system. Arteries that are 
further from the heart are more likely to encounter backward travelling waves during systole, as 
they are closer to the wave reflection sites. Pex at these points will thus be a combination of pressure 
due to viscous effects of the forward flow, Qin, and the backwards flow, meaning that the 
assumption that the shape of Qin is equal to the shape of Pex will no longer be valid. 
 
9.6 SUMMARY 
A model of arterial flow has been adapted to represent blood flow in the central aorta. This model 
separates aortic pressure into two components representing the compliant nature of the arterial 
system, called the reservoir pressure, and wave-phenomena, called the excess pressure. The model 
developed provides a foundation for subject-specific modelling of the aortic hemodynamics, 
specifically, how blood and energy is passed from the left ventricle to the aorta and onto the 
capillaries.
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CHAPTER 10: AORTA MODEL ENERGETICS IN SEPTIC SHOCK 
The aorta model of Chapter 9 is identified using aortic pressure and SV measurements from a 
porcine study of septic shock. The goals of this chapter are to: 1) help understand how the transfer 
of flow and energy, through the arterial system, is affected during septic shock; and 2) explain why 
the shape of aortic pressure waveform changes during septic shock. 
10.1 INTRODUCTION 
Arterial pressure and cardiac output (CO) are two of the main measures of cardiovascular health in 
the ICU. However, recently, the efficiency of hemodynamic monitoring to affect outcome has been 
questioned (Pinsky, 2003). The positive impact of CO and/or stroke volume (SV) monitoring has not 
been proven to affect outcome (Mutoh et al., 2007, Pinsky, 2007). Furthermore, although 
continuous blood pressure monitoring of the arterial waveform is commonplace, the most 
commonly used blood pressure indices ignore the shape of the arterial waveform and are calculated 
from discrete measurements of systolic and diastolic pressure. All the valuable morphological 
information stored in the form of the arterial pulse is ignored. These findings suggest that arterial 
pressure and SV are underutilised in guiding diagnosis and treatment in the intensive care 
environment. 
This chapter looks at utilising SV and the shape of the aortic pressure waveform to better 
understand the dynamics of arterial flow and ventricular arterial coupling. The approach used in this 
chapter was based on the work of (Wang et al., 2003, Davies et al., 2010, Tyberg et al., 2009), where 
the aortic pressure is separated into two components representing the reservoir pressure and the 
excess pressure. These components were identified using measurements from a porcine study of 
septic shock (Lambermont et al., 2006) to create subject-specific models of aortic blood flow.  
It is hypothesised that the work of the excess pressure represents the contractile state of the 
ventricle and that the reservoir pressure component is the energy that needs to be overcome for 
forward flow. Hence, the ratio of the excess pressure and reservoir work may represent a metric of 
ventricular arterial coupling. To test this hypothesis the modelled hydraulic energies of these 
components were compared to metrics obtained from left ventricular pressure-volume (P-V) loops, 
to understand their relationship to ventricular arterial (de)coupling during septic shock.  
 
  Aorta Model Energetics in Septic Shock  
165 | P a g e  
 
10.2 METHODS 
10.2.1 PORCINE TRIALS AND MEASUREMENTS 
All procedures and protocols used were approved by the Ethics Committee of the Medical Faculty at 
the University of Liege, Belgium. Experiments were performed on 4 healthy pure Pietrain pigs 
weighing between 20-30kg. The animals were premedicated, anesthetised, and ventilated as 
explained in (Lambermont et al., 2006). The animals received a 0.5-mg/kg endotoxin infusion over 30 
minutes (from T0 to T30) to induce septic shock. Micro-tipped catheters were used to record 
continuous hemodynamic measurements during the study. Every 30 minutes (T0 to T120) 6-20 
central aortic pressure waveforms (Pao) were recorded. At the same time, descending left ventricular 
pressure-volume (P-V) loops (Plv, Vlv) were stored during transient occlusion of the inferior vena 
cava. All measurements were recorded at a 200Hz sampling rate. In this study, 36 sets of 
measurements from the 4 pigs were used. Further details on these trials can be found in 
(Lambermont et al., 2006) 
 
10.2.2 MODEL IDENTIFICATION 
The measurements used in this study to identify the arterial model were the Pao waveform and SV. 
Both measurements can be measured or inferred in the ICU. SV can be measured using a thermo-
dilution technique (Ganz et al., 1971, Stetz et al., 1982), and Pao can either be measured or estimated 
using one of the following methods (Chen et al., 1997, Cloud et al., 2003, Hope et al., 2004, 
O'Rourke, 2004, Pauca et al., 2001, Westerhof et al., 2008). To personalise Equation (9.8) from 
Chapter 9 to each subject the parameters τ, C, Rprox, and P∞ must be identified from these 
measurements, along with the Qin waveform.  
Initially, Qin was estimated by drawing a line, across the aortic pressure pulse, from the start of 
ejection to the first diastolic point. The diastolic point was assumed to be the point of the maximum 
negative gradient between the aortic notch and maximum pressure in the measured Pao. The 
difference between this line and the aortic pressure was used to approximate Pex. To approximate 
Qin, Pex was scaled to have an area equal to SV, as Qin is assumed to be linearly proportional to Pex. 
The model was then fitted using this estimate of Qin and initial approximations for τ, C, Rprox, and P∞. 
The non-linear optimisation routine ‘fminsearch’ in Matlab, utilising a Nelder-Mead simplex method, 
was used to fit the model to one full period of the Pao waveform.  
During fitting a greater weighting was applied to the minimisation of error in the last 2/3 of diastole 
as it is believed that wave effects are minimal at this time (Wang et al., 2003). The Pwk and Pex were 
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then separated from the modelled Pao, and Pex was scaled to calculate a new Qin. This whole process 
was repeated with Equation (9.8) re-fitted to the measured Pao to calculate new approximations for 
τ, C, Rprox, and P∞. This process was repeated until the root-mean-square error over systole was less 
than 0.1%.  
 
10.2.3 DATA AND STATISITICAL ANALYSIS 
Hemodynamic measurements are presented as mean +/- standard deviation (SD). A paired sample t-
test was used to check temporal variance over T0 - T60 to analyse the effect of the endotoxin 
intervention. P<0.05 was considered a statistically significant result. Windkessel models were fitted 
to 36 sets of measurements from the 4 pigs, over all time points.  
Hydraulic work (Wao) was calculated for each measurement by summing the work of the reservoir 
and excess pressure components of the aortic model (Wao = Wwk +Wex) at the end of systole, where 
Wex is defined as the hydraulic work done at the end of systole. Left ventricular work (Wlv) was 
calculated from the area enclosed by the measured P-V loop. Wao and Wlv were calculated using: 
 ∫∫ +−=+=
eses t
t
inex
t
t
outinwkexwkao dttQtPdttQtQtPWWW
00
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where t0 represents the start of ejection and tes stands for the time of end systole. End of systole 
represents the time when the maximum amount of hydraulic energy is stored in the aortic reservoir.  
The ratio of the Wex to the Wwk was analysed and compared to the clinical gold standard ventricular 
arterial coupling metric, Ees/Ea, calculated from ventricular P-V loop analysis, as shown in Figure 10.1. 
End systolic elastance (Ees) is defined as the gradient of the linear least squares fit to the end systolic 
points in a series of descending P-V loops, representing the left ventricular contractility. Left 
ventricular afterload (Ea) is the gradient of the line from the origin in Figure 10.1 to the end systolic 
point of the first P-V loop, recorded before vena cava occlusion, a highly invasive manoeuvre. 
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Figure 10.1: Left ventricular pressure volume loop analysis used to calculate end systolic elastance 
(Ees) and afterload (Ea) during a vena cava occlusion manoeuvre. 
 
The volume stored in the aortic reservoir (Vwk), which is equal to the aortic volume (Vao), was 
calculated by multiplying Pwk by the aortic compliance. 
 wkwkao CPVV ==  (10.3) 
 
10.3 RESULTS 
The windkessel model was fitted to the 36 sets of measurements from the 4 pigs. In this study, each 
animal acts as their own control with baseline (T0) measurements reflecting the undiseased state of 
the pig. The temporal variance in the measurements of the cohort were analysed between T0-T30, 
as well as T0-T60 and T30-T60. The reason temporal variance was analysed over T0-T60 and T30-T60 
is because sometimes the symptoms of septic shock do not manifest immediately after the 
endotoxin infusion at T0 to T30. Statistically significant temporal changes (P<0.005) were noticed in 
the measured mean arterial pressure (MAP), left ventricular end diastolic volume (LVEDV), heart rate 
(HR), and maximum left ventricular pressure (Plv,max) over the first hour, underlining the pathological 
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changes occurring in the animals due to the endotoxin infusion. A summary of the main 
hemodynamic measurements is seen in Figure 10.2. 
 
 
Figure 10.2: Evolution of mean arterial pressure (MAP), left ventricular end diastolic volume 
(LVEDV), stroke volume (SV), heart rate (HR), and maximum left ventricular pressure (Plv,max) 
measurements during the trials. * indicates P<0.05 for expected temporal changes over T0-T30, T30-
T60, or T0-T60 due to the induction of septic shock. Data presented as mean +/- SD.  
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10.3.1 COMPARISON OF VENTRICULAR AND ARTERIAL WORK 
To verify the aortic model, the hydraulic energy of the aortic flow, calculated from model, was 
compared to the measured left ventricular work. The comparison between the hydraulic work and 
the area enclosed by measured P-V loops, is shown in Figure 10.3. Wao matched Wlv to a bias and 2 
standard deviations of -0.15 J +/- 0.13 J (as seen on Figure 10.3), and with a correlation coefficient of 
R2 = 0.88. These results indicate that Wao underestimates ventricular work, but, more importantly, 
closely follows the changes in Wlv that occur during the trials. 
 
10.3.2 EFFECTS OF SEPTIC SHOCK ON AORTIC ENERGETICS AND VOLUME 
The effects of septic shock on the aortic model were analysed by tracking the changes in Wao, Wex, 
and Wwk, throughout the duration of the experimental study. In this analysis, Wex can be interpreted 
as the work required to overcome the resistance of the large arteries, whereas Wwk reflects the 
maximum potential energy stored in the arterial reservoir due to elastic distension of the arterial 
walls. The change in magnitudes of Wao, Wwk, and Wex (averaged across the four pigs) at 30 minute 
intervals during the experimental study are shown in Figure 10.4. Initially, at T0, Wwk makes up the 
majority of Wao. However, after the endotoxin infusion, the magnitude of Wwk decreases, and Wex 
increases to a point where they are approximately equal by the end of the experiment.  
A decrease in Wwk indicates that a smaller proportion of the SV is being stored in the elastic arterial 
system for release during diastole. Figure 10.5 reinforces this point, showing the percentage of SV 
stored in the arterial reservoir, averaged across the four pigs. This ratio drops from a baseline level 
of 59.2% to 48.6% by the end of the study. This result is most likely due to a decrease in vascular 
tone due to the inflammatory effects of the endotoxins in the circulation. 
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Figure 10.3: Regression (top) and Bland-Altman (bottom) analysis comparing work derived from the 
aorta model (Wao) with work calculated from the area enclosed left ventricular pressure-volume 
loops (Wlv). 
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Figure 10.4: Temporal change in the total hydraulic work of aortic flow (Wao) and its components, 
reservoir work (Wwk) and excess work (Wex), across the duration of the pig study. Each bar represents 
the averaged value across the four pigs. 
 
 
Figure 10.5: Change in volume stored in the arterial reservoir (dVwk) as a percentage of stroke 
volume (SV). Data is presented as mean +/- SEM. 
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10.3.3 ESTIMATION OF VENTRICULAR ARTERIAL COUPLING 
It was hypothesised that the ratio of Wex to Wwk may be an indicator of ventricular arterial coupling, 
given that Wex is a function of the flow energy ejected from the ventricle, and Wwk represents the 
work required to distend the arterial volume. Hence, Wex/Wwk was compared to Ees/Ea to check this 
claim, as shown in Figure 10.6. Analysis of Figure 10.6 showed a very weak relationship between 
these indices, with low correlation of R2 = 0.24, indicating they are not directly related, and proving 
this initial hypothesis wrong.  
On further analysis, it was noticed that Wex is strongly related to the inverse of Ea (R
2 = 0.76), as seen 
in Figure 10.7. However, changes Wex or Wwk, or any combination of these two indices, were not 
reflective of changes in left ventricular contractility (Ees). Hence, demonstrating that the energetics 
of the aortic model are only capable of representing changes in the state of left ventricular afterload 
and not changes in left ventricular contractility. 
 
 
Figure 10.6: Comparison ventricular arterial coupling (Elv/Ea), derived pressure volume loop analysis, 
with the ratio of excess to reservoir work (Wex/Wwk), derived from the fitted aorta models.  
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Figure 10.7: Comparison of the inverse of afterload (1/Ea) calculated from pressure-volume loop 
analysis with excess work (Wex) derived from the aorta model. 
 
10.4 DISCUSSION 
A model of aortic blood flow, based on the works of (Davies et al., 2010, Tyberg et al., 2009, Wang et 
al., 2003), was identified using measurements from an experimental animal study on septic shock. 
Aortic models were fitted using only measurements of the aortic pressure waveform and SV, 
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clinically. In this study, the models were successfully fitted to 36 sets of these measurements and the 
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prosthetic porcine aortic valves using SV between 60-80mls. Indicating that a bias of -0.13J, given 
that measured SVs in this study are around half those used in (Fisher and Wheatley, 1988), is a 
reasonable approximation for aortic valve energy loss. This result verifies the accuracy of the fitted 
models.  
 
10.4.2 SEPTIC SHOCK TRENDS 
The identified aortic models also appeared capable of capturing the effects of septic shock on the 
pig’s hemodynamics. As the state of the pigs worsened, due to the inflammatory effects of the 
endotoxin, modelled systemic resistance decreased substantially and arterial compliance increased, 
as seen in Figure 10.8. The drop in resistance was generally larger than the increase in compliance 
causing the decay constant, τ, to decrease as τ = RC. The combination of these factors caused the 
aortic reservoir to charge and discharge quicker than it would have done for a healthy subject.  
The volume in the arterial reservoir could not accumulate faster than it was discharging, resulting in 
a flattening in the Pwk component of the aortic pressure. Hence, in the subjects with a low decay 
constant when normalised by heartbeat (τ /T), the shape of the aortic pressure begins to look similar 
to the shape of Qin, as seen in Figure 10.9 with a noticeable flattening of the diastolic pressure 
observed when compared to the aortic pressure waveform measured before the endotoxin infusion. 
This effect is responsible for the relative decrease in the proportion of Wwk compared to Wao and Wex 
that occurs during the study, as shown in Figure 10.4.  
These factors could explain why left ventricular afterload (Ea) decreases during septic shock as 
arterial pressure can never build up during the heartbeat because less energy and volume are stored 
in the arterial reservoir. Clinically, the inability of the arterial system to store volume in sepsis 
gradually leads to a decrease in mean arterial pressure resulting in hypotension. Hence, monitoring 
and understanding the reasons why the arterial reservoir loses its ability to store hydraulic energy 
and volume during sepsis could help develop and implement treatments for maintaining arterial 
pressure in ICU patients. 
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Figure 10.8: Temporal profile of systemic peripheral resistance, R (top), aortic compliance, C 
(middle), and ratio of the decay constant to heartbeat period, τ / T (bottom), during the pig study. 
Data is presented as mean +/- SD. 
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Figure 10.9:  Example of the aortic pressure separated into reservoir and pressure (Pwk) and excess 
pressure (Pex) components before the endotoxin infusion (T0) and 180 minutes (T210) after 
endotoxin infusion. 
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10.4.3 VENTRICULAR ARTERIAL COUPLING 
The ratio of Wex/Wwk did not relate well to Ees/Ea, a common clinical measure of ventricular arterial 
coupling, as seen in Figure 10.6. This result indicates that the initial hypothesis was incorrect. No 
relation was found between Wex and Ees, which suggests that Wex is not a function of the contractile 
state of the ventricle. However, Wex did relate well to inverse of afterload (R
2 = 0.76), which was 
unexpected. Overall, these results show that Wex could be a useful metric for describing acute 
changes in afterload (Ea) due to septic shock, which is important because septic shock is 
characterised by a sudden decrease in afterload due to a systemic inflammatory response to an 
infection. 
 
10.4.4 LIMITATIONS 
The main, and most controversial, assumption made during the fitting process is that Pex is linearly 
proportional to Qin, and thus, the two can be represented by a purely resistive relationship (Pex = 
RproxQin). This assumption is based on the work of (Wang et al., 2003), which shows that the 
magnitudes of backwards travelling waves in the aorta are minimal. In future work, this relationship 
needs to be tested and validated with accurate aortic flow data. However, the author feels justified 
in using this assumption in this study for two reasons: 1) the model was only fitted to central aortic 
pressure measurements, where backwards travelling waves are small during systole (Aguado-Sierra 
et al., 2008), due to the central aorta’s distance from major reflection sites; and 2) in sepsis vascular 
tone decreases, reducing the production of reflective waves (O'Rourke and Yaginuma, 1984). 
However, the author realises the assumption may not be valid in subjects with high arterial stiffness, 
such as with hypertensive subjects. 
 
10.5 SUMMARY 
Measurements of SV and the aortic pressure waveform were used to identify subject-specific models 
of aortic flow and pressure in a porcine study. Analysis of the components that shape the aortic 
pressure waveform suggests that one of the main reasons left ventricular afterload decreases during 
septic shock is because the arterial reservoir loses its ability to store hydraulic energy in the form of 
stressed volume during systole. However, a larger more comprehensive study with accurate aortic 
flow measurements is required to validate the method and results of this work. 
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CHAPTER 11: CONCLUSIONS 
This chapter presents the main conclusions of this research. Conclusions regarding the accuracy and 
validation of the model-based hemodynamic monitoring methods presented are outlined along with 
the clinical relevance and potential of these approaches. Suggestions for further possible 
improvements to this work and future avenues to expand into will be discussed in the subsequent 
chapter.  
 
11.1 PATIENT-SPECIFIC CARDIOVASCULAR SYSTEM MODELS 
The aim of this research was to identify subject-specific physiological models to assist with the 
hemodynamic monitoring of critically ill patients in the ICU. A parameter identification method was 
used to identify subject-specific six chamber lumped parameter models of the CVS from commonly 
available ICU measurements. Subject-specific models were retrospectively fitted to measurements 
obtained from two animal studies on pulmonary embolism and septic shock and one human study 
on cardiac recovery from mitral valve surgery. Static and dynamic variables of cardiac and circulatory 
function, derived from the subject-specific CVS models, were used to analyse the pathological effect 
and progression of disease along with the effectiveness of treatment in these studies. 
The main accomplishment of this thesis was extending the parameter identification method of 
Starfinger et al (Starfinger, 2008) to uniquely identify patient-specific models of the CVS using 
typically available measurements in the ICU. This method utilises discrete measurements which are 
commonly recorded or inferable in the ICU including: mean aortic and pulmonary artery pressure, 
amplitude of the aortic and pulmonary artery pressure waveforms, maximum gradient of the aortic 
and pulmonary artery pressures, stroke volume, heart rate, and central venous pressure or 
measurements of the mitral and tricuspid valve closure times. These discrete measurements negate 
the need to use full waveforms, which are less robust and more difficult to use, simplifying and 
strengthening the reliance of the method.  
More specifically, a proportional gain parameter identification method was developed on top of the 
scaling method of Starfinger et al (Starfinger, 2008), replacing the earlier integral-based method of 
Starfinger (Starfinger, 2008). The integral-based method required measurements of the ventricular 
volume waveforms that are infrequently measured in a critical care setting. The scaling method of 
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Starfinger (Starfinger, 2008) also required ventricular volume measurements (or estimates of them) 
and population-based assumptions to identify the valve resistances. These considerations all limited 
the patient-specificity and robustness of the method. Hence, the need for ventricular volume 
measurements and population-based assumptions reduce the real-time clinical applicability of the 
old approach. However, the proportional gain method described in this thesis relies only on the 
cardiac measurement of GEDV, which can be measured at the bedside, increasing the clinical 
applicability of the approach.  
To develop a model-based approach one must find the optimal balance between model complexity 
and clinical applicability. A more complicated model than the six-chamber model could be used to 
better simulate the dynamics of the CVS. However, a more complex model requires a larger number 
of parameters, and is thus, more difficult to identify given the limited measurement set available in 
the ICU. Some of these additional parameters would need to be held constant or identified from 
estimates of pressure, volume, or flow. This approach limits the clinical usefulness of these 
parameters and potentially compromises the identifiability of the other model parameters. This 
research modified the minimal six chamber CVS model developed by Smith et al (Smith, 2004) to 
provide the optimal mix of model complexity and parameter identifiability. Hence, this balance 
enables the identification of patient-specific CVS model to realistically represent a patient’s 
cardiovascular condition from available ICU measurements.  
A proportional gain-based parameter identification method was developed and validated in two pig 
studies on septic shock and pulmonary embolism, as described in Chapter 5. The model outputs 
were shown to consistently converge to the observable hemodynamic measurements. The identified 
subject-specific models also matched independent measures of left ventricular pressures and 
volumes within an acceptable error range providing a true validation of the identification method. 
Moreover, model-based metrics and parameters were seen to track the experimentally derived 
metrics of right ventricle contractility and afterload in these studies. These results indicate the six-
chamber CVS model and parameter identification method are able to extrapolate cardiac dynamics, 
such left and right ventricle preload and contractility, from known circulatory measurements. These 
findings indicate that the identified CVS models is a relatively accurate description of global 
cardiovascular dynamics, justifying the use of the six-chamber CVS model, and validating the 
parameter identification method. 
Chapters 6 and 7 demonstrate that the subject-specific models are able to track clinically-relevant 
disease and treatment dependent changes in pulmonary embolism and septic shock which are 
common CVS diseases in the ICU. In the pulmonary embolism study, a decrease in pulmonary 
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vascular resistance was identified in all the swine after the insertion of autologous blood clots into 
the blood system. In the pigs near death, acute right ventricle dilation was noticed in the subject-
specific models, resulting in left ward shift in the inter-ventricular septum, indicating cardiac 
decompensation. In the septic shock study, a decrease in the modelled systemic vascular resistance 
was seen in all the pigs after an endotoxin infusion. However, after hemofiltration therapy was 
initiated an improvement in systemic vascular resistance was noticed in two of the pigs, whereas, no 
improvement was noticed in the other two pigs. These studies indicate that the subject-specific CVS 
models can help track important diagnostic markers of two common disease states in the ICU. 
Analysis of the personalised models also made it easy to explain why some pigs were compensating 
well to the induced disease while others were not, a critical distinction highlighting the clinical value 
of the model. 
The parameter identification was further tested with human measurements in the ICU on post mitral 
valve surgery patients. The retrospectively identified patient-specific CVS models observed two 
different responses to mitral valve correction. Three of the patients showed good recovery post 
operation with improved left ventricle function and decreased pulmonary vascular resistances, 
indicating decreased pulmonary congestion. The identified models of the other patient in the study 
observed left ventricle impairment and increasing hypertension due to elevated systemic vascular 
resistance and decreased left ventricle contractility. This finding indicated that the weakened left 
ventricle in this patient, due to the chronic effects of prolonged mitral regurgitation, was not 
compensating well to the affect of the mitral valve correction. These results illustrate how the model 
can be used to distinguish between patients who are responding well to surgery from those who are 
not initially recovering in the desired manner. Again, it shows the model’s ability to clearly 
discriminate clinically relevant dynamics. This study, as shown in Chapter 8, provides the first clinical 
test of the model-based approach and proves it is possible to identify relevant diagnostic 
information from real clinical data.  
More specifically, Chapters 5-8 demonstrate that the identified subject-specific six-chamber CVS 
models are capable of monitoring clinically useful metrics of left and right ventricle preload, 
afterload, and contractility. These determinants of cardiovascular function are of significant 
importance clinically as they can be controlled using common therapies. Preload can be increased 
using fluid resuscitation; afterload can be altered using vasodilators (noradrenaline, nitric oxide, 
milrinone) and vasoconstrictors (vasopressin, adrenaline, noradrenaline, dopamine); and 
contractility can be changed using inotropic agents (dopamine, dobutamine, adrenaline, 
noradrenaline, milrinone). However, in a clinical setting it can be difficult to directly and 
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continuously measure indices of preload, afterload, and contractility. The identified subject-specific 
CVS models solve this problem by aggregating known ICU measurements in a mathematical 
framework of cardiovascular physiology. The outputs and parameters of these identified models 
provide a direct and clear means of monitoring the effect of different hemodynamic therapies on 
cardiac and circulatory function (preload, afterload, and contractility). Hence, the approach shows 
the potential to be able to improve the medical decision support pathway for hemodynamic 
management in the ICU. 
Overall, the model-based approach has been able to aggregate common ICU measurements into a 
clear physiological picture of a patient’s cardiac and circulatory function. The method is capable of 
monitoring the progression of a disease and can be used to discriminate between hemodynamic 
recovery and deterioration as shown by tests in pig and human studies. Thus, this research suggests 
the approach has significant clinical diagnostic and therapy guidance potential. 
  
11.2 PULSE WAVE ANALYSIS OF AORTIC FLOW AND ENERGETICS 
A model of arterial flow has been adapted to represent blood flow in the central aorta. This model 
separates aortic pressure into two components representing the compliant nature of the arterial 
system, called the reservoir pressure, and wave-phenomena, called the excess pressure. The model 
developed provides a foundation for subject-specific modelling of the aortic hemodynamics, 
specifically, how blood and energy is passed from the left ventricle to the aorta and onto the 
capillaries. 
Subject-specific models of aortic flow were identified using measurements of SV and the aortic 
pressure waveform in a porcine study of septic shock. Analysis of these models show the arterial 
system loses its ability to store blood as a hydraulic reservoir in septic shock. This phenomena was 
shown to be responsible for significant change in shape in the aortic pressure waveform. 
Furthermore, analysis of aortic flow energetics showed that the model could be used to estimate the 
left ventricular work and that the excess pressure hydraulic work was inversely related to changes in 
afterload. These findings suggest the aortic model could be used provide important additional 
information on ventricular arterial coupling in septic shock patients. 
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CHAPTER 12: FUTURE WORK 
This chapter summarises further validations and tests to increase the clinical utility of the patient-
specific CVS models. Potential further changes and improvements to the model identification 
methods are suggested and a further extension to the CVS model in the model in the form of gas 
exchange modelling is proposed.  
 
12.1 INTEGRATE MODEL WITH CLINICAL THERAPIES AND TREATMENT PROTOCOLS 
A main use for the patient-specific CVS models is to quantify response to therapy. For the approach 
to be clinically useful it must influence treatment decisions to manifest a physical change in the 
patient. Therefore, the method needs to be incorporated with a treatment protocol to provide a real 
world benefit as part of a functional hemodynamic management approach. A basic example of such 
a treatment protocol could be: if left ventricle contractility drops below a certain level in the model 
then titrate inotropes at a certain dosage in an attempt to increase contractility. However, in this 
thesis, the influence of common clinical therapies such as the use of inotropes, vaso-active drugs, 
and fluid resuscitation on the model metrics of preload, afterload, and contractility were not tested. 
Hence, the approach must be further validated for these treatment modalities before it can be used 
to influence therapy in the ICU. This could be done through retrospective analysis of the recently 
installed database in the Christchurch Hospital ICU. 
 
12.2 TESTING ON OTHER DISEASES STATES 
At the moment the patient-specific models have only be tested on humans recovering from mitral 
valve surgery. These patients, although common, only reflect a small portion of the patients in the 
ICU. Hence, the clinical applicability of the model-based approach in humans needs to be further 
tested using measurements of other disorders, including but not limited to: sepsis, acute respiratory 
distress syndrome (ARDS), pneumonia, and cardiogenic shock. These tests would help quantify the 
response of the parameters in the CVS model to these common ICU disorders. 
The post mitral valve surgery patients are normally monitored using regular hemodynamic 
measurements, as well as a Swanz-Ganz catheter that measures CO and pulmonary artery pressure. 
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However, other patients are monitored using a different array of measurements. For example, in the 
Christchurch Hopstial ICU, the PiCCO monitoring system (PULSION Medical Systems AG, Munich, 
Germany) is normally used for CO and GEDV monitoring in septic shock patients. In these patients 
the pulmonary artery pressure is not normally measured. In this case, the parameter identification 
method would need to be adapted to use GEDV instead of pulmonary artery pressure. Hence, in 
summary, the approach needs to customisable to the variety of different measurement 
combinations that are commonly used for the typical ICU patient. 
 
12.3 RELATIONSHIP OF LEFT AND RIGHT VENTRICLE END SYSTOLIC ELASTANCE 
Few measurements of the heart are available in the ICU. As a consequence, an empirical relationship 
was required in the identification process to fit the left and right ventricular end systolic elastances 
based on the ratios of the aortic and pulmonary artery pressures. This relationship was based on 
earlier results where the subject-specific CVS models were fitted to a complete set of pig 
measurements, including the left and right ventricular volumes. However, it was difficult to find any 
empirical data in the literature to reinforce the use of this relationship in humans. Although the 
relationship is conceptually based on known physiological phenomena (the Anrep Effect), it still 
needs further validation in humans. 
 
12.4 COMPUTATIONAL SPEED 
Currently, the parameter identification method is run in Matlab. In Matlab, it takes around six 
minutes on average to identify one patient-specific CVS model from a set of measurements. For 
these models to be a hemodynamic monitoring utility, this run time must be significantly decreased 
to provide real-time information. Computational speed of the approach could be improved in a 
number of ways, by: 
• providing better/smart parameter estimates at the beginning of the identification process, 
• increasing the numerical efficiency of the ODE solvers and identification method, 
• and/or running the models in a faster program language such as C or java. 
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Initial tests have shown that a compiled C-version of the 6 chamber model can run up to 100 faster 
than the Matlab code. Hence, these preliminary results indicate that patients-specific CVS models 
could be identified in as little as three to four seconds, which is an acceptable delay in the ICU. 
 
12.5 PULSE CONTOUR CALCULATION OF CO 
The parameter identification method is limited by the number of measurements available in an ICU 
setting. The approach cannot be used when CO is not measured. Hence, the measurement of CO 
limits the use of this model-based monitoring method.  
To rectify this problem, CO could be calculated using the contour of the arterial pressure waveform. 
This is already done in a number of commercial medical devices (Cottis et al., 2003, Linton et al., 
1993, Opdam et al., 2007). However, the published algorithms used in these proprietary devices are 
not fully reproducible. Therefore, a new method must be developed to identify CO from radial artery 
pressure.  
To accomplish this goal, the model of aortic flow, in Chapter 9, could be used to infer SV or CO from 
the arterial pressure waveform. Morphological features of the arterial pressure contour can be used 
to identify the parameters in this model. Thus, arterial flow can be backwards calculated using the 
model. The accurate calculation of CO would significantly improve the clinical applicability of the 
model-based approach as it would greatly increase the number of patients it can be applied to.  
 
12.6 CARDIOPULMONARY GAS EXCHANGE MODEL 
One of the main jobs of the CVS is to deliver oxygen from the lungs to the tissues of the body. 
However, many pulmonary and cardiovascular disease states can disrupt the balance of oxygen 
supply and metabolic demand. For example, septic shock is known to impair oxygen saturation in the 
microcirculation. Hence, it is important to monitor oxygen perfusion in critical care. 
In recent research there has been significant development in measuring blood oxygen concentration 
and tissue perfusion. These techniques include: 
• sublingual carbon dioxide (PCO2) monitoring, 
• near infrared spectroscopy for tissue oxygenation and haemoglobin monitoring, 
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• fluorescence spectroscopy for monitoring mitochondrial energy state, 
• as well as, the traditionally measured oxygen saturation via pulse oximetry (SpO2). 
In addition, information about inspired and expired O2 and CO2 are available in mechanically 
ventilated patients. Blood gas analysis can also be used to evaluate the concentrations of O2 and CO2 
in the blood, and thus, evaluate how effectively the lungs are delivering O2 and removing CO2 from 
the blood. Hence, with these monitoring techniques, it may be possible to identify a cardiovascular 
gas exchange model. This could be done by integrating a gas exchange model with blood transport 
equations of the six-chamber CVS model. Such a model would provide parameters of arterial and 
venous oxygen 02 saturation, which would provide important information on the amount of shunting 
in the lungs and end organ oxygen uptake. Details of models which already incorporate O2 and CO2 
components can be found in (Batzel et al., 2005, Harada et al., 2005, Hardman et al., 1998, Kappel et 
al., 2007, Lu et al., 2003). 
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APPENDIX A: STRUCTURAL IDENTIFIABILITY TEST 
The following sections show the input file used to test global identifiability of the simplified six-
chamber and the corresponding output file produced by DAISY. 
12.7 INPUT FILE OF SIX-CHAMBER CVS MODEL 
  WRITE "SIMPLIFIED CVS6 MODEL"$ 
 
% B_ is the variable vector 
  B_ := {e_lv,e_rv,GEDV,CO,Pao,Ppa,Pvc,Vlv,Vrv,Vao,Vvc,Vpa,Vpu}$ 
 
  FOR EACH EL_ IN B_ DO DEPEND EL_,T$ 
 
% B1_ is the unknown parameter vector 
  B1_ := {Rmt,Elv,Rav,Eao,Rsys,Evc,Rtc,Erv,Rpv,Epa,Rpul,Epu}$ 
 
% Constraints 
  LET Tp = 1$    % period of one heartbeat 
 
% NUMBER OF STATES 
  NX_ := 6$ 
 
% NUMBER OF OUTPUTS 
  NY_ := 5$ 
 
% MODEL EQUATIONS 
  C_:={ df(Vlv,t) = (Epu*Vpu-Elv*e_lv*Vlv)/Rmt - (Elv*e_lv*Vlv-Eao*Vao)/Rav, 
 df(Vao,t) = (Elv*e_lv*Vlv-Eao*Vao)/Rav - (Eao*Vao-Evc*Vvc)/Rsys, 
 df(Vvc,t) = (Eao*Vao-Evc*Vvc)/Rsys     - (Evc*Vvc-Erv*e_rv*Vrv)/Rtc, 
 df(Vrv,t) = (Evc*Vvc-Erv*e_rv*Vrv)/Rtc - (Erv*e_rv*Vrv-Epa*Vpa)/Rpv, 
 df(Vpa,t) = (Erv*e_rv*Vrv-Epa*Vpa)/Rpv - (Epa*Vpa-Epu*Vpu)/Rpul, 
 df(Vpu,t) = (Epa*Vpa-Epu*Vpu)/Rpul     - (Epu*Vpu-Elv*e_lv*Vlv)/Rmt, 
 GEDV    = max(Vlv)+max(Vrv), 
 Pao    = Eao*Vao, 
 Ppa    = Epa*Vpa, 
 Pvc    = Evc*Vvc,  
 CO    = int((Pao-Pvc)/Rsys,t)}$ 
 
% Limit randon number generator to a range of 1:SEED_ for parameter estimates 
  SEED_ := 100$ 
 
% Run daisy 
  DAISY()$ 
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12.8 OUTPUT FILE OF SIX-CHAMBER CVS MODEL 
  WRITE "SIMPLIFIED CVS6 MODEL"$ 
 
SIMPLIFIED CVS6 MODEL 
 
% B_ is the variable vector 
  B_ := {e_lv,e_rv,GEDV,CO,Pao,Ppa,Pvc,Vlv,Vrv,Vao,Vvc,Vpa,Vpu}$ 
 
  FOR EACH EL_ IN B_ DO DEPEND EL_,T$ 
 
% B1_ is the unknown parameter vector 
  B1_ := {Rmt,Elv,Rav,Eao,Rsys,Evc,Rtc,Erv,Rpv,Epa,Rpul,Epu}$ 
 
% Constraints 
  LET Tp = 1$  % period of one heartbeat 
 
% NUMBER OF STATES 
  NX_ := 6$ 
 
% NUMBER OF OUTPUTS 
  NY_ := 5$ 
 
%MODEL EQUATIONS 
  C_:={ df(Vlv,t) = (Epu*Vpu-Elv*e_lv*Vlv)/Rmt - (Elv*e_lv*Vlv-Eao*Vao)/Rav, 
 df(Vao,t) = (Elv*e_lv*Vlv-Eao*Vao)/Rav - (Eao*Vao-Evc*Vvc)/Rsys, 
 df(Vvc,t) = (Eao*Vao-Evc*Vvc)/Rsys     - (Evc*Vvc-Erv*e_rv*Vrv)/Rtc, 
 df(Vrv,t) = (Evc*Vvc-Erv*e_rv*Vrv)/Rtc - (Erv*e_rv*Vrv-Epa*Vpa)/Rpv, 
 df(Vpa,t) = (Erv*e_rv*Vrv-Epa*Vpa)/Rpv - (Epa*Vpa-Epu*Vpu)/Rpul, 
 df(Vpu,t) = (Epa*Vpa-Epu*Vpu)/Rpul     - (Epu*Vpu-Elv*e_lv*Vlv)/Rmt, 
 GEDV    = max(Vlv)+max(Vrv), 
 Pao    = Eao*Vao, 
 Ppa    = Epa*Vpa, 
 Pvc    = Evc*Vvc,  
 CO    = int((Pao-Pvc)/Rsys,t)}$ 
 
% Limit randon number generator to a range of 1:SEED_ for parameter estimates 
  SEED_ := 100$ 
 
% Run daisy 
  DAISY()$ 
 
seed_ := 100$ 
 
NUMBER OF EQUATIONS$ 
 
n_ := 11$ 
 
VARIBLE VECTOR$ 
 
b_ := {e_lv, 
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e_rv, 
gedv, 
co, 
pao, 
ppa, 
pvc, 
vlv, 
vrv, 
vao, 
vvc, 
vpa, 
vpu}$ 
 
UNKNOWN PARAMETER VECTOR$ 
 
b1_ := {rmt, 
elv, 
rav, 
eao, 
rsys, 
evc, 
rtc, 
erv, 
rpv, 
epa, 
rpul, 
epu}$ 
 
RANKING AMONG THE VARIABLES$ 
 
bb_ := {e_lv, 
e_rv, 
gedv, 
co, 
pao, 
ppa, 
pvc, 
df(e_lv,t), 
df(e_rv,t), 
df(gedv,t), 
df(co,t), 
df(pao,t), 
df(ppa,t), 
df(pvc,t), 
df(e_lv,t,2), 
df(e_rv,t,2), 
df(gedv,t,2), 
df(co,t,2), 
df(pao,t,2), 
df(ppa,t,2), 
df(pvc,t,2), 
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df(e_lv,t,3), 
df(e_rv,t,3), 
df(gedv,t,3), 
df(co,t,3), 
df(pao,t,3), 
df(ppa,t,3), 
df(pvc,t,3), 
df(e_lv,t,4), 
df(e_rv,t,4), 
df(gedv,t,4), 
df(co,t,4), 
df(pao,t,4), 
df(ppa,t,4), 
df(pvc,t,4), 
df(e_lv,t,5), 
df(e_rv,t,5), 
df(gedv,t,5), 
df(co,t,5), 
df(pao,t,5), 
df(ppa,t,5), 
df(pvc,t,5), 
df(e_lv,t,6), 
df(e_rv,t,6), 
df(gedv,t,6), 
df(co,t,6), 
df(pao,t,6), 
df(ppa,t,6), 
df(pvc,t,6), 
vlv, 
vrv, 
vao, 
vvc, 
vpa, 
vpu, 
df(vlv,t), 
df(vrv,t), 
df(vao,t), 
df(vvc,t), 
df(vpa,t), 
df(vpu,t)}$ 
 
NUMBER OF INPUT(S)$ 
 
nu_ := 2$ 
 
NUMBER OF OUTPUT(S)$ 
 
ny_ := 5$ 
 
MODEL EQUATION(S)$ 
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c_ := {df(vlv,t)=(eao*rmt*vao + epu*rav*vpu - (rav + rmt)*e_lv*elv*vlv)/(rav*rmt), 
df(vao,t)=( - ((rav + rsys)*eao*vao - evc*rav*vvc) + e_lv*elv*rsys*vlv)/(rav*rsys), 
df(vvc,t)=( - ((rsys + rtc)*evc*vvc - eao*rtc*vao) + e_rv*erv*rsys*vrv)/(rsys*rtc), 
df(vrv,t)=(epa*rtc*vpa + evc*rpv*vvc - (rpv + rtc)*e_rv*erv*vrv)/(rpv*rtc), 
df(vpa,t)=( - ((rpul + rpv)*epa*vpa - epu*rpv*vpu) + e_rv*erv*rpul*vrv)/(rpul*rpv), 
df(vpu,t)=( - ((rmt + rpul)*epu*vpu - epa*rmt*vpa) + e_lv*elv*rpul*vlv)/(rmt*rpul), 
gedv=vlv + vrv, 
pao=eao*vao, 
ppa=epa*vpa, 
pvc=evc*vvc, 
co=(int(pao,t) - int(pvc,t))/rsys}$ 
 
CHARACTERISTIC SET$ 
 
aa_(1) := co*rsys - int(pao,t) + int(pvc,t)$ 
 
aa_(2) := df(gedv,t)*e_lv*eao*elv*epa*rmt*rpv*rsys*rtc + df(pao,t)*e_lv*elv* 
epa*rpv*rsys*rtc*(rav + rmt) - df(pao,t)*e_rv*epa*erv*rav*rsys*(rmt*rpv +  
rmt*rtc + rpul*rtc) - df(ppa,t)*e_lv*eao*elv*rpul*rpv*rsys*rtc + e_lv*e_rv* 
gedv*eao*elv*epa*erv*rsys*(rmt*rpv + rmt*rtc + rpul*rtc) + e_lv*pao*eao*elv* 
epa*rpv*rtc*(rav + rmt + rsys) - e_lv*ppa*eao*elv*epa*rsys*rtc*(rmt + rpul +  
rpv) - e_lv*pvc*eao*elv*epa*rpv*(rav*rtc + rmt*rsys + rmt*rtc) - e_rv*pao* 
eao*epa*erv*(rav*rmt*rpv + rav*rmt*rtc + rav*rpul*rtc + rmt*rpv*rsys + rmt* 
rsys*rtc + rpul*rsys*rtc) + e_rv*pvc*eao*epa*erv*rav*(rmt*rpv + rmt*rtc +  
rpul*rtc)$ 
 
aa_(3) := df(pao,t)*e_rv*erv*evc*rav*rsys + df(pvc,t)*e_lv*eao*elv*rsys*rtc -  
e_lv*e_rv*gedv*eao*elv*erv*evc*rsys - e_lv*pao*eao*elv*evc*rtc + e_lv*pvc* 
eao*elv*evc*(rsys + rtc) + e_rv*pao*eao*erv*evc*(rav + rsys) - e_rv*pvc*eao* 
erv*evc*rav$ 
 
aa_(4) := df(e_lv,t)*df(pao,t)*elv*rav*rpul*rpv**2*rsys*rtc**2*(rav + rmt) +  
df(e_lv,t)*pao*eao*elv*rpul*rpv**2*rtc**2*(rav**2 + rav*rmt + rav*rsys + rmt* 
rsys) - df(e_lv,t)*pvc*eao*elv*rav*rpul*rpv**2*rtc**2*(rav + rmt) - df(e_rv, 
t)*df(pao,t)*erv*rav**2*rmt*rpul*rpv*rsys*rtc*(rpv + rtc) + df(e_rv,t)*e_lv* 
gedv*eao*elv*erv*rav*rmt*rpul*rpv*rsys*rtc*(rpv + rtc) - df(e_rv,t)*pao*eao* 
erv*rav*rmt*rpul*rpv*rtc*(rav*rpv + rav*rtc + rpv*rsys + rsys*rtc) + df(e_rv, 
t)*pvc*eao*erv*rav**2*rmt*rpul*rpv*rtc*(rpv + rtc) + df(gedv,t,2)*e_lv*eao* 
elv*rav*rmt*rpul*rpv**2*rsys*rtc**2 + df(gedv,t)*e_lv**2*eao*elv**2*rpul*rpv**2* 
rsys*rtc**2*(rav + rmt) + df(gedv,t)*e_lv*eao*elv*rav*rpv*rsys*rtc**2*( -  
epa*rmt**2 + epu*rmt*rpv + epu*rpul*rpv) - df(pao,t)*e_lv*e_rv*elv*erv*rav* 
rpul*rpv*rsys*rtc*(rav*rpv + rav*rtc + rmt*rpv + rmt*rtc) + df(pao,t)*e_lv* 
elv*rpv*rsys*rtc**2*( - eao*rmt*rpul*rpv - epa*rav**2*rmt - epa*rav*rmt**2 +  
epu*rav**2*rpv + epu*rav*rmt*rpv + epu*rav*rpul*rpv) + df(pao,t)*e_rv**2*erv**2* 
rav**2*rmt*rpul*rsys*(rpv**2 + 2*rpv*rtc + rtc**2) + df(pao,t)*e_rv*erv*rav**2* 
rsys*(epa*rmt**2*rpv*rtc + epa*rmt**2*rtc**2 + epa*rmt*rpul*rtc**2 - epu*rmt* 
rpv**2*rtc - epu*rmt*rpv*rtc**2 - epu*rpul*rpv**2*rtc - epu*rpul*rpv*rtc**2 +  
evc*rmt*rpul*rpv**2) + e_lv**2*e_rv*gedv*eao*elv**2*erv*rpul*rpv*rsys*rtc*( 
rav*rpv + rav*rtc + rmt*rpv + rmt*rtc) - e_lv**2*ppa*eao*elv**2*rpul*rpv* 
rsys*rtc**2*(rav + rmt) - e_lv**2*pvc*eao*elv**2*rpul*rpv**2*rsys*rtc*(rav +  
rmt) + e_lv*e_rv**2*gedv*eao*elv*erv**2*rav*rmt*rpul*rsys*( - rpv**2 - 2*rpv* 
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rtc - rtc**2) + e_lv*e_rv*gedv*eao*elv*erv*rav*rsys*( - epa*rmt**2*rpv*rtc -  
epa*rmt**2*rtc**2 - epa*rmt*rpul*rtc**2 + epu*rmt*rpv**2*rtc + epu*rmt*rpv* 
rtc**2 + epu*rpul*rpv**2*rtc + epu*rpul*rpv*rtc**2 - evc*rmt*rpul*rpv**2) -  
e_lv*e_rv*pao*eao*elv*erv*rpul*rpv*rtc*(rav**2*rpv + rav**2*rtc + rav*rmt* 
rpv + rav*rmt*rtc + rav*rpv*rsys + rav*rsys*rtc + rmt*rpv*rsys + rmt*rsys* 
rtc) + e_lv*e_rv*ppa*eao*elv*erv*rav*rmt*rpul*rsys*rtc*(rpv + rtc) + e_lv* 
e_rv*pvc*eao*elv*erv*rav*rpul*rpv*(rav*rpv*rtc + rav*rtc**2 + rmt*rpv*rsys +  
rmt*rpv*rtc + rmt*rsys*rtc + rmt*rtc**2) + e_lv*pao*eao*elv*rav*rpv*rtc*( -  
epa*rav*rmt*rtc - epa*rmt**2*rtc - epa*rmt*rsys*rtc + epu*rav*rpv*rtc + epu* 
rmt*rpv*rtc + epu*rpul*rpv*rtc + epu*rpv*rsys*rtc - evc*rmt*rpul*rpv) + e_lv* 
ppa*eao*elv*rav*rsys*rtc**2*(epa*rmt**2 + epa*rmt*rpul + epa*rmt*rpv - epu* 
rmt*rpv - epu*rpul*rpv - epu*rpv**2) + e_lv*pvc*eao*elv*rav*rpv*(epa*rav*rmt* 
rtc**2 + epa*rmt**2*rsys*rtc + epa*rmt**2*rtc**2 - epu*rav*rpv*rtc**2 - epu* 
rmt*rpv*rsys*rtc - epu*rmt*rpv*rtc**2 - epu*rpul*rpv*rsys*rtc - epu*rpul*rpv* 
rtc**2 + evc*rmt*rpul*rpv*rsys + evc*rmt*rpul*rpv*rtc) + e_rv**2*pao*eao*erv**2* 
rav*rmt*rpul*(rav*rpv**2 + 2*rav*rpv*rtc + rav*rtc**2 + rpv**2*rsys + 2*rpv* 
rsys*rtc + rsys*rtc**2) + e_rv**2*pvc*eao*erv**2*rav**2*rmt*rpul*( - rpv**2 - 2* 
rpv*rtc - rtc**2) + e_rv*pao*eao*erv*rav*(epa*rav*rmt**2*rpv*rtc + epa*rav* 
rmt**2*rtc**2 + epa*rav*rmt*rpul*rtc**2 + epa*rmt**2*rpv*rsys*rtc + epa*rmt**2* 
rsys*rtc**2 + epa*rmt*rpul*rsys*rtc**2 - epu*rav*rmt*rpv**2*rtc - epu*rav* 
rmt*rpv*rtc**2 - epu*rav*rpul*rpv**2*rtc - epu*rav*rpul*rpv*rtc**2 - epu*rmt* 
rpv**2*rsys*rtc - epu*rmt*rpv*rsys*rtc**2 - epu*rpul*rpv**2*rsys*rtc - epu* 
rpul*rpv*rsys*rtc**2 + evc*rav*rmt*rpul*rpv**2 + evc*rmt*rpul*rpv**2*rsys) +  
e_rv*pvc*eao*erv*rav**2*( - epa*rmt**2*rpv*rtc - epa*rmt**2*rtc**2 - epa*rmt* 
rpul*rtc**2 + epu*rmt*rpv**2*rtc + epu*rmt*rpv*rtc**2 + epu*rpul*rpv**2*rtc +  
epu*rpul*rpv*rtc**2 - evc*rmt*rpul*rpv**2)$ 
 
aa_(5) := df(e_lv,t)*df(pao,t)*elv*rav*rpv*rsys**2*rtc + df(e_lv,t)*pao*eao* 
elv*rpv*rsys*rtc*(rav + rsys) - df(e_lv,t)*pvc*eao*elv*rav*rpv*rsys*rtc + df( 
gedv,t)*e_lv**2*eao*elv**2*rpv*rsys**2*rtc - df(pao,t,2)*e_lv*elv*rav*rpv* 
rsys**2*rtc - df(pao,t)*e_lv*e_rv*elv*erv*rav*rsys**2*(rpv + rtc) - df(pao,t)* 
e_lv*eao*elv*rpv*rsys*rtc*(rav + rsys) - df(pao,t)*e_rv*erv*evc*rav**2*rpv* 
rsys + e_lv**2*e_rv*gedv*eao*elv**2*erv*rsys**2*(rpv + rtc) - e_lv**2*ppa* 
eao*elv**2*rsys**2*rtc - e_lv**2*pvc*eao*elv**2*rpv*rsys**2 + e_lv*e_rv*gedv* 
eao*elv*erv*evc*rav*rpv*rsys - e_lv*e_rv*pao*eao*elv*erv*rsys*(rav*rpv + rav* 
rtc + rpv*rsys + rsys*rtc) + e_lv*e_rv*pvc*eao*elv*erv*rav*rsys*(rpv + rtc) +  
e_lv*pao*eao*elv*evc*rav*rpv*rtc - e_lv*pvc*eao*elv*evc*rav*rpv*(rsys + rtc) -  
e_rv*pao*eao*erv*evc*rav*rpv*(rav + rsys) + e_rv*pvc*eao*erv*evc*rav**2*rpv$ 
 
aa_(6) := df(pao,t)*rav*rsys - e_lv*vlv*eao*elv*rsys + pao*eao*(rav + rsys) -  
pvc*eao*rav$ 
 
aa_(7) :=  - df(pao,t)*rav*rsys + e_lv*gedv*eao*elv*rsys - e_lv*vrv*eao*elv* 
rsys - pao*eao*(rav + rsys) + pvc*eao*rav$ 
 
aa_(8) := pao - vao*eao$ 
 
aa_(9) := pvc - vvc*evc$ 
 
aa_(10) := ppa - vpa*epa$ 
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aa_(11) := df(gedv,t)*e_lv*eao*elv*rmt*rpv*rsys*rtc + df(pao,t)*e_lv*elv*rpv* 
rsys*rtc*(rav + rmt) - df(pao,t)*e_rv*erv*rav*rmt*rsys*(rpv + rtc) + e_lv* 
e_rv*gedv*eao*elv*erv*rmt*rsys*(rpv + rtc) + e_lv*pao*eao*elv*rpv*rtc*(rav +  
rmt + rsys) - e_lv*ppa*eao*elv*rmt*rsys*rtc - e_lv*pvc*eao*elv*rpv*(rav*rtc +  
rmt*rsys + rmt*rtc) - e_lv*vpu*eao*elv*epu*rpv*rsys*rtc - e_rv*pao*eao*erv* 
rmt*(rav*rpv + rav*rtc + rpv*rsys + rsys*rtc) + e_rv*pvc*eao*erv*rav*rmt*( 
rpv + rtc)$ 
 
THE SYSTEM IS ALGEBRAICALLY OBSERVABLE$ 
 
RANDOMLY CHOSEN NUMERICAL PARAMETER VECTOR$ 
 
b2_ := {rmt=8, 
elv=91, 
rav=28, 
eao=20, 
rsys=75, 
evc=67, 
rtc=83, 
erv=88, 
rpv=30, 
epa=5, 
rpul=35, 
epu=49}$ 
 
EXHAUSTIVE SUMMARY$ 
 
flist_ := {rsys - 75, 
(7*epa*rmt - 8*rpul)/(8*epa*rmt), 
(5896*eao*elv*rtc - 5395*erv*evc*rav)/(5896*erv*evc*rav), 
( - eao*elv + 65*rav)/rav, 
( - 1320*eao*elv*rtc + 1079*erv*rav*rsys)/(1320*erv*rav*rsys), 
( - 15*eao + 4*rsys)/(15*rsys), 
( - 15*eao + 4*rsys)/(15*rsys), 
(eao*elv - 65*rav)/rav, 
(23584*elv*rsys*rtc - 80925*erv*evc*rav)/(80925*elv*rsys*rtc), 
( - 6*eao*elv + 13*rav*rpv)/(6*rav*rpv), 
( - 83*eao*elv + 65*rav*rtc)/(83*rav*rtc), 
(1245*eao*erv*evc - 23584*rsys*rtc)/(1245*rsys*rtc), 
(1125*eao*evc - 268*rsys**2)/(1125*rsys**2), 
(1213875*eao*erv*evc*rav - 94336*elv*rsys**2*rtc)/(1213875*elv*rsys**2*rtc), 
(105*eao*rav + 105*eao*rsys - 103*rav*rsys)/(105*rav*rsys), 
( - 9*eao*rmt + 40*rav + 40*rmt)/(40*eao*rmt), 
( - 50*rav + 3*rmt*rsys - 50*rmt)/(50*rmt*rsys), 
(4972*eao*elv*rpv*rtc - 80925*erv*rav*rpv - 80925*erv*rav*rtc)/(80925*eao*elv*rpv*rtc), 
(1245*erv*rpv + 1245*erv*rtc - 4972*rpv*rtc)/(1245*rpv*rtc), 
( - 19888*elv*rpv*rsys*rtc + 1213875*erv*rav*rpv + 
1213875*erv*rav*rtc)/(1213875*elv*rpv*rsys*rtc), 
(8*elv*rav + 8*elv*rmt - 117*rav*rmt)/(8*rav*rmt), 
( - 80*elv*rav - 80*elv*rmt + 39*rav*rmt*rpv)/(80*rav*rmt*rpv), 
( - 664*elv*rav - 664*elv*rmt + 117*rav*rmt*rtc)/(664*rav*rmt*rtc), 
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(18675*erv*rpv + 18675*erv*rtc - 2486*rpv**2*rtc)/(18675*rpv**2*rtc), 
(105*eao*rav + 105*eao*rsys - 103*rav*rsys)/(105*rav*rsys), 
( - 1245*erv*rpv - 1245*erv*rtc + 4972*rpv*rtc)/(1245*rpv*rtc), 
( - 105*eao*rav - 105*eao*rsys + 103*rav*rsys)/(105*rav*rsys), 
(249*eao*elv*erv*rpv + 249*eao*elv*erv*rtc - 64636*rav*rpv*rtc)/(249*rav*rpv*rtc), 
( - 9*eao*rmt + 40*rav + 40*rmt)/(40*eao*rmt), 
(18675*eao*erv*rpv + 18675*eao*erv*rtc - 19888*rpv*rsys*rtc)/(18675*rpv*rsys*rtc), 
( - 93375*eao*evc*rsys - 93375*eao*evc*rtc + 42344*rsys**2*rtc)/(93375*rsys**2*rtc), 
( - 8497125*eao*erv*evc*rav - 8497125*eao*erv*evc*rsys + 
2429152*elv*rsys**2*rtc)/(8497125*elv*rsys**2*rtc), 
(660*eao*elv*rsys + 660*eao*elv*rtc - 1027*erv*rav*rsys)/(660*erv*rav*rsys), 
(200*rav - 37*rmt*rsys + 200*rmt + 200*rsys)/(200*rmt*rsys), 
(98883136*elv*rpv**2*rsys*rtc**2 - 1511274375*erv**2*rav*rpv**2 -
3022548750*erv**2*rav*rpv*rtc -
1511274375*erv**2*rav*rtc**2)/(1511274375*elv*rpv**2*rsys*rtc**2), 
( - 840*epa*rmt**2 + 840*epu*rmt*rpv + 840*epu*rpul*rpv -
6289*rmt*rpul*rpv)/(840*rmt*rpul*rpv), 
(73*rmt*rpv - 240*rmt - 240*rpul - 240*rpv)/(240*rmt*rpv), 
( - 4150*rav*rtc + 299*rmt*rsys*rtc - 4150*rmt*rsys - 4150*rmt*rtc)/(4150*rmt*rsys*rtc), 
( - 24720784*eao*elv*rpv**2*rtc**2 + 100751625*erv**2*rav*rpv**2 + 201503250* 
erv**2*rav*rpv*rtc + 100751625*erv**2*rav*rtc**2)/(100751625*eao*elv*rpv**2*rtc**2), 
( - 6446*elv*rmt*rpv*rsys*rtc + 93375*erv*rav*rmt*rpv + 93375*erv*rav*rmt*rtc + 
93375*erv*rav*rpul*rtc)/(93375*elv*rmt*rpv*rsys*rtc), 
(3223*eao*elv*rmt*rpv*rtc - 12450*erv*rav*rmt*rpv - 12450*erv*rav*rmt*rtc - 
12450*erv*rav*rpul*rtc)/(12450*eao*elv*rmt*rpv*rtc), 
(2490*erv*rmt*rpv + 2490*erv*rmt*rtc + 2490*erv*rpul*rtc - 
41899*rmt*rpv*rtc)/(2490*rmt*rpv*rtc), 
( - 1550025*erv**2*rpv**2 - 3100050*erv**2*rpv*rtc - 1550025*erv**2*rtc**2 + 
24720784*rpv**2*rtc**2)/(1550025*rpv**2*rtc**2), 
(3729*eao*rmt*rpv*rtc - 4150*erv*rav*rpv - 4150*erv*rav*rtc - 4150*erv*rmt*rpv - 
4150*erv*rmt*rtc)/(4150*eao*rmt*rpv*rtc), 
( - 130725*eao*erv*rav*rpv - 130725*eao*erv*rav*rtc - 130725*eao*erv*rpv*rsys - 
130725*eao*erv*rsys*rtc + 512116*rav*rpv*rsys*rtc)/(130725*rav*rpv*rsys*rtc), 
(830*elv*erv*rav*rpv + 830*elv*erv*rav*rtc + 830*elv*erv*rmt*rpv + 830*elv* 
erv*rmt*rtc - 48477*rav*rmt*rpv*rtc)/(830*rav*rmt*rpv*rtc), 
(512116*elv*rpv*rsys*rtc - 8497125*erv*rav*rpv - 8497125*erv*rav*rtc - 8497125* 
erv*rpv*rsys - 8497125*erv*rsys*rtc)/(8497125*elv*rpv*rsys*rtc), 
(1400*rav**2 - 309*rav*rmt*rsys + 1400*rav*rmt + 1400*rav*rsys + 1400*rmt* 
rsys)/(1400*rav*rmt*rsys), 
( - 3231*eao*rav*rmt*rpul*rpv - 5600*eao*rmt*rpul*rpv - 5600*epa*rav**2*rmt -  
5600*epa*rav*rmt**2 + 5600*epu*rav**2*rpv + 5600*epu*rav*rmt*rpv + 5600*epu* 
rav*rpul*rpv)/(5600*eao*rav*rmt*rpul*rpv), 
(331969*elv*rmt*rpv*rsys*rtc - 1307250*erv*rav*rmt*rpv - 1307250*erv*rav*rmt* 
rtc - 1307250*erv*rav*rpul*rtc - 1307250*erv*rmt*rpv*rsys - 1307250*erv*rmt* 
rsys*rtc - 1307250*erv*rpul*rsys*rtc)/(1307250*elv*rmt*rpv*rsys*rtc), 
(25200*epa*rmt**2 + 25200*epa*rmt*rpul + 25200*epa*rmt*rpv - 25200*epu*rmt* 
rpv - 25200*epu*rpul*rpv - 25200*epu*rpv**2 + 
10439*rmt*rpul*rpv**2)/(25200*rmt*rpul*rpv**2), 
( - 2546240752*elv*rpv**2*rsys*rtc**2 + 10578920625*erv**2*rav*rpv**2 + 21157841250 
*erv**2*rav*rpv*rtc + 10578920625*erv**2*rav*rtc**2 + 10578920625*erv**2*rpv**2* 
rsys + 21157841250*erv**2*rpv*rsys*rtc + 10578920625*erv**2*rsys*rtc**2)/(10578920625 
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*elv*rpv**2*rsys*rtc**2), 
(2583375*erv*rav*rpv*rtc + 2583375*erv*rav*rtc**2 + 2583375*erv*rmt*rpv*rsys +  
2583375*erv*rmt*rpv*rtc + 2583375*erv*rmt*rsys*rtc + 2583375*erv*rmt*rtc**2 -  
743314*rmt*rpv*rsys*rtc**2)/(2583375*rmt*rpv*rsys*rtc**2), 
(619648381*eao*elv*rmt*rpul*rpv**2*rtc**2 + 1410522750*epa*erv*rav*rmt**2* 
rpv*rtc + 1410522750*epa*erv*rav*rmt**2*rtc**2 + 1410522750*epa*erv*rav*rmt* 
rpul*rtc**2 - 1410522750*epu*erv*rav*rmt*rpv**2*rtc - 1410522750*epu*erv*rav* 
rmt*rpv*rtc**2 - 1410522750*epu*erv*rav*rpul*rpv**2*rtc - 1410522750*epu*erv* 
rav*rpul*rpv*rtc**2 + 1410522750*erv*evc*rav*rmt*rpul*rpv**2)/(1410522750* 
eao*elv*rmt*rpul*rpv**2*rtc**2), 
( - 21700350*epa*erv*rmt**2*rpv*rtc - 21700350*epa*erv*rmt**2*rtc**2 - 21700350* 
epa*erv*rmt*rpul*rtc**2 + 21700350*epu*erv*rmt*rpv**2*rtc + 21700350*epu*erv* 
rmt*rpv*rtc**2 + 21700350*epu*erv*rpul*rpv**2*rtc + 21700350*epu*erv*rpul* 
rpv*rtc**2 - 21700350*erv*evc*rmt*rpul*rpv**2 - 619648381*rmt*rpul*rpv**2* 
rtc**2)/(21700350*rmt*rpul*rpv**2*rtc**2), 
( - 145250*erv*rav**2*rpv - 145250*erv*rav**2*rtc - 145250*erv*rav*rmt*rpv -  
145250*erv*rav*rmt*rtc - 145250*erv*rav*rpv*rsys - 145250*erv*rav*rsys*rtc -  
145250*erv*rmt*rpv*rsys - 145250*erv*rmt*rsys*rtc + 128029*rav*rmt*rpv*rsys* 
rtc)/(145250*rav*rmt*rpv*rsys*rtc), 
( - 871500*epa*rav*rmt*rtc - 871500*epa*rmt**2*rtc - 871500*epa*rmt*rsys*rtc +  
871500*epu*rav*rpv*rtc + 871500*epu*rmt*rpv*rtc + 871500*epu*rpul*rpv*rtc +  
871500*epu*rpv*rsys*rtc - 871500*evc*rmt*rpul*rpv - 281369*rmt*rpul*rpv*rsys* 
rtc)/(871500*rmt*rpul*rpv*rsys*rtc), 
( - 1239296762*elv*rmt*rpul*rpv**2*rsys*rtc**2 - 10578920625*epa*erv*rav*rmt**2* 
rpv*rtc - 10578920625*epa*erv*rav*rmt**2*rtc**2 - 10578920625*epa*erv*rav* 
rmt*rpul*rtc**2 + 10578920625*epu*erv*rav*rmt*rpv**2*rtc + 10578920625*epu* 
erv*rav*rmt*rpv*rtc**2 + 10578920625*epu*erv*rav*rpul*rpv**2*rtc + 10578920625* 
epu*erv*rav*rpul*rpv*rtc**2 - 10578920625*erv*evc*rav*rmt*rpul*rpv**2)/(10578920625 
*elv*rmt*rpul*rpv**2*rsys*rtc**2), 
(72334500*epa*rav*rmt*rtc**2 + 72334500*epa*rmt**2*rsys*rtc + 72334500*epa* 
rmt**2*rtc**2 - 72334500*epu*rav*rpv*rtc**2 - 72334500*epu*rmt*rpv*rsys*rtc -  
72334500*epu*rmt*rpv*rtc**2 - 72334500*epu*rpul*rpv*rsys*rtc - 72334500*epu* 
rpul*rpv*rtc**2 + 72334500*evc*rmt*rpul*rpv*rsys + 72334500*evc*rmt*rpul*rpv* 
rtc + 16860877*rmt*rpul*rpv*rsys*rtc**2)/(72334500*rmt*rpul*rpv*rsys*rtc**2), 
(63823783243*elv*rmt*rpul*rpv**2*rsys*rtc**2 + 148104888750*epa*erv*rav*rmt**2* 
rpv*rtc + 148104888750*epa*erv*rav*rmt**2*rtc**2 + 148104888750*epa*erv*rav* 
rmt*rpul*rtc**2 + 148104888750*epa*erv*rmt**2*rpv*rsys*rtc + 148104888750* 
epa*erv*rmt**2*rsys*rtc**2 + 148104888750*epa*erv*rmt*rpul*rsys*rtc**2 - 148104888750 
*epu*erv*rav*rmt*rpv**2*rtc - 148104888750*epu*erv*rav*rmt*rpv*rtc**2 - 148104888750 
*epu*erv*rav*rpul*rpv**2*rtc - 148104888750*epu*erv*rav*rpul*rpv*rtc**2 - 148104888750 
*epu*erv*rmt*rpv**2*rsys*rtc - 148104888750*epu*erv*rmt*rpv*rsys*rtc**2 - 148104888750 
*epu*erv*rpul*rpv**2*rsys*rtc - 148104888750*epu*erv*rpul*rpv*rsys*rtc**2 + 148104888750 
*erv*evc*rav*rmt*rpul*rpv**2 + 148104888750*erv*evc*rmt*rpul*rpv**2*rsys)/(148104888750 
*elv*rmt*rpul*rpv**2*rsys*rtc**2)}$ 
 
MODEL PARAMETER SOLUTION(S)$ 
 
g_ := {{eao=20, 
elv=91, 
epa=5, 
epu=49, 
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erv=88, 
evc=67, 
rav=28, 
rmt=8, 
rpul=35, 
rpv=30, 
rsys=75, 
rtc=83}}$ 
 
SYSTEM GLOBALLY IDENTIFIABLE$ 
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APPENDIX B: MITRAL VALVE REPLACEMENT PATIENT TREATMENT DATA 
The following tables list the cardiovascular therapies used to treat the 4 patients post mitral valve 
surgery. 
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Table B.2: Treatment received by patient 2 (Weight = 56.5Kg) in the first 12 hours post mitral valve surgery 
Therapy Therapy type T0 T1 T2 T3 T4 T5 T6 T7 T8 T9 T10 T11 T12 
Ventilation PEEP (cm H20) 5 5 5 5 5 5 5       
PIP (cm H20) 10 19 19 11 11 11 11       
Inotropes Noradrenaline (μg /kg/min) 0.02 0.05 4 0.07 0.02 0.02 0.01 0.01 0.01     
Milrinone (μg /kg/min) 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.04 
Dobutamine (μg /kg/min)              
Adrenaline (μg /kg/min)              
Fluids Fluids in (ml/hr) 134 937 639 351 27 27 246 26 26 65 25 25 72 
Fluids out (ml/hr) 140 90 170 70 220 120 90 140 90 120 100 110 100 
Fluid balance (ml) -6 841 1310 1591 1398 1305 1461 1346 1282 1227 1152 1067 1039 
 
Table B.3: Treatment received by patient 3 (Weight = 65Kg) in the first 12 hours post mitral valve surgery 
Therapy Therapy type T0 T1 T2 T3 T4 T5 T6 T7 T8 T9 T10 T11 T12 
Ventilation PEEP (cm H20) 5 5 5 5 5 5 5 5 5 5 5 5 5 
PIP (cm H20) 19 19 19 19 11 11 11 11 11 11 11 11 11 
Inotropes Noradrenaline (μg /kg/min) 0.07 0.06 0.06 0.03 0.02 0.04 0.04 0.03 0.03 0.03 0.03 0.03 0.03 
Milrinone (μg /kg/min)              
Dobutamine (μg /kg/min) 3.2 3.2 6.4 6.4 3.9 2.6 2.6 5.8 5.8 5.8 4.5 4.5 4.5 
Adrenaline (μg /kg/min) 0.03             
Fluids Fluids in (ml/hr) 533 639 534 28 528 30 181 32 63 32 32 532 261 
Fluids out (ml/hr) 230 320 420 340 220 180 130 60 124 105 35 65 35 
Fluid balance (ml) 303 622 736 424 732 582 633 605 544 471 468 935 1161 
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Table B.4: Treatment received by patient 4 (Weight = 69Kg) in the first 12 hours post mitral valve surgery 
Therapy Therapy type T0 T1 T2 T3 T4 T5 T6 T7 T8 T9 T10 T11 T12 
Ventilation PEEP (cm H20) 5 5 5 5 5 5        
PIP (cm H20) 17 19 18 18 10 11        
Inotropes Noradrenaline (μg/kg/min) 0.16 0.11 0.07 0.08 0.08 0.06 0.03       
Milrinone (μg /kg/min) 0.09 0.09 0.04 0.04 0.04         
Dobutamine (μg /kg/min)              
Adrenaline (μg /kg/min)              
Fluids Fluids in (ml/hr) 52 547 40 41 531 26 123 220 220 120 120 170 120 
Fluids out (ml/hr) 155 195 115 115 60 175 40 70 75 110 60 40 70 
Fluid balance (ml) -103 249 174 100 571 422 505 655 800 810 870 1000 1050 
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